var title_f11_23_11632="Fully developed papilledema";
var content_f11_23_11632=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F64616&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F64616&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Fully developed papilledema",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 322px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Don C Bienfang, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_23_11632=[""].join("\n");
var outline_f11_23_11632=null;
var title_f11_23_11633="Supraspinatus isometric abduction exercise";
var content_f11_23_11633=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1140px;\">",
"  <div class=\"videoplayer\" h264=\"./images/EM/86055/Suprasp_isomet_abduct_video.mp4?title=Supraspinatus+isometric+abduction+exercise\" style=\"width:496px;height:288px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Supraspinatus isometric abduction exercise",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Isometric exercises with the shoulder held in mid-abduction&nbsp;are performed early in rehabilitation to begin strengthening the supraspinatus muscle.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Craig Parsons, MS, PT and the Physical Therapy Network.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_23_11633=[""].join("\n");
var outline_f11_23_11633=null;
var title_f11_23_11634="Cheek structure lacerations";
var content_f11_23_11634=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F77364&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F77364&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 511px\">",
"   <div class=\"ttl\">",
"    The parotid gland and facial nerve underlie the zygomatic and cheek areas",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 491px; height: 517px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The parotid gland and facial nerve branches are superficial to the masseter muscle and can be damaged in lacerations to the cheek and zygoma that are anterior to the ear.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_23_11634=[""].join("\n");
var outline_f11_23_11634=null;
var title_f11_23_11635="Patient information: Prosthetic valves (The Basics)";
var content_f11_23_11635=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/83801\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?35/42/36516\">",
"         Chambers and valves of the heart",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/7/14452\">",
"          Aortic stenosis",
"         </a>",
"         <li>",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/35/34354\">",
"           Transthoracic echocardiogram (echo)",
"          </a>",
"         </li>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?31/35/32306\">",
"         Patient information: Aortic regurgitation in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?35/53/36690\">",
"         Patient information: Aortic stenosis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?24/13/24787\">",
"         Patient information: Echocardiogram (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?25/48/26370\">",
"         Patient information: Endocarditis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?19/39/20083\">",
"         Patient information: Exercise (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?18/60/19394\">",
"         Patient information: Mitral regurgitation (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?12/31/12787\">",
"         Patient information: Mitral stenosis in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?21/4/21571\">",
"         Patient information: Mitral valve prolapse (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?23/55/24435\">",
"         Patient information: Stroke (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?26/59/27575\">",
"         Patient information: Mitral regurgitation (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?37/37/38484\">",
"         Patient information: Stroke symptoms and diagnosis (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?21/15/21747\">",
"         Patient information: Warfarin (Coumadin) (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Prosthetic valves (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/prosthetic-valves-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H1669114789\">",
"      <span class=\"h1\">",
"       What is a prosthetic valve?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A prosthetic valve is a valve that a doctor puts in the heart to replace a damaged heart valve (",
"      <a class=\"graphic graphic_figure graphicRef58389 \" href=\"UTD.htm?35/42/36516\">",
"       figure 1",
"      </a>",
"      ). Prosthetic valves are used to treat different heart conditions, usually when they get severe. These conditions include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Stenosis &ndash; This is when a valve doesn&rsquo;t open fully. Examples include aortic stenosis (",
"        <a class=\"graphic graphic_figure graphicRef74714 \" href=\"UTD.htm?14/7/14452\">",
"         figure 2",
"        </a>",
"        ) and mitral stenosis.",
"       </li>",
"       <li>",
"        Regurgitation &ndash; This is when a valve leaks, and blood flows in the wrong direction. Examples include aortic regurgitation and mitral regurgitation.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      There are 2 main types of prosthetic heart valves:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Mechanical &ndash; These valves are made from man-made materials. They can last 20 to 30 years or longer.",
"       </li>",
"       <li>",
"        Biological &ndash; These are made from valve tissue from a pig, cow, or horse. In some cases, they come from another person. These valves usually last 10 to 15 years.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Although prosthetic valves help treat heart conditions, they can cause problems of their own.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1669114847\">",
"      <span class=\"h1\">",
"       What problems can happen with prosthetic valves?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The problems that can happen depend mostly on the type of valve and where it is in the heart. In general, mechanical valves cause more problems than biological valves.",
"     </p>",
"     <p>",
"      Problems that can happen with prosthetic valves include the following:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Blood clots can form on the valve. This is a problem because clots can break off and travel through the blood vessels to other parts of the body. They can then get stuck in and block off small blood vessels. This can cause organ damage and symptoms. Sometimes, a blood clot can also block the valve.",
"       </li>",
"       <li>",
"        People can have side effects from their treatment. Some people need to take a type of medicine called &ldquo;anticoagulation&rdquo; medicine every day to help keep blood clots from forming. Anticoagulation medicines can make people bleed much more easily than normal.",
"       </li>",
"       <li>",
"        The valve can get infected, which doctors call &ldquo;endocarditis.&rdquo; With endocarditis, small growths can form on the prosthetic valve. These growths can break off, travel to, and block small blood vessels in other parts of the body.",
"       </li>",
"       <li>",
"        The valve can leak or get blocked by scar tissue.",
"       </li>",
"       <li>",
"        The valve can damage red blood cells as blood flows through the heart. This can cause a condition called &ldquo;anemia.&rdquo;",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1669114862\">",
"      <span class=\"h1\">",
"       How do I manage my prosthetic valve?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Long-term management for a prosthetic valve depends on the type of valve, where it is in the heart, and your individual situation.",
"     </p>",
"     <p>",
"      All people who have a prosthetic valve need to take some kind of medicine to help keep blood clots from forming. People who have a mechanical valve usually take an anticoagulation medicine called",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?33/2/33830?source=see_link\">",
"       warfarin",
"      </a>",
"      (sample brand name: Coumadin&reg;). Some people with a biological valve might also need to take this. But most people with a biological valve instead take",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?6/12/6342?source=see_link\">",
"       aspirin",
"      </a>",
"      every day.",
"     </p>",
"     <p>",
"      If you take",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?33/2/33830?source=see_link\">",
"       warfarin",
"      </a>",
"      , you need to take it exactly as instructed. If you forget or miss a dose, call your doctor to find out what to do. People who take warfarin also need regular blood tests. That&rsquo;s because the medicine&rsquo;s effects can change over time. At the wrong doses, the medicine can either stop working or lead to serious bleeding.",
"     </p>",
"     <p>",
"      Other parts of long-term management usually include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Follow-up visits and tests to check your prosthetic valve &ndash; Your doctor will talk with you and do an exam. Sometimes, he or she will order an echocardiogram (also called an &ldquo;echo&rdquo;). An echo uses sound waves to create a picture of your heart as it beats. It shows the size of the heart chambers, how well the heart is pumping, and how well the heart valves are working (",
"        <a class=\"graphic graphic_figure graphicRef77971 \" href=\"UTD.htm?33/35/34354\">",
"         figure 3",
"        </a>",
"        ).",
"       </li>",
"       <li>",
"        Taking antibiotic medicines before going to the dentist or having certain dental or medical procedures &ndash; This can help prevent endocarditis.",
"       </li>",
"       <li>",
"        Avoiding certain activities or sports &ndash; If you take anticoagulation medicine, your doctor will probably recommend that you avoid sports and activities in which you could easily get hurt or bleed.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1669114900\">",
"      <span class=\"h1\">",
"       What if I have a prosthetic valve and want to get pregnant?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you have a prosthetic valve and want to get pregnant, talk with your doctor. Women who take anticoagulation medicine might need to change their medicine during pregnancy. There are different anticoagulation medicines. Some have a higher chance of harming an unborn baby than others.",
"     </p>",
"     <p>",
"      You, your heart doctor, and your pregnancy doctor will work together to decide which anticoagulation medicine is right for you.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1669114915\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?18/60/19394?source=see_link\">",
"       Patient information: Mitral regurgitation (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/53/36690?source=see_link\">",
"       Patient information: Aortic stenosis (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?25/48/26370?source=see_link\">",
"       Patient information: Endocarditis (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/13/24787?source=see_link\">",
"       Patient information: Echocardiogram (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?23/55/24435?source=see_link\">",
"       Patient information: Stroke (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?19/39/20083?source=see_link\">",
"       Patient information: Exercise (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?21/4/21571?source=see_link\">",
"       Patient information: Mitral valve prolapse (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?12/31/12787?source=see_link\">",
"       Patient information: Mitral stenosis in adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?31/35/32306?source=see_link\">",
"       Patient information: Aortic regurgitation in adults (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?26/59/27575?source=see_link\">",
"       Patient information: Mitral regurgitation (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?37/37/38484?source=see_link\">",
"       Patient information: Stroke symptoms and diagnosis (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?21/15/21747?source=see_link\">",
"       Patient information: Warfarin (Coumadin) (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?11/23/11635?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83801 Version 4.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-D34A3220F9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_23_11635=[""].join("\n");
var outline_f11_23_11635=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1669114789\">",
"      What is a prosthetic valve?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1669114847\">",
"      What problems can happen with prosthetic valves?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1669114862\">",
"      How do I manage my prosthetic valve?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1669114900\">",
"      What if I have a prosthetic valve and want to get pregnant?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1669114915\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/83801\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?35/42/36516\">",
"      Chambers and valves of the heart",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/7/14452\">",
"       Aortic stenosis",
"      </a>",
"      <li>",
"       <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/35/34354\">",
"        Transthoracic echocardiogram (echo)",
"       </a>",
"      </li>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?31/35/32306?source=related_link\">",
"      Patient information: Aortic regurgitation in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/53/36690?source=related_link\">",
"      Patient information: Aortic stenosis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/13/24787?source=related_link\">",
"      Patient information: Echocardiogram (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?25/48/26370?source=related_link\">",
"      Patient information: Endocarditis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?19/39/20083?source=related_link\">",
"      Patient information: Exercise (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?26/59/27575?source=related_link\">",
"      Patient information: Mitral regurgitation (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?18/60/19394?source=related_link\">",
"      Patient information: Mitral regurgitation (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?12/31/12787?source=related_link\">",
"      Patient information: Mitral stenosis in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/4/21571?source=related_link\">",
"      Patient information: Mitral valve prolapse (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/55/24435?source=related_link\">",
"      Patient information: Stroke (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?37/37/38484?source=related_link\">",
"      Patient information: Stroke symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/15/21747?source=related_link\">",
"      Patient information: Warfarin (Coumadin) (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_23_11636="Misoprostol: Patient drug information";
var content_f11_23_11636=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Misoprostol: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"     see \"Misoprostol: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/31/17908?source=see_link\">",
"     see \"Misoprostol: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F197188\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cytotec&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F197189\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Novo-Misoprostol;",
"     </li>",
"     <li>",
"      PMS-Misoprostol",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10023644\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700360",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking this drug to stop gastric ulcers, do not take it if you are pregnant. Use a helpful kind of birth control.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700903",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share this drug with others.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10023646\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691481",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop NSAID-associated gastric ulcers in patients with a history of ulcers.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10023645\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702536",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to misoprostol or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10023650\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697739",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug to stop ulcers.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10023651\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10023653\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698699",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If taking to end a pregnancy: Upset stomach, throwing up, loose stools, or weakness with or without belly pain or fever.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10023648\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695907",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug with food.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10023649\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10023654\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10023655\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11798 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-200.131.240.2-0CE6B713CC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_23_11636=[""].join("\n");
var outline_f11_23_11636=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197188\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197189\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023644\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023646\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023645\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023650\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023651\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023653\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023648\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023649\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023654\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023655\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=related_link\">",
"      Misoprostol: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/31/17908?source=related_link\">",
"      Misoprostol: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_23_11637="Elastosis 1";
var content_f11_23_11637=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F61033&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F61033&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Photoaged skin: solar elastosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Yellowish discoloration and pebbled appearance of photodamaged, elastotic skin. Note the lighter color and even appearance of the adjacent, sun-protected skin.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_23_11637=[""].join("\n");
var outline_f11_23_11637=null;
var title_f11_23_11638="Biclonal pattern immunofix";
var content_f11_23_11638=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F66994&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F66994&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Biclonal gammopathy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 299px; height: 358px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This figure illustrates the immunofixation pattern of a single serum specimen with antisera to heavy chain determinants of IgA, IgG, and IgM, and to kappa and lambda light chain determinants. It shows a discrete IgG band (seen as a dark band) and a discrete lambda band with similar mobility, indicative of the presence of an IgG lambda monoclonal protein. There is also an IgM kappa monoclonal protein.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_23_11638=[""].join("\n");
var outline_f11_23_11638=null;
var title_f11_23_11639="Innervation of the adrenal glands";
var content_f11_23_11639=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F71492&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F71492&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 543px\">",
"   <div class=\"ttl\">",
"    Innervation of the adrenal glands",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 523px; height: 698px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAK6AgsDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACijNJQAuaTNFFABmjNIaQ0ABY0m40UlIYu40bjRRTAXLUuTTc0hagB+TRuqIyAUxpwO9K4WLG6jdVNrpR3qNrxfWi4+Vmhuo3VmG9HrR9tHrRcORmnuo3VmfbR60ovB60XDlZpbqN1Z4uxUguR60XDlLuTRk1VFwvrT1mB707isT5NGTUYcGnZoEOyaMmm5paADJoyaKSgB2TRmkooAXNLSUUALRSUuaACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoooNABRmkooAKKKKACkNBppNAATSZpCajZ8Uh2JSaTPNQGSonm96B2LZcUx5gO9Z0tzjvVOa796TZahc1XulXvVaW/A71izXXvVOW596lyNFTNuXUPeqkmoE96xZLoetVnuxnrUuRqqRuNfE/xUw3hP8VYn2jPel+0e9LmK5DZ+1H1oF2fWsT7Tz1ppu+cA0XDkN8XfvTxd+9c+Lr3pwufU0cwvZnQi7PrTxee9c018B3pBqA9aOYPZHVref7VTJeH1rk49QHrVqO9B701Il0jqkvferMd4D3rlFu/erCXWO9UpGbpnVpcA96nVwe9cxDee9XoL33qlIzcDcBzS1RiuVbvVpJAadzNokopAc0tMQtFJS0AFFFFAAKWkooAWiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAA0lFFABRRSGgANBNJSE0ABNMZqRmxULyUikhzvVeSWopZwAeaoT3IGeaTZpGJbknxVOa7xnms+4vQM81mXF915qHI1jTNSe896ozXfvWRLe5PWuIsfiRpd/qVvaCDUIBcTyW0M80IEUkiEgqGBPPHeovc2UEtz0GW796py3fvXNL4o0e4E5t9WsJFhXfKUuEIRfU88D3rJvvG+h2zWgbUrd0upTCkkcqsqsBk7jngYI/MetTdmiUV1OulvDnrUQnJ71z41vTnvDaDULQ3fP7kTLv6ZPGc9OaZF4k06SSzjsrq2vTcTCHMFxG2wkEgn5snODwMn2pas0fKjq/NwoprT1ir4h0iYzJBqljI0Cl5Qlwp2KOpPPAHc0tjqVpqMTS2F3BcxKdpeGQOoOAcZHfBH50CSTNOS5Kr15pqTHGT1qjuMknXgVJv/KlcvlLwn296ikvTnCnj1qlLIegPJqlLKxOxCc9z6f/AF6TY1A0pL5Yx8zD8TSC+744rM2rHywLOeg6k1DNO6glmjQe/P65FK5XKjdS8VuhwasR3rKeTxXMw3CyLlXViOu1s1ajuCOCcijmE6aOqgvsjBNXUuuOtclBcc8GtCC5ypGelWpGUqZ0sd371civPeuXjuferMVyfWqUjJ0zrre9wRzWpbXucc1w8F4c9a0ra8/2qtSMZ0juIZww61ZVgRXKWl905rZtrsMBzWikc0oWNSlFQxyBhxUgNUZ2HUUUUAFFLijFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFJRRQAUUUUABpKCaYxoACajZ8Ujviqk02O9JspIfLKB3qjPcgd6gubrGeaxry8xnmobNowuT3l9hW574rLu7/rzVC6uC1rJID0f/ANmrKmuiwOTXLCrzN+R1Qpl64v8AJPNZ015nPNUJpjnrVZpcmqbOiMEXXuTnrXEeH/BNjYJNJeYuL55J2SYO2IhIT91ScBsHqBXStJ81cb4h8U6jpviA6RbwW7T3fkfYGZWIOWIl34PO0DPGKItvRBNRVnIhTwNevAkV9Pp8qW1gbCBFjdVkUsDukwc547d+aLfwdq0NvZyHU4Zrm0vftUUc++RFTZt2bj8x9arN47vW19YLZILmzeS4jC+XskzGrEAfvCeSMZKjPaq1p471KXTp5lk0y5lXTHvvLhjf9zIGA8tvnOcA89Kv3jFeyNmz8Fzwa0bozW01v9ra8UyNLvjZuoChtnfqR0rRsfB/2bSvDdms0CyabKJJpI02mb5GXj3+bvWFL44vZYtR/sv+zpzbxWjxkvgFpAS4yWAJGOBkVuaV4nmvfBt5rCGN57eKdgDCY13ICQCu4+nZvype8UlTbsjNg8DXsFlBZT31oYLKzubS1eKNld/O/ik5xx6Cuv0GxTSNBtLNRHuiiVGaNdodgoBb8cVymjeLLtrkHxBLYxWr6ZDqIkijZBHvbbtbLHP1rrDf2rahBYmUCeRPNRSCN699p6HHcDkcVMm+pdOMEro0UGyMDu1NZvnPotI75mOOiioN2c+5qTVIdI+1Gc8k8AVGo8uPceT2/wBo0S/NKqDooyfqf8mmTOAWb+GPIH17n+n50DKeo3qWcLPI2WPU+p9BXJXGoS3cuWPy9l7Cm+IbySe9VOkYGR784z+lR2ceACetJagaVo7xurocMP19jXSW8oliV1zhh+Vc9CvStrSwfJdT0V+PxAP9aRaNCNiKuwPhj9KogYqaNsMfpTQpK5djnqzHNz1rJV8VKsvIqrmbiasU+H61dhusd6wUl/eGpxN0ppkOB1FteYI5ras77BHNcLDckHrWjb3xVhzVqRjOlc9Hs7sMBzWpFKGFcFp+odOa6SzvQVGTWqkcc6djfBp1U4Jdw61aVqtO5g0PFFJS0xBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUhoooAKKKKACkNBprGgAJqGR8USPgVn3VwFB5pNlpXHXE4Hesi7vAM81De3gGcGufvr0jPPFZuR0Qp3Ld5fYzk1jXV7nPORVO4ut5IB4rNnmKNycqaycjrhTNiNvM0W9IPKbj+QDViPJk5rW8POsyXlux4cA/gRg/wBK5qRnjID8MOD9e9cGHdqlSL7l01q0SSvtYg9Krs+D1pzt5iZ7iqrNXWbpEsjfMDTCsbypI0aNImdrEAlc9cHtTHOUBpqvzSCxY+y2qymVbeFZWO4uqAMT6565rO0zw/p+nXEtxEksk8kflF55GkOzOSoz2J6+taO/gU7dxRcXKuw0WFkIjELO2ETAbk8pcHHTIxToo4kTyUjQQ42+WFAXHpj0qQtxUS/eFA0kSm2t3YBreErtCYKDG0dB9PalutPtdQjMV3EHRTuQglWRh0ZSOVI9RToz8xNSq2FJpia6GDBqF1o7GDWn821Y4i1HAA9llHRT/tfdPseK3IfmIx061HdIklsYpVV0kG1lYZBB6gisJIrrw7HJJaJLdaUFJMAO6S2/3P7y/wCz1HbPSjcWsV5G8smFllAySTtHr2H9Koau5jt1hjPzNhR9TU1ldW93aWklpKk0DDcGU5BAH884rPuZhLrVtD1zk/kKzqy5IOXYG7K5z+vQhdWiRRgCFQPzNPt06Vd8Uw7NcjGOsCn9TUVuvSs8K70ohDYtwJ0rYsYykbE/xNu/QD+lULdMlQOta6gBcDtxWxoKacp2ozGm9qa78BR3NADhwKAxIprt8uO54pc8UASo+3JJpwlqqTlsDtS7u1O4rF1JiBnNSxXBz1rO30ok285ouJxOitb3YRzwK6GyvJE2GQ4kb7qnsPU1zmm262Vt9v1AbRx5UZ659cev8v5Mhv3kuGlfAZj0HYdhWEazrT5Y/CupzSjzvQ9S0+8BVRmtmGUMBzXnOmajyvzV1en3oYDmvRjI4alOx0itxThVSCUMBzVlTWpztWH0UlLQIKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoooxQAUYoooASig0jHFACMahlfFEj4HWs66uAAeaTZaVwurjaDzWDf3uM80zUb7GRmubvr7OQTWUpHVTpkl9dHkqcisS4uyc9x3FRXV0ynIORVCWUOMoefSsWzsjCw+5c43xmq63AkBSTr2NRiUqcjp3FV7nGd6dDUmqXQ1tAuTbaxCjH5ZMxn8en6gUniSD7Pqcy4+ST96v49f1zWOsjEghiHU5BHY11Gsf8TbQre/iGZYv9Yo7dmH4EZ+lcVX91WjU6PRkS92aZy6vtb2pswwcjoaY/BpQ29Cp69q7DYbnKGmA0KeSKZnmgC0rcCpAaqqanU8UASu1In3qYTmlXqKBllD1p6H5frUKHk1PHyQKBCXB+dVHYZqO5cCHZnkkA/iaV23Tuc9OP8/nVSZ9zpjuxP4AYpAjOvrCa1vpL3RWRJ3UtLbyHEU5yOePuvx94de4NZ/hrUItV8Z2qhXjdcrJDIMOjYPBH9ehroJDiX/gH9a5TTrJ77xrbPaXBtL0SERXCqGKnb0IP3l9R/I81Fb3qck+xlUVlodL8QLfyPEUAAwDbL/6E1ZtsvSt3x9Hcf2hpz3vlfafsqiXyc7N245255x9axoBhc4yew9azwv8KJVJ3ijTsY/m3dhV41Hbx+VCqZyQOT6mnE1uaATiogcy+wFDlg4x93Bz+mKjjbhm9TSTuFyYnMgHoM/5/WlZsVBG2SzepwPw/wAmldsA0wFDdTRupmcDFNLUASbq6LQ9MSOH+0dS+SFBvRW7+5/oKh0HSEaP7fqeEtUGVV+A3ufb27/zqa5rEmoylUylqp+VPX3NcVScq0vZ09urMZSc3yxHarqj6jc7yNsScRp6D1PvUMMpBqipqRWrrhBU48sTRRSVkdBZXZUjmuo0q/6c1wMEuD1rZsLoqRzW0ZGNSnc9U0673KOa2oX3AV5/pF705rsLC43Ac10RkebVhY1wacKijbIqStDnFooooAKKKKACiiigAooooAKKKKACiiigAryzxN8YrLQPEGuadcaNezW+jTW0N3dRyxcGdQUKoWDP15wD0r1OvKfEXwZ07WfFWs+IzqEtvrN3c2l1Z3KQqWsngTbgZPzq2BkHHQelAHR3PxE0TTjqzazdRWcFjex2IILyPLI8auqhAmd2G+6u7gZrI1b4xeGrCXQpo5zcaTqb3KNfKkg8loACwMe3cxyccCsnxp8Or8ebrGjyXN9rjazDq0fkeVEInWARHiQlWU7c4yDz145Z4A+Fl9aaX4duvEF55OqWE+oXEkMYVwxusjBYYGQDngYzQB1dn8T/AA7feJ9M0WynmuG1KzW8trmKB2idWbaBnHB9zgDGCQeKveKfiB4Z8K3xste1MWt0LcXZj8iSQiLcV3nap4yD9KwfCPwzbwtdeHJ9O1hmOlWD6bKstsCLiJpfMyMN8jZ4zzx2qj418C634i+JF7dWl2un6ReeGzpM915aysS05LoqlhglD97kCgDSPxa8PW/i/UdC1O4Sz+ztbJb3JLOlwZ13KflXCDkDJOOetas3xK8Iw3+pWUuuWyXWm7/tcbKwMWwqDnj1ZQMdScDODXP3XwjspLfXLeDUp4oNTSwjAMYYwraBQvOfm3BRnpU+o/Cqx1Hw/wCLNKutQuPL1/UzqhkRADA/yEKM5DAFB165PSgDWl+JfhKLTlvp9WEMDXQssS28qSLMV3hGjK71JUZGQM9qrp8R9DvLjQm028tbjT9VW4dLppGj2CFcv8pXtzncVx71jWHwot7VtMke+to5rLVYdUJtLIQrKY0ZArAux53Zzn6AVmSfCLT47SztrjVLiWCBtS3hYwpdbxSrDOTjaDweaBpXOw0PxroniYT/ANhXpulhCszeTJGCrZAZSygMDtPK5HFcu/xD8O32tDSbPVEfUGeSIReW65dM713FcZGDxmpNBsb/AMO6ZDp11qy39pawR21qv2YRMiIMDcQTuONozwOOnNcKfCUNvd6dOt9IzWOo3OoKpjHzGbOV68Yz1rKUkdVOnLodrfXokBGea529nIJql5NwdIW0u7+ee527XukAidjnqNvAP0rDl0VD11TWPxvGrBs7oxa2RsNcHODyKrSMQdynisSTQ1B/5CWq/wDgW1MGir0/tLVcf9fbVOhqr9jcaTIz370iuOQehrBbRFB/5COq/wDgU1N/sZc/8hHVP/ApqNA17GuzbW610XhLU0guWtpz+5uOOegb/wCv0/KuCl0VT01HVP8AwKamJpC9P7R1T/wKasqtKNSLixSTkrWO08Q6a2nXhRQfIk+aJv6fhWOrbWFbXhIWt1HLZ6pf6hcTuNqG6uTIvsVz0b+dQa3od3pzs5Qy2/aRBx+I7VhSrcr9lUeq/EmE7e7LczpOHBHQ1DK23J/GnA7ovpUDnLkeorrNkTo3zAVZU8VRRv3q+4q4p45oAkpydadbW090cW8Mkv8Aurkfn0qz9mhts/a7gNJ/zygIYj6t0H61lKrGLtfUTmloRRgswVQWY9ABkmrCqyA8gN7HOKYZyUKRIsMZ4IUklv8AeJ5P06e1Ep2wbR1bgULnlvovxFqyuF2RM6jMjdCfU9KgbH2pEXoi4/z+VWpD8yr2HzVStjvupn9PlH+fxq0raItKw24fE7egVsf+O/8A16xPCD/8VvYH1uCP5itKSTfFLIeu5gD7Z/8ArVi+EG/4rHTj/wBPQ/nU1f4cvRmVTY774lr/AKdYN6xsPyI/xrD0yHc3mMPlTp7mug+JWWudNVRliJAP/HazLaMRIqDoo6+p71jhP4K/rqFH4ETsajzxQ7cfWkJ4rpNRjyiNt5GQvUeo7j8RTbhfs6gZ3KV3K394VFKdzqvqc/gP8ip7a7SM+RcxCe3Zslc4Kn+8p7H9DWc04vmiS7rVDIxtRR6CmufmA/GtgaVFdjdpd3HL6xTHZIP8aaPDt/uLTeRAn955BgflUfWafV2J9pHuY7NXSaJoixRm+1cCOFBuWN/5t/hVjStLsoLea5t50nniVitxKv7lHA4OMjOPr+Irjtc1fxJqRERudJECMcBLaVd/uQZKwdSWIfJT0XVmcqjm+WJta9rD6lNtjylqn3V6bj6msoGsXZruP+PjS/8AwHk/+Lpduvf8/Gl/+A8n/wAXXZTpRpx5YmkfdVkjazTg1Ye3Xv8An40v/wAB5P8A4ul269/z8aX/AOA8n/xdXYfN5HQI1XLabBHNcqo17P8Ax86X/wCA8n/xdTRjX88XOlf+A8n/AMXTsJvyPRdLu9pHNdXpviCxj1a20uS6Rb+eNpYoDncyL1I+leYaHNfIh/tGS2eTd8pgRkAHuCx5qPVI9ai8f6Lr2kaYNRitbOa3eP7SkJy5GOWrWDOWvHS9j6HtZdyisWw8d+G768ktbfVIzKl2LAFo3RJJzu/dozAK5+Rs7ScY5rxY+EfEmpfEH+2L2C7kjlu7a5gmt7yJfskYUB4G3DdtHzAhOHznrSN8Ibq38M6KyeHre8vLLxDNe3Fqt0qtNZsz4UMW25x5fGQeK6EebJWZ9JA1n3Gs2FvrlppEs4XUbqGSeGHax3ohUMc4wMbl6nvXmvxzt3uX8EW6adLqCPqu2Sxjm8rzl8iT5C2QAPqcVydh8JNbutH0W0161E8drpmpxrCL0n7NJLIrW8W7cCwXHXkAj6UyT6Horw/wj8Ntck1yyvfE3nLLZ6DZwW8wvWIjvoi3zsqth9uQfmBBrk7L4X+ME8M61ZrY3sOq3Glm0kk+3weRdzCVGD/KA5bAY73IIzjmgD6O1fVbTSIIpr5pFSWVIFMcLynexwMhASB7ngdzV6vBb34aa9ZazrkWg2zx6NPq+kX1tGbwtxED9pb5mJyTjOfvV0PgTwpqmk+Nru71zRDd3r3lzOPEH2/O6BwfLj8rOeAQu3G0YyKAPWc0V4b46+HGuaz4n8W6xaW7m5kk06XR5VvDHsaMjzW2hgAcA9R9K9d0a51Se61NNU0+O0ghuClpIkwkM8WB85A+6c5GPagDVooooAKKKKACiiigAooooAKKKKACkY0tRSNgGgCG4kCg1zerXm0HmtHU7oIp5ridXvT83NZTkdNGncqalfbiQxrnLuchyQeKfe3G49ayppiQRXO2elCFh88ufmU81VkcOOeDTWaoWNSa2sDNxioyaCaYxpDFZs0wmkLVGWoAcTUMnB3Cn5pHyQRTATdyCK6DTfE9/ZgLI4uYh/DL1x7N1/PNc2p6r+VSqcrWc6caitJClFS3OxTXNDvDm800xyHqVUEfmMH9KZIPCTsCWkjb0Hm1yUB5x6Gi5HzA1h9Uivhk18zP2SWzOtin8JW7jZG8r9BuVz/PitK11jw+rBVgSEnoWg/wzXngGJ/xq3IfmWk8HGS1kwdFPds77V7FtWgMmm325AMeSH/dn8uh+ufwrj3jeGQxyoUdTgqwwRUVveT2d3BLbSNGR94joR2BHeupuFh8S2ZaECLU4Vztzww9Pp/Ks4Xwzs9Y/kSr09HsYMQyRSud83+yv8/8/wA6ZE5RZBIpWRCVZT1B9KcqkR9fmPf3rvvdaHQRTNtikcnr0+lUoH8mxklbg4LfjU2psBEsQ/iOKpao222jhHVuT9B/kUB0IiMWrj0JrG8KHHirTj/09p/6GK3XX9w9YfhZc+KbAf8AT2n/AKGKmp8EvQymem+OFU39g7fwLJj/AMdrFUlU569TWt4+P/Ew01f7xfP/AI7WQ7bQSa58H/CQ6PwIbu3P7CkdsCo4z8m49+aiEobewOQpI/L/AOvXUaCj77t6DaKYp+cnsBj/AD+lITtjAJ9yaaMhAD1PJpiJQ3BZulXNG06XVb1IAWEa/NK/90f4+lUCrO0cMalndgoUdTW/rNz/AGBpCaTauP7Ruhvndf4FP+cD8TXNXm1aEfif9XIm+i3IvEGtRzt/Z2mYWwg+Ulejkf0H61iZ5qFAI0AHQU4Hj3NaUqapx5UOMVFWRNupA1RFuaA1aFE26gGot1G6gCcNUitVUNTg9AGnBLgjmtzTbray81yscmK0rK4ww5qkyJRuen6Le5A5rsLGYMo5ryvR7zBHNd3pF3uUc10QkedWgdUuGwSAcdKkFVbdwwFWRWxxtC0UUUCCiiigAooooAKKKKACiiigAoor538dfFPxTpPxG8Q6Rpd7a7bK9sLWxsZdPLJcmeMM6vcbgIyOSM9e3Q0AfRFFeT33xLuNH1fV7L7Hc6pfvrcOk2Np5kcKB3gWQ/vNvCjJ5bJz7dMS8+LWuX174UutD0h9l1PqUF1pZnizK1uvH71h8oBBPH60Ae50hryXwt8TdV8T+MfD8Ol6Og0PU9I+3uZJlEsR83Yze4UgjHfrx0rS8e/E5vDOtX+m2Ohy6o+m6YdVvpPtKwLFDkgBcgl2ODwKAPR2OBVG9mCKa86v/iyLbUtZhPh69ksNHtYry9vY548RI8JlA2EhmbOFAGfUkCufk+Lj3mlXdzNojWjIkEkAmutsc4lJG0OyD5xjlQGznjNJlwV2dprl9jdg1xOoXRYnmuH1f4k6nqDaM+maUENxfTWdxBLMAdyLnCsQMZ65I7YxVD/hPUu9Qkig064e1WSWITgn7yAkkjGApIwDn8K55Js9Ck4o6y4lLGqbtWR4e1yXWtN+3Pp81pA6B4t0iuZAQc4A6dO+M1zw8dodOvrttPZPswU+Q04EvzOE+ZSMr1z3HvWXKzq9pFJNnZsaYxrkJfE9zPd29ssDWVxFqUdrcRsyyBkZSeGx3xSx+Mkee4R7P5UglnjkimEiyCPqMgYz9M0+Vh7WPc6pjUbGuTHjaNLa6lvNPngMVvFcxoJFcyLIQF6dOSKj1fXdXttQ0tP7PMbSmbfaiZG8wKgIIfHHU/lS5GL20bXOtY0yuTl8Y5s4bi102WdXszeuPNVdihipHPXGO1K/ihYJr2UpNNGFtfIg+UZaUEgZ7dOck0+Rj9tDudYKcDmsuXUZrbRbq+vbMwyW8byNCJA2Qozww9fpVbQteOo3ckNxZtZt9njuULSqwdHzg8dOnSlZ7lc6ukbEi4IIp6fe9jTbq4t7aHddzxQqTgNK4UE/jVNNY0zZ/wAhGyyP+m6f41NmVdLcugeXN7GppxlKzbjWNLMYZdSssj/pun+NPGs6W0fOpWXT/nun+NOzFzLuWD/rVPtVp+WSsf8AtjTNy/8AEysvT/Xr/jVlta0rcv8AxMrHp/z3T/GizHzR7mzPaH+wJ73+5NGB+YH9TUun3EttcpPC2JEOR6fQ+1WRfWN78PL1bK8triSIrI6xSq5X94MEgHjpWfasBFuJ4xmuTDrmU1LuzOnaSfqb/iKKO7totZtFwMhblPQ9Afw/listZAxGORV3w1eLDcPFdAG2uvkdW6Anp/hVG/tjpF5dWzklE+eMnuh6f4fhRRbpydF/L0HD3XyMz5282/x/Cn86oSSm6vp/7ka7R9e/+fanySmC1llPLnp7k0zSIiIFLcs6Ek+prqNGXZlxHKPof0/+tWJ4RTPjCxX/AKeVP65ropVz/wACT+X/AOusnwfF/wAVzZjHSQt+Smoqu1OXozKpsdp46OdV032Mn/stYF1ISwjXvxWv4zlDavZr3RXb8yP8KxIvnmeQ9BwP8/lWOD/gr+uo6PwImfOML16CoJIRbyNAMgBu/wCBrS0OL7Tq9sjDIMgJHsOf6VX8QFV8Q3aJ0XH8qbm/bqK7A5e+kUpTuYL2J5+n+f50gOXpq9Wf8BUlnC9zPFBEMySsFX8a6G0ldl7am94cjis4LrW70fubZdsQ/vN3x+gH1PpXNy3M19dTXt0czTNuPoo7AewFbXja4jSW00S0b/R7RQ0uP4nPTPv1P/Aq5932rx+Fc1BczdWXXb0M4K/vPqSbsn2FAfPNVy3RR+NaNhpV9fnNvAxT++3C/nW8pKKu2aFUvSKxP0rtLHwvb2kYe/ImlP8ADnCj/GrxhsEULFbxA+yCuKeYQi7JXA8/3Uhau/Ok2lwMtbxj/gIH8qE8OWQbPkKfrk1KzGH8rA4HfRvru7nw5YOP+PfYfVGIrD1TwvJEhksHLj+4/X8DWkMdSk7PQDER6tQS4IrLYvDIY5lZHHVWGDViGSu1O+wHVaZc4I5ruNEvPu815hZzbWHNdZo13grzWkWc1WF0etadPuUVqociuQ0a63Bea6m2fcorqizzKkbMtCikFLVGQUUUUAFFFFABRRRQAUUUUAFcxqXgPw3qb6y1/pUU7aw0LXpZmzK0QxGevylR0K4rp6KAOB8X/DXTdZ0W4stPjtbaa4u47yWa6ia53ukflg8uGDbQBuBB475NO8FfDHRfDejaRaSqb6605riSK5cFMNPnzMKDgAg4xzgCu8ooA5Wy8AeG7GXRpLLTvIfSEMVm0c0ilELbip+b5lzzhs1zPxW+FsXjzUIrh721swLb7LI5s/Mm2FiTtfcMdeAQQDyOa9PJqtcSbVNA0jlpfDui2I1Jo7GNm1GBLe78zLCdETYoYHjG3jpXmmreDfDUFnJaR2D/AGclCqNcyt5ew5XYS3yYz/DivR9dvdqsM159q12Wc81hOR20KSe5yl/4a0RrRbUWeIUnNyuJXDCQjBbdnOT9az38PaUL2S6S22SSMzsFkYKWIwTtBxk564rauJSSaqs1YOTO9U49iC1tLe0sY7O3jCW0aeWqZJwvpXPap4Q0+50u7tbUG3kuQitMzNIwVXDBRuPTjpXSFs00tSUminCLVmjLg0HTLZESG1ChJvtAJZiTJjAYknJ/Gq8HhnSLfd5VmFBR48eYxAV/vKBngH2rZJzTSad2HJHsZj6FpjK6taIyvAtswYkgxr0X8PXrTIdC063eFo4DviLMjNIzEFgFPJPoAK1aZIOVPoaLsOSPYy49A02ODyUtVEfkG227j/qyclevqaV9B0x4pontEZJkjjcEnkIMJ34x6itSkzzgck9KXMw5I9inFpVnFp0lisRNtKGV1Z2YsG65JOajuNC02aJ0ktgytCkBG48xocqvXtXVadoU9xhrgmJT2A5rZi8M2m3DtLn/AHq5J4+lB2vf0Hyrsce8cToodEdB2YZFQ/Y7ZZcfZ4cN/sCtvXdGbTIjLFIZIAcMCOVz/SsZZd8e4cspranVjVjzRY9ByWNsVZTbw/8AfAqO2tLfDobeHg/3BVxGBZWHQ1EfkvPZhWg7IqPaW4x/o8PB/uCpRbWpGfs8PAI+4O1OuOA3sc0kTg717gkf5/Oi4rI662tIW8A6okEUaMEkyVUAnA3VzNo2+zgXuwGfpXZeE1+0aXqVof4x/wChKR/SuJ0f/U5b+D5RXJh9KlReZnT0ckX5DyEFa/iGJtT8OW98p3T2jeXMR1ZeOv8A46fxNY8RG9pG6KM/5/z3rU8IXH2iTUbKbmK6iJx7jjj8D+lViVZKot0OpouZdDjbmQXFzHBGcqnLfWtnTYR9niPoo/lWHodu4urhZf8AWLIQfwNdRaJshQegxXSnfY0I5Fzbxt6Y/wAP61X8HW+fGyyY4jhd/wBMf1q6V3QMp9xVzwZbf6dqF2RykIQf8COf/ZawxUuWlIyrfCZ3iiXfruM/ciA/Un+tU0ylsv8Aebk/jUesyefr91g91T9AKllOZkWjDq1KPoXTVoo6HwdFi8nuD92CI/mf/rA1w1/4l0iXVL2b+0rU7nwp8wduK9C0nFl4ZubluPOYn/gK8f41xalick/MSWP1NY0Gp15y7aGMbym2jNbxDo4QKupWuP8AroK1vDfibQbOW51G41OzP2WMmKPzRl3I4x/nvUKybgz54BwK2PEsh0/RNN0ZDiWf/Sbj8eg/z6VvXadqfcqfM7RvuceviPTJHlnn1K2aaZi7nzByTUT+INKLf8hC2wP+mgrZbJIRASegArvfC/hKK3t47nUU824b5tjcqn4dzTq1YUY6op3XX+vvOQ8K3fhv5bvVdZ08E8rC0w/8e/wrY+IHidtO07QZ9Cu4vLu9RghZ0CsrxNnIH145FdfqmoNCpSPr0yKwL/QrLWoBFq9rFeR7g+yUZAPr+prx6mJjOopSQnGUluc14w8a3tnrMWl6bpk2oXbWxuiqBz8gbaANisckjqcAcc81y2t+IvEkd54jvrJvstvpllBNHA7D5fMXOXUodzcnjIxjvXpo8D+HZLSC1fRrMxRMxjUJjZu+9gjnmttPDOkBLqNtPtmS7iWGdSgxIijCqR6AcCnTqUYWfLf19V59iJRnLrYxtX1248O+CJNb1SzRrmJFJt4ZcqWZgq/MQOOQSccVkTeP7+0iu47rSLZ723v7Sx8uC73I5nUkEMVHTgdK7Wbw7Yt4bk0S0ijtbJozGqLGsiqCcn5XBU856g1meGPh/ouh2txF5S3ZmuY7smSKNFV4xhCqIqquOT0zknNVTdFRfMtbikp30Zzt7491GHXZdLTw7PcS2Qh+3fZzJL5ZkAJ2lU2kKDnLFc4OKpN46ubjxDJpltYxSwStdRWt2kknltJCCSCWQA9s7S2PevRtT8K6FquoR32o6VaXF4mAJnj+bAOQD6ge+ahh8IaBa6m2oW2k2kV6XeTzljAbc4wx/HvTboNfDrb8fvFapfc8UfxLf3vhjw+bzTxc61qYleGSAOwMceMllRCc5OMAEDGc1SsNfu5tWisTpzQv5KzTCZ9rRZYgjGOSMV7HdeB/D32I2g0ez+zCUziMJgK5ABYenQdK4jxToNnpV3BdWFpFApjEH7tcYC8gV14bE0+b2aVr3KjGp1Zz+u+J5dGvYIxaA27qGe5kLBFJbG3KqcH64Faem+NriLVreJ7CP7DJqf8AZnmrNl9/ZtuOnrzVBtP0+9uUnvLSGaVAAGcZ4ByB781oaHoOm2epS3/kJLeSTvOJpFBaMtjIX/Oea9JOIpxm3voW9A+Keo6L4O0q5kgTV742013cqzOsgjSRl3fJGVAwMZYgcV6BqnxfvNMuNQe10KK50zTo9PmuZXu9kgS6HG1NpBIPuKwdN8M+HbyO2iutHspY4UaONWjyFVjkj6ZJP1r0rTvDmg3cFzHcaVaSJdJDHOrJkSLF/qwf93tW8ZJnBVpyW5Tu/Hes6pZ+KZtH061g0rSzd2RvJbvbcCeKFm3LFtII3YwC2cc4rnNN+MGsaT4ZuTr2jRTXtnoFvrEUqXeftSOyoS/yDYxJzgZr0x/BXhm71iXV59EsX1KVWSScxjc4ZChz6kqSueuDirNx4N8OXMTRz6NZSRtaLYFWjBBt1IKx/wC6CAcVqcp5prnxM1Vp7/S7/T30vUdN1jTLdzZXiyLJFdZK5Zo/QcjA9iK7HwZ4y1LxTqdxLb6Xaw6BHdz2S3El3/pBkiJBPlbcYJB43ZxzW/deE9Bu7u4urnSrSS4uJYJpZGTJd4eImPuuTj0ptr4P8PWniGTXbXSLOHV5Cxa6SMByWGGPpkjqepoA4Xxb8U7/AELxFr1nBoUNzp+iyWYu7g3ex9lxgAom05IJ9RXqNtd29y8yW9xFM8L+XKI3DGNv7rY6H2NZl74W0S9lv5LvS7WZ7/y/tTOmTN5f3N3rtxxVzTdIsNMmvZbC0ht5L2Y3Fw0a4MshABZvU4AoAvUUUUAFFFFAAa+X/iL4u8TWfxL8WW1hrOr2dvZ3+mwW04lQWFmJYwX+0KQTtbBwRxnOTyK+n6pTaRp032vzrC0k+2bRc74VPnbeF38fNjtmgDx7XPiPqeh6nrMFmbHfN4gg0yO81GeQ2tsj2ySF2+bgdcBSo7/XD/4WJ4s8Q3Hgy80qfTYbye41WF4laT7HOIF+VmAYlhwSOepr2fxH4P07WtIfT1MmnRPKkrtYqkbOVXaA2VIIxgYI7D0o8MeDtF8NaPZ6fp9orx2pkaOW4Akl3SEl23EdWyc4xQB5f4N8f+IvE3jLwncyXem2Omapon2qWycNhpBPsbyzu+/xx1wOoJ5pfiZ411Dwv8QtYniM91ZWfhYXiWIciNpjdbN5A9AeT6A16xcaPpMYsyumWINlk2pECfuM9dnHy/hXM+IfspnknaCFp2j8kyFAWKZzsz1255x0qZOxpTjzM8Q1P4ma9Jpd3JJY2ckyTxJHLGB80bqxLCESsxI29A3I57Gua1L4gXZj02ZPsZtbiESSXIhkZdxkZdu3duQfL1IbJ6ZxXoup6ZpKwyW8emWCwM25o1t0Ck+pGOtYd1Y2LyxO1nbF4RtjYxLlB2A44rnlJdj0adKaWjOSg8YXtxrr26WkQtFuXt2DfK67QcNktzkj7u3p3NanhjU9Q1LR01DUI7SNZoxJEsLN0wc7t3StF7O0a6+0m1gNx/z1MY3fn1p8aRxRCKNFSNRgKoAAHpis209kbxhJPVnCx+N7/wDs2/nmgto7qBEdYDGwADSBc79xDDB6jH0qS61+/uLi1haWENFq9vA0tox8uVGUkrye3eujvtC0+70+ezFvHBFMVMhgRULYIIzx7VbSztY40jjtoFRG8xVWMABv7wHY+9VzR7EKnPZs42LxrdvczqiWs0H2aeeJ1Rk5jBPOWJIOPRae3i3UbWzuJby2tXb7FDeQiEsABI23Dk+nXiusXT7FGZks7ZWbO4iJRnPXPHepBbW4ziCLlBH9wfdHRfp7UuaPYpU5/wAxyV7qOrvquhxW95p8k8r3APkM3ktiJSN4yTkZJ6+nSq8vi/UZrGCa1t7MFtOa+kEm44KsQQuD7cZrsobO0t9nkWsEewkpsjA2k8HH1qM2tqBtW2hC7DHgIMbT1X6e1HMuwezl0f8AWhylz4ouLeS9njiUlorMoJJG8uMyg5LdgB7YzXqHhuCa08I6lrV21hd3drBNMhgJaLKIWAPOQeOea0fBnhW3lge5urSFhMgTY0YIKDoCO/0rtYdNsrCy+yW1pbw2bAq0KRhUIPX5RxzXmYrEqfuRWi/ELSW7PN/DPjG+m1aW38R/2VZWv9mQ6ms8LMixpIQNrlzjOT1rudTuoNNtTPMlxKmQMW8Dzsc/7KAn8cVJd6bYOGD2VqwaMQkGJTlB0U8fdHp0p6tzjtXnVZQcrpWKgpJaswW8V6YyFWstbKngg6Ld4I/79V5vrmoW9jqUslvZ6slhIf3bSabcIAfT5kFezswKms2SOK/triyuF3I4P4fStaGJjRlotH5/8AdpdzyK28Q2u3aYdR+U8YsJzx/3xU1zr1qRG4g1LIOedPnH/slS3MEumarLaT9R0b+8Ox/nWgf3lnXuJxkroa5u5j3Wu2pR8QalyO+nzj/2Sr8c0U9rYXcEd2itI8UpntpIRknK4LqN3fpnFSStvtyfVa6mztxrHgaa3jGbi1fzEHfI5H5jIrnrzUOWXmTNuLTZa8FTBNUmhz9+Ld+II/xNc3cQ/YdRvrboFlbH0z/hU3hW+26/p7Z4ZjG34ggfqRWh41tfJ8QxTY+SdQT9Rwf5Cs0+XEtd0C0qW7mPcEpbqn8TctUnh268jxRp0a/xMVb6FSP5kVFcn5yx6CqfhpjN4gt7gdBcxhfpuFdFVXpy9Cp6xaL9xCtt4ovkHAaQn8+f61ejO0sD0z/X/wCvVbxCPL8VSP2Zx/IVM33z6Nx+n/1qVB3px9Bw+FEv98ehzXS+H7UW+gTSEYMzF/w6D/PvXOWyPc3MUUQ/eTYQZ9f85/Ku31QpbaRMI+EijwB6ACuTMJ2ioIxry0UTyKCTztYuZCc7p3b8Mmr0ZL3Lkc4GAB3rD0WXcwc9SCT9cius8I2/2rVI2Yfu42Mz/Ren64rsb9lTv2Rq3yxubHiuRbPSrfT0I+VQp/r/AJ965extXu5TGg6AsT6AdTVzxHcm61N+c44FS29tbr4Z1Se9hSWKRRCqsOCep/XbXFSvSw/N1l+pkrwp36soaJZrfaxbWigeUZCzgdAg5P6cfjVTVb06nrt5escpu2x+yjgfpUeheGdGg0DU9RudOt2YKIYdy/xt1I+gwai07wtolnpX9p6jp9uUfK28TD/WN6n2FbqUYyb3tovUalJO9vI67wRojXGoi6u1xFCNwVupJ6E1315cLFHgEACuP0DwN4fTR4Xu9ItHuJB5jll6Z5x+FUtV8MeHEO2PR7QMfRa8+vVTbcn+H/BBKcnqaErNdXRI+6Dmtm2QELXH2fg7QMfPpNqT/u10mg6HpukNI2m2cVsZQA5jGM46fzriShum/u/4JreXVEXizXz4bj0eX7KLn7dqMNhjzNmzzCfn6HOMdP1qx4m8Y6L4auEh1S4kWZozMUihaQpGDgu20HC+5pnjDw3D4osLO2lu7iza0u47yKWDaWWRM7fvAjvn8KyNS+HUOpXFreXmr3U+pQxtAbqe3gl8yMtuClGTbkHOCBmuumqLS536/oYy57vlMzXfip/Z+p60tnpcl3p2l20UzzBZQZjKMqVYIVVMHO5jz1Ga6bxJ4t/s34f3fiWztJGMMIkW3uUaFjlguCCAR19OarXPgHT7qHXLd7m52ava21rMRtGwQJtUrgYyep7fStLVfCkeqeDJvD2o39xOs0Yie62oshAYEcAbewHSrbo+7ZdVf00v+pK9prca3jvQY9dXSGu3N0ZltiwiYxLMw4jL427vbPXiqcfxH8OT2N3qEV1cf2faDL3JtZBE43bcI235juIGBzUI+HlhD4ml1i1uXhM1yt3LCYIpMyAg5V2UsgJHIB+mKo23wwsoH1CX+0pzcXkIhZxbQKpUOG+dAm1ySOSwpr2Ft30/4PQP3nY1bzx7oUWn211K14huXdIYGtJBM+0AsQmM7QCPm6c+tYOreINB1qe3061nkuJLyFLiBooHYBXJCsSBheQc5xjvTh8KdIhsLSKK7mW5tZ5Z0mMMTrmQKGXyipTb8owAODzWhp3hi00fVBfxXEss32JbIgqiqVVi27CgAHJ7cVnP2EVzRbuv67FQ9pfVHl2rahDo2qDT7sS/a8bvLjjZyFzgNwOlWLHxNYC/jtGklDtObcMYmCeZ/d3Yxn8asfFrQ7bUtVsp5JyH8va0aquQFbIIbGRnJHXtXKaZpeL9p7+aTykvmvIoUwU3cbWPGcj0r2aFaFSmpPcpqrfRaHcaB49s7fQ7HUtWjmgWcMzGGF5EjCsRkkDjpXo9t8SfD2lXZtry5uAY/JMkkdtI8cYlGY2Zwu1Qfc14va+CtPvrS2gW+n8uKB7fICNlWYsTyDtbJ6jBr0Sx8DadqVrqdvLd3SrqEVnFIV25UW/3ccd+9dcXHoclWNS2p6ldfETS7catb2CXl5dWEU26SO0la2WaOMyGJpguwNgcjPfHXioND+MHh270CW+1N7mxuLTT4dQu4ZLSVcRvgbo9ygyKGOMjNVdO8CIJtUW01zUbbS9UaeW509BGY2kljKOwYruA53YzjIH0qbUfhFpOpWctvLqF8qyaJFoZK7MiKNw4fp97Kj29q3RwSVmWdQ+KelSW8n9kSbLq21G1sbmHUra4t2QTk7CF2bvmAJUkAepFdBpPjfR9X1yXS9N+23DxyPCbpLOX7N5iffQTbdhYYPGfbrWHq/wu0zVNb1PU5r68Sa/u9Pu3Rdu1WtAQgHHRs8/pitDwz4H/AOEb1iebTdav00mS4luv7LIjMSySZLHdt34ySQM4BpkjNb+JnhrRdcudK1C4u0ubWSGO4ZLOV4ofN+4XkClVByOSa7UHNcHr3w003WbrxLPPe3cba6bQzhNuI/s5BXbkd8c5zXT6LpUum3GpSy6leXovLk3CpcOCtuCAPLj9F4zj3oA1aKKKACkNLSUAKKKKKAA1G5wKearzvtU0DRm6pPsQ81574hvMs3NdTr91tVhmvNtbutztzWFRndh4GLfz5Y81lSPk1LcyZJ5qqxrnZ6EVYC1ITTSaKRQuaaWpGbFRrvkcJGrOx6BRkmgB++jcScAEn0Fb2keFb26kRrxHghJGePmP+Fd9Z+G9Pso1EEK7u7Hkn8a5amKjHSOrJckjzrSNAu9SIOPKj9WHJ/Cuv0/wXaQYabdK/q/QfhXUWdqkBIC4544q5s/OuKdapU3diXMrWkYggCKAMcU24IKkVMwwp3VSnAzxXPJ2VhLUqTtVUuQeKnnqox5rmkzVIkUswx0FQECK8QjgHipAeKZfECIMfz9KQzkvHWnm4mimgXM8eTgdWXjI/U1h2Lb7dhXVa/cwRy2cl3L5IkJCSZxg49ahOjJcr5tnIhduuPuv7jHQ/wCeK9LB4r2ceSe3RmTnyyszlYzmNl9CRXUeAr77PqCQNjZcx4/Ecj+Z/OseTRdSt5JA9jOVPIKJvH5jNS6dY6hCYZBazRyRgFS6FeRj1+ld1aVOdNrmRU3GUWri6jYtpXi+SOIHYZFlhH1OQPz4/Cut8cwiawt5kGSpOD7H/wCuBUHip40+wauUyoTaTjO0nkfrkfjUWn3Dah4Tlik/10THA9jyv65H4Vwe1lLlqW+G12c/O3aXY4rV7hltCFPzsNorR8J2+2/tBjpMh/UVnOguL1hjKJwPx6/0rrfC1sBqFsWHyqS5/BSf5gV6lV2pyfkbzdk2ZniBfN17I7ykflxVtoDwK5/V/EMSas5tIvtEqMxJPCg5NX/Cc2s67qyrK0ENjF887rH91fQEnqe1TTlGnSV+xqqM1S53okjqtCii063m1S7OFTKRDuT3I/kPqaiudTe88H6ncSKFf5l478cfzrJ1bXbHV9SfTbWXaIm8uJP4SB1Knv3/AJ1NrQ+x+B5Y+jTSNgewwP6VxVafOlUlu2rehySg7pz3Z53p7+WPoDXpnheNdP8ADMl5JxJOD17Iv+Jz+Qrz3QtNl1LVbeyhB3SkAn+6vcn6AV3vjW7jt7eKwtfljAEaqOyj/IrfGS5rUluy6ju+RHOITLK0jckkk/WtrxeDZ6VpuljhseZL9ep/U/pUfhiz+0anaxsuVDeY30Xnn9KZrDHVvFHlg5RpREPZQeT/ADoq29pGPSOo5fEl0RYNj59lpWlM/lxFGvbl+mxD3/Lj8a529vG8QeILUFfLsVkSGCEdFTIFdD4juwbO4aEhWvpTECO0EeAQPq38qpaLZR2N5YPccXM8q+XH3Vc9awhPlh7R7u9v1YoOyuz0TULlba3OOABgCucjzNIZH6npVzXXZjjnbmq9oOBXkTd3Y3ii7AnTFaUfCgCqsQwBVhKa0EyzGcc1ZRHcZJ2iq0Xarm8kY6CtY26ksYBsbd1p5NNbpVY3KKCGPSi4EzvgGq73ICZJrM1HVobeF3d1RB1ZjxXCar4xupmaPTkEcY4EjjLH3A6Cqp051X7pcYNncajq8NnG0lzIscY7k1xmr+NUYFdOgZ3/AL8owB+FcrcvcXsnmXUryv6selNWAAdK7aeDitZ6myppbla4eW6uHnuHZ5XOSxqMpVwx4pjLXatNi7EMDyQSB4mZWHcV3HhXxWsEyx6gMLwPNUdPqP8ACuJZcUikqcg4qoycdUZzpxmrSPqXw/dR3FvHJDIrxsMqynINdPC2QK+X/Bni690C5Xyn8y2Jy8Dn5W+noff+dfRXhrWrLW7BLmwlDr/Ep+8h9GHY13Uaqnp1PFxWGlSd+huinCmKadXQcQtAoooAKKKKACkFLQKACg0UhoARjgVm6hLtQ1elbArndauNsbc1MmXBXZyfiO7+9zXnupz7nNdH4guss3NcXeS5Y81yzZ6tGNkV5GyahJpryVC8wUZJAHvWZ0on3U1pABVJrtf4ct9BUTzO/RDj3NTzIrkk+ho2scl9dx28GN7nA9B716p4Y0G102IYUPLj5pCOTXlPh27Npq0LyKoVzsLZ+7k9a9utojsXDENivOxdSTmo9DOonHcvBB2Ap4Aquruo+bBHrTmdj04Fc90jGxMzAcDk0gbHeqhR0y4kJ9jTw5I5pc4+UdM2apzd6nkJxVaU8GsZu5pFFKbk1VkGGxVi456dars4PD8H1rFlgvIqC+Ja3IHQdanGMHHNNkTNuQepFSMxfFGnrqfhnYoHmR4dCexH+TXIaZEdKx52oCA/3InJJ/Cu1u5hDo90ZVLRopJA5471zEPh+3vbY3ui/v06vF1I+nf8DXdhajceSTtH0Mpuzsy5b+NIrOTaDeXGB92Rxg/oTVa/8XajqSN9ngS3QcZ6n8zWG8aLdjaoHB7VZjG20YjuWNelHCUo9LlKlBdDufDsL6t4LltLlvMuAGAJ9T8yn8/5Vy9rfy20Bjt1Z5Zh5YQDknPFdN4Qn+z34tyfkmj2/wDAgMj/ANmH41z+tW76frF3GjOsLN86r/FGecfrWahGM503s9R4eMPauFTZmdpMkb391GXXEfzs2QRk53YPcA963PDGq/bJtSnhG2ytYPLViOXZj1+mFNcNr2nzWszvaOTDKMqVPDD0NdP4czF4GmcKVmu5igXvgDaP1LVWJly0uX5HZjaEIxcl1sl5dzK0PSZb+4RLePdNO5xn9Sfauk8XX0HhzR10LSn3XUg3XUo68j/P0H1q3FcxeHNLC24Vr+VdoJ5x/wDW/nXB6osjySSSsXlclmZupNZqXtnf7K/E6qVP67Lm/wCXcfxf+Rz8m8TK0RYShgVK9Qe2K9S8cOYrex01nDTRwjfju2PmP5muP8F6d9v8U2SuuYom8+T0wvP6nA/GteaO48QeOXug5i0+xz9onPQL3H1PQU5zXtY32Wpz5ik6qj/Km/8AI6TwDpg07TrnVbhQGlXy4s9Qo6n8T/Kua1e6+3a25ByqHaP61o+I9Xu59NxYAx2hCsADgRxdE/E/yxXMaI0rSD7Su2Q/MRnPc0YaLqVHWl8jip4efI67PRPDwFlpOo6iRyqeVH9ep/XbWDoqssk1wuWl2+VF7u/H8s/nW9ryvaeHtN0yJSbif946jrk8n9SB+FQxRQeHraG71JsyplobZOWdz/Ef88e9YVanNzKO8nb5HLzXvbdhrOnW+mvHc6kwFlaQrHGmfmmbqePck/8A6qz/AIdLJrmu3uq3eD5WEiX+6T6fQfzrnvEuoXesz/aL07UAwkS9FFdr8J0SLw9cTEY3TNz+ArSVJ0qV5b7ehqo8q13NDX8CTA6A1FAAqgnpTdUkE90VXlc8062QHGckCvGk7yNlsaER4GetW4xVaMdM1ZT5VJq0JlqICpxwKjiXbEM9aJG2rmtNiSO6mEaE5rhPEXiRbK4MMKebPjJycKtbfiPVFs7SSViPlHyj1PYV5f8APcTPNMSzuSSa3w1FVXzS2RtThfVkl7dXWoyb7qQsOyjhR+FNSHFTxx+1TiOvTSUVZHQkVhHimslXCuBULCmOxTZahcVbkFV3FBLKzCmNUriomqiWIrYNdV4K8TXOg6pFcwMSAcSRk4Ei+h/oe1cmadG5VgRTV1qiWlJcr2PsHQdWtdb02K+sX3QvwQfvKR1UjsRWnXz18JvFf9j6n5Ny2LK6ISXJ+4egf+h9vpX0IpyODXo0antI36ngYqg6M7dOg4UUlLWpzBRRRQAUUUUABpp6UpprnigCrdPtU1xfiG5wrc11WoyYQ15z4pvEhilklcIijJJ7VlN6HTRjdnHa7cgFizAKMkknpXFNrlhdSOlneQXMi8lYZA5H5Go/GV3Prmm3tnYExiWMqrNwWJ/kK5dtM1a50BrWy0trK7jhWMSeYg3YZdyqQc4IB5OK5HJPZnqqEobrodFcXe14llkWIytsRe7HGcA/hS2ax3kSzwuJY2zhxznBxWNpPhvU1l09niuDFHfiZll2L5aeWwOAHbjJHGaqXHhzxA/h+wtWtJTcxwTkyLMC6yGQlQTvAAxjn5vSo5E/tGiqyjqof1odgtqfSni29qxbXSL8awk2q2d5dHZbeRJFchVhKgeZuG4Z5yTwc1nfEpmtr1JJpv8ARjZSiGJbkRMJuz4yC3bgZ+lSqd3a5pKs4wcmtjqpLbjpXX+F/GUliI7XVtzwjhZ+pUejeo968cvdI125GnyW9rMrw29oVlWXDMQB5gbLjBHPG05q5PoOpf2ol4iT+YNXLk+f8v2Ujk7c4xntjNTOhGSs2RKbno4M+lJr+1+wveefH9mRDI0gb5QoGSc+mKi0rWbG/kRLW6jmLwpcJsOcxt91voa+UNCutQjvktLOeSa6a1u0utt15schZCoJAbC9ccgV3GnDXr3R307T2ltrldGsbNYhcBDI0bnzVQ5wGKcZ4+tctTB8ju5HIpSaulofRMnzHANM7146/hfXbhIIrW11Gz0Vtdtp1tXvv3sNqImWYlg5IUsQdoYnvius8AaXrem+Dp7C5lMF5HdzfZnum+0bYd+UzhskbffIrnqUopXUgjNt2sdpIaqueDWLJa+KAP8AkMaUSf8AqHP/APHagez8TYx/a+l/+C9//jtc7iv5l+P+Rqn5GrLzmq0i7qyXtfEoJzq2mf8AgA//AMdqL7L4k/6C2mf+AD//AB2s3BfzL8f8ilJ9jajG0gVNLzGfpXPG18Sbh/xNdM/8AH/+O082viTB/wCJtpn/AIAP/wDHaXIv5l+P+Q+Z9i4yo2nXizEBTGwOTjsa5Xw7Ztp90j6dfeXL0IZ0dWHowBBxU2pWHiCfTNRibU9PYGFsgWTAng9D5nFeY29lqDQsRd2wwP8An3b/AOLrvwlB1INRn+BnO8j2vxN4bS8X+0LBAt0ozJEnIf1x7/zri40PlhGBB3kEEdPmxVLw7q/iTT3hjXVbZ7dsDElqz7B7fOPyzXYXnh3WNVlW7TWNLWRgGDJYMFk7gn97XTCTw75Kr06bkRnKnpJaDUka3lSaP78bBl+o5rX8SWsc3iLRpF+aO5cIT6gc/wAjXNS6L4jw3/E10ggE5It2GPzkroPDEWt3lnEo1nR3a1fYhfTmYggdQfNHY0q84TknCS6kVKi3RmxeFLufVL23VSmnpJ+7LDp649q1X0SztYYrfzpTJF8yjPy5+lbM+oarYSONSv7C7jKkKltZtCQ3qSZG468Yrh/EmtPE7pHn7TKvB/uDpn61xVVKclTTuVGdbEtQbuTi0tTM7398HuSOYoQJHA9Cei1Q1WLSrUI1xZ37xv0fzFH8hTPCkA+zXc7DjIUE98f/AK6j1DWlh024tLiPdIMiKTGcZPX8P6V3KjZWcn+R9TSwsuSzm9O2i/A67wLc+GJwYtPjEVy67HLD58Z6En3HbiovFXhm5eRLeC4WHSRJvlihXbuXqcn1rzHwbqcel6wXuW2LIwCv/CD6fT3r1jU/EV1JaounrZ+aTh/tW7aVx221x1o8k7fifOYyEsPXbTb83qec3t7favcTW9pA6Way7W2JzjoMj2GOK6Dw/oVol/aRFGd3kUPHu7DqTjpwOn6Cobmz125kJt5NFhV+Sq+aBn1PrUnh3S/Eul3V5qUlxo9wIYSAX8wBc9cADrgEfjT9pKStzJJfiZVcVKpFRWiXQ1tc8SWsHiGZ2jkuJIj5aInA465J96pz+IEuLiOSfQ7dmn+bMkpY4x9PesGHRtdmczTXOiRyOSx3u45Na0DXuntvku/Db3SDAYtLIUHsADjpWsIUYxvH3mQnBLRNsvT3NuLfzZ9FtbNF5EkjqM/QMhrZ8KXIvdCaaPPltKwB46DjjgfyrzDXL26vLgyaje2d4c8BFlVfyIFdz4ZXXx4agawTQxalSyAtNnk1lVovl5n/AMAqGju0y9Kv+lnb0NXoI8DpXPRp4leZjt0bOfWWroHicD7uifnL/hXCqXmjo5/I30FTYyAK5tT4ozwuifnLVmA+KcnCaH9SZapU/NC5vI6oMNvHSqN7cBFOOTWMr+KlTG3QvzmrE17UvEVjaPJKNF9AFMuSav2bk7Jq4k9djH8XXbXWpiDdlIxkgdmP/wBbFUIYuBWRCmuSytK39ns7HcSS/JrQji1zHC6Z+clevTpezio3OyLsrWNBI6gvtRsNPZFvry2tmf7ollCk/TNS2Eep+d/pwshFj/liX3Z/GsS/sbyz8VXWorprajb3NskKBGQNEVJyMMRwc5yK0STeoTm0rpG98rxq6MGRhkMpyCPWs2PUbOdoxDcRuZGZU2nO4r94fhXNXmjazJr/ANoKTwxCSF4PIZSsSADdGcuMDOc/Kc1XtdG1m1isdls37t713jMwVTvz5ecHufy9qrkjbcy9tO/w/wBXOxkFVnFcTBo2vJZX6wpNAZ4Yj5fmhfmDHeqne2OO5IzXRW9u0Oh3UdpBNZOVfyxPJvKtt4OcnAz70Sgl1KhVlLeNi64qBhXBaUZ7hruPTommZbFVdTc+YrS7xk7g2MkZOMirkGj6p5YgdZxb/bo5MeaFIi2/N0Y457Zq3SS3ZisQ5K6j/X3HXEVWnvbeCRo5pkR1TzCpPIXOM/nXI31vPp0douoMws0mnIia6CMy/wAByW5x6ZzSR6dqVxp8M0UchkbTPKDFwG3l845Oenemqa3uQ8RK9lHU9D0y42SKwOVNfSvws13+1vDywTS77q0xG2epT+E/zH4V8aXGnaq+ovJGsxlMkJgmE2EjQD5wRn69jmu9+Ftnqlj470DUEkuox/asqXR+0nYbZwQoK7sYyR2yKujaEr3MsU3Vptcux9h0tIKWu48YKKKKACiig0AJUUpwKlNQTnCmgaMDXrqO3t5ZZnVIkUszMcAAd6+ePFOuza/esEylkjfIndv9pvf+Vdh8XPEjXt+2kWUn+jQn9+yn/WP/AHfoP5/SuK06z3MCRXn16l3yo9zBYfljzy3G2FhuwSK3LezVB0qeCJY1HFOeT0rmPRsRsFUcVExp55pNtIZERmmPErYLAEjpkdKnxSGgLFZlqFlqy9QPQBWaJRnCgE9cCqUn7mdJF4KMGH4VotVK9XigTR7Rpsi3GnRyddyg1XbzY5iqMAvXmuS8C+IQ9qNPnyZYhwfVa7NjvG7HAryqkeV8vY89xcXZkZdgcsQaY785qQsCO1VZcAnHSsGUiKRuajzjrQx5phas7lDi1I0m089DTCeKVVDDkUAQIym4K9Q4wa8luITbXN7b4JMbuoH0Jr1mZBHOjLwDXEa74hmsNQvYraGMSI3+sYZJzXdgKk4ycYK9yJtrYZomgapeCFo7R1QdXk+QdPeu80LR7qyglt7i8haNyW8tckrznIORiub02S8SzF94gvZY4iMrBvKlvqB/Kqo8SSysyaRbCFM4LhQWb610TdXEPkVrfh95i+epojqtX0uCXPmSJK4H35E+b8SpGao6BCovri1tZ48hBKhjA4YHB7nsa5q7Go3ChrqdiOeC2aveAkdPEkiq3P2d+v4VM8FKnTcnLboTKlyx1Yur6peT332eZlVfnB2DGSpqhd6Tcarq3+ij/RwiBpT90HHP1NXvFwjg/wCJgYGkSRTKI1Yj5wQrrn2OTVLR/FfnwNEu5Sg5gb7wHqp7j2/ybwtNWVQ9nLcOpQjUW+vz1NDU2h0nTRaWp4A5JPJPc1g2yNeRtnmsbV9WkvrgqjE5OABWh4X1GMTGBjx2bPDeuK6nqz6CDVNGBq1u0bSRkfMp3L71u+C9b8yUafckskoxExPKN6fQ1v8AiHRYbqA3UYG0DJIrgA8cGqxR2qgzrIMzZ+62e309TU1KXtIuLOLFU4YiDT6/maHiu/1axvXge9mVAwKFPkyp+mK7z7RdaZ8N7IzSNJd3jCQmQknBORn/AICorFutDm8TXOhPMmyPBe7kxgKgwTn9QK0PiJqKS3GmW0I2xiHzgnoDwo/IH865qajUUKdl5/I+WqNS5Ul6kOmeIYpHjj1WxRkB4dRnH9R+db+oWOiMIri1htmFwuQ8k8ihz6Bs4yPQ1x2mqr43DPU/oals57jTVdYkSe2dyZLeUZRuf0PuK3qYTl1pO3kN0/5dC1qWlaYMi7t7+yY/dkRhNF+eM/rXZ+ClRPDUUUciyqhZdy9DzXHRxQ3gDaFqLWVwetjcSbcn0Rjw34810HgC4uo4r201NTHMkmQGXbkEf/Wrkrc7jZvbp1/r5gr3s2bkSYuXParDCq0jeXc5z8pqwTkZFecbCL1qzG3y4Xk1U5zjtVmMhVwKaAjvpltrcszYUDJJ7CvLtS1CbV7ze+VhU4RPQev1rufGTkaLcbT2x+ZxXB2CdOK9DBQTvM2pR6ly1hwBxV5IsClt4+KshcCu46CvtxUbirTCoJKAKkgqtJVqWq0lAFWQVXcVakqu4piKpQKMKAB7VGwqw4qFqaJZXkVSPmAP1FRnrUrmoGPNUZskj610/hokTqASPeuYi+8K6bw9xcJ9apIzk9D6k0+f7VZW8/8Az1jV/wAxmrIrG8Jyb/D9kT2Tb+RIrYFenF3R87JWk0LRRRTJCg9KKDQA09K434k+If7C0UiBsXtzlIf9n1b8M/ma7FyFUknAA618/fELV21jWpZsnyU/dxD0Uf49axrT5Y6HVhKXtJ67I41IzJMS2SScknvW9ZxCNBxWfaRgtmtFn2pivNZ9FHYkkk7CmDmqV5dx2lpPczttihQyMfYDNcL4a8fvJper3OrGGV7WJbqNLfGfLY4CH3BwCf8Aapxg5K6JnWhBqMup6T2pCa42bxncWxube60vF/BLbx+THOGVxMcKQxA59j+dV5/EmsreaxFcWUVvFaWK3B2TBpI2Kseu0huVx7e9Hs5C+sQ/pf12O3JqNmrldL8R3l/PFb2dj9oEUFvJdTSTBCPMXPAAwSBknpVBPHDG3juZdOKW1zBPPasJgWfygSQwx8uce9Hs5B9Yhbc7RzULGuQuPGVxFa2LyaUyS3qNLChlLZQKpydqkjJbAGPriobvxrOkUkkOkuVhtEu5lll2MiliCMEdRin7KQvrNNdfzOxNQXC5Fc9deKhDrcNktukkMk0cBkSQlkZxxuG3A+m7NO0LWJpfDt3f6g5kMEs+dqgHajHAwPYUvZtK7KVaDfKv6salhdtpupw3AzhT8wHcd69p0i6jvLIOhDZHavmgeJ5JllNzZxW+LNbxC1xkFWbaATjg/nW74J+JV5YhLVNPM0zXiWiRmbYMsMjll6fUVz18NN++l6nLWqQkrpnt97utzkD5c1Bv3jIrhh8R7nVbOzgtdFU6pPPdwywvdBUj+z7d5D7ec7hjj1rmk8fX9ys93CWt7T/hH5NQWBNjMsqzbMhip7DoRj2rgeEqXMlWjY9aeo2NcRc+PHhurkLpzS6fYzQW13cmYBw8uMFUx8wG4Z5HtUdh47lutegspNKMdrNqFxpyXAnBPmRc5246Ee9ZPDVbXt/W5ftYbXO6Az1qxbqWGR0FZGq6i1gsQWxvbsyZH+jRh9uMdckev6UkXiNkhwNB1zP/AF7r/wDFVnCk5alSkload2uZIxXD6hBbWer6jq+p4MMTARR/32AGP1rbufEbmdT/AGHrQwO9uv8A8VXmfjnxBJeagYBp9/HGhBKPGAdx9efSurC0ZynyrS+/oROSasaMl7c61M9zdsdgyVQdAPQV0mjQrHCwVQACf5muH03VGWJE/s3UDlh0iHPP1rqdP1h47YA6PqxPqIFx/wChV7sIKKsloPnVrI1r77hHpUvgdlj1+7mkOI47c5PpllArn73XG2sTpOqqMd4V/wDiqk8Pa09vpd9O2j6q73k8cERWFcHByRnd1rLFXVJmU5LlOm8l9R/taxQDfbXIli3dCHHzL/P864TW9HOn3u5XFu0ZDfPn5Pxxgj9a9SstVjs7TfJ4c1/e53s32ZcE+v36w/GDw6rZzL5bKxQMqkYZTwdp/lXmQlOhbm2Zvg8wlRnZfC7f8OeYzBJ7uZLFTtkblyMcd8frWm+mtBbpt+R15Ujsa2dD0+EMgSGUyn+HYc1tX2gahNGWSzlKgegz+VdsqkV1Pp416K/iTWvmcrFrkgtTaXTbDnIYn5SQOM+nPP4VS8H6I+pavFBCjXD5+dlHyIPc+p6Vdu9ImUs10Ps0Q6tKMfkOpr1j4b3Wnaf4bi+zbTkkliMFjnkn3rOdeOyfzPPzLFxpQapO7el10+fcj1/S7m30aDTbEKoldEnkJwRGT82PfGa8v8cStJ4smfGItoSP6Lx/MV33jDW9bbUWGn2+nPajGxpLh1c8c5AQgc57157Kut+IrSQx2mmG8s5WVgty+5vw2dD9e1YYdqnU5tLHzdN21sWtH5APsf5Vbm449z/M1z2lza0qLttbDjI+adx/7JVu4l1zzDm004f9vL//ABFew0dSlqSahbLK8fZs9fwNdD4LN3HdodSkJtmOyIu3zE+g9RWGdM8RGFLq5s9PggByu64kDSeyjy8/pVi70/xPdIupX1rp1jaW2DFG906EAenyfqa4cROM/dTXr/kROqmemanBtTK9McVDaPuhFcpoPiPxBrNowis9IfyzsJe6kUn3x5dWkPii33N9h0gqT0+1yf8AxuvIqUZKT/zNFPTU6fvT9+F61zIufEzDIsdHx/1+Sf8AxumTXHigjmx0gL/1+Sf/ABuo9m+6+9D5kReNNTQQmyQ7pHwW/wBkZrC09MAZrH1fU2UXmo34RTEhd1RiV+UdASBnpXIeH/Fmoabp+qm/MtzcpbLeQrPGycnAZeQMqCR0969rDYdxp2Ru6saVlLqewQjipTXnU3jHVLZ7q2RdMuriK4tYkmj3iJhMDwfmJBGOue/Si61fW4dU8R299e2YFvpomEMQdfm8tzmM7gwOQMn8sda29kxvEx6f1v8A5HoLVBJXIab4kvbnUlskext4baC2Z/tJZpZ/MUE7DuHPOOc5NZlr42v5rSC5kisWW5trqdIYw2+AxdBJzzn6Cj2Ug+sQ/r7juZKqPXHXfirWIbfSPMtrLz9RjaZCgJVVCKQuGZfmyTnnp61V1DxZqscU0kVvZJ5FjHdyo+5ySzbSoKtj8aFSkDxMEdq9QPXK33iuePXorWBYJLZrmO3kBQhkLgH727k/8Bx71NoF/OPDl7dTNJcSQy3DAMxJIVmwufwxQ6bSuNV4ylyo3WqCTiuSh8V3JSUzy2DKtmtzugRm2MzAbCN3J59qjTxLqEimPybUXH21LXJB24Zc5wGPP4mq9lIj6zBnUyVXJ5rmm8R3hNtFJ9ihleWeOSaQN5Y8v0Gep+tZt3q91NF9qLsm/TPO8tHZVDb8ZGDmqVJmcsTA72HlhXT+Hh++WvLW8Q3NvdSKiQGKCSGIxtkyybwORz/Q11HhvxFqI13T4pIrM2Vzfy2OFDCQbAcNnOO3pVRpsynXjsfVvgi4zpawN1Xlfoa6YVyXg9dsC11imu2Gx5FVe8ySiiirMgoNFB6UAYPjW8+xeHrpg2GkHljHv1/TNfPGpzb525r2D4uagIrO3tQeTmRh+g/rXiE7lpCa4sRK8rHsYCFo37l62cBakeTNZ8TkAVYBzXIz1EJd20F9ay213GJYJBh0PRh6VHJo2mTPvlsYGbyTbn5eDGeqkdxTNTvV07Tbm8dC6wRtIVBwSAM4rI0fxfa3ksyXMLWYjtVvDI8iuojPqR0PseaaUrXREpU07S3NiDQNKgjKRWaANIkpJJYlk+6SSc8dqfeaRYXd09xcWyvM8RhdskbkORggHnqetUf+Eq0gQPK9y8YSRYnWSGRXVm+7lSueexxSL4o0p7FbyOaWSAuyZjt5GKlfvBlC5GM9xRae+oc1LbT8CdtB0szxTfZEEkSoispI4X7oODzj3zUMfh3SImkMdhEN6NGRkkBW+8AM4XOecYpll4ggv9ZSytAJIZLIXiThuGBcrjGPai68SaXb6gbKW5P2gOkbBY3YKzHCgsBgE+5o9/YL0rX0J7rR9PuYbaKa2UpbLthwSpjGAMAg5HAH5VGdD00xyobSMrLEIHySdyA5Cn8TTRr2nm+a0MsiTjfgPC6htn3trEYbHsTVa08VaNdiUwXqkRQ+exZGQCP+8MgZ/Ci0/ML0r9PwLDaFpn2v7T9kTz/MWXdk/fXo2M4z71JHYW1vZy21vEkcUm4lQMjLdTg/WsqfxXYG2eWyLzujxI8bI0ZAkYAH5h75pR4kskW4N04Qx3T2qrGHkZyoBPyhc557ZHvT5ZiU6S2sZtj4Ps7M3RuWW6E8YiKeUI0Cg56DvnBz7U5tKs7Zw0MCqwlEwOSTvHRs561cuvE+jxRRyNeApLGZUKxu2VBwTwOMGnXU0H2ZZzNGsLgFXZgFIPTmm3PdkRVJaRsdjP4M0/xHotp/Z8sNipeS4cm2WYl5AN5G4/KeO3HtU2neENI0q0WwmtROq2hsjJKfmkiJ3FTjsTzVb4d+JtMitWtbnUbOPy24LzqMqefX1zXY6tqWhTRBo9Y0wnH/AD9x/wCNePVVZXgm7JnO404yMmXw1os98t7Lp8LXIKNuyQGKfdJXOCR2JBxTl0DS4popY7KJXjuHu1PPEr/efr1NRQa7pYUq2qaflf8Ap5T/ABqZdf0dlIOq6f8A+BKf41zXq+f4lWh5GmCTIpPQVaSQDknisMa/pGMf2rp//gSn+NV313S5GKLrFgFPX/SE/wAahRl2Kuu5o3N6oeeQtlVXHHevI9ejn/taZ7kHfLJvB7Fe2PbFaHifxLZXOoJDpl/CsMDZMgmUb29evSuu8PyaL4o0hYtYvdOiuIm2Ry/aY0Y+4Gff6V6uGpVMMlUavf70ZVKiWvQ5XSlzNEvpk/5/Ou2hAjtlDYHFaEvgG30394t9Juxj5lBH6VVvrGGLab7UIoIvQDJP54rs+uUlo3qSqkWYk8M+qXS2tmm4k8nsB6k9hW7qC6fpUFpJeSmO2sATbw/xSyHrIR+ePzpIPFHh7SITBbLLJn7zhOW+prF1LxfplzfmSy0c3F6eBJcHIT6DmuSvKpXfwtRHGFSrNRhFnRalrsk9rE32nbE4GzIKk59utc5qEbG4FvLM8RZjudRnGMHn25q/oFrd6pfvf6o6stuvmMOir6AfUj9KrWoa4uJ7uTneSF+mck/nWEcO3OzfqddHL26ypN7avy7I7XwXaWunwme6vFvN/wBxw2VA9MVp65r9tFGRFtz2xXnsF5LaPLAgzblGlK/3WBA4+uafq0c1ram4lQMxUMqlvX1okpwvBL+mcuJwc6dVx3/4OxneIpbCWZbnUnlJbISKL7zn8eBWfp/iSK3XbY6cI7c84MxJPv061gXlxPc6j5tywLjgAdFHoKZo2GiZe6sR+tdEMMuW09T3cPl69nGFdt+V9Ed4LgXdi97bLLOqAkxLywI7VjaF4p0CHUFnmtZLW4VsbwCufY46j6iq2nX15o919pssMGGJIm+7IPf/ABqzqEfhPX5DPdSTaTeNzIduVJ9eBg/Xislh4wb5r28jzMVl9TDyfKm4vqvyZ199pml62pu9HuYY7lzym4bZD/Q1BZabLpaXWqanbHFsv7qNsHc3r9BU3gJNC0VylpqlrqErnO5QNwH4E4rovFPiGWJIo9LsrO5LZ8zz5zFt6YxhGz39KFUkoumpaeeh5jqNe70ODm8bay0Zkj+yYPTdGSR+tVLpr3WJkF3NLduwysYGFB9gOPxqrrEd1JLJdzafp9tbry6x3zAE+37rj6VDF4p1g23laJo1hboRtZ2uWdj26lK6qfK1ejDX1WhvGUbXhEvLcDQZ0j0pDd3T488qTs/3Vx17812mlal9uiCyqYZQMtG55WvMpNQ8VqpASxiBGP3Uu0/mI6x7S/17Tr9rqKGBps/PuuWO4eh+Ws54KdRXdr+u5UW1v+p7mIwjexrmvGGtrbIbO1cG4cYYg/cH+NcVJ4/1by2T7BbRSEYDNcsQD/3xWHHdatJIZHtbZ2Y5LG5PP/jlYUMFNSvUVjam4t3/AEZ0kFnFPCUnjSSNvvK4BB+oNX/scEkgeWCJ3ClAzICQp6j6VgW19qygAWNn/wCBTf8AxFWRqGsf8+Fl/wCBbf8AxFehZnTzx7fgzbttOsLeEQw2VtHEHEgRYlA3Do2MdferEtlZ3E4nntYJZthj8x4wW2kYIz6YJ496wFv9aY8WFl/4Ft/8RVmK51wj/kHWJ/7fG/8AjdFn3Dmj2/A1JdPspZYZZLS3eWHAidowSmOmDjiohp1lHJPJHZ26vOCJWWJQZAeueOais59Ua4UXlnaxQ85aO4LkfgUH865v4g3d5DqOhQWct6qzyTCSO0cJJIAgIAJ4pxi27XJnOMY89joruxtLi3WCe1gkhTG2N4wVXHTA7VVlsbTay/ZYNpQRkeWMFR0X6e1cVYeK9Rh0bSIg6XN1dmc+dPjKBDwhyVy/Izz+dSal4s1ONJZIbazVYLKO7lVnL8ltpVWU4P1q/ZSWhl9Zp2vY6mWwszP57WsBm4PmGMbuOnPtTPKjjjZIkWNTkkIMcnqfrXM3fiqdNfitYVgktmuUtnBBDqWUHrnnHsuPeptAvph4evLqYyTvDLcMAWySFZsKPyxScJJXY1Wg5WXmWLHw/YWTzOqNM8qeWxmIbK5zjGMYzzVj7DaxqBHbQIAwYbYwMEdD9a5iDxZcFJWmlsGC2i3AaEM2xmYDawz159qI/Et/JGYvJtvtIvUtcnO0hlzngnn8TVuE3uRGtSSskbGpaTb3kSo2+JQxf90QuSepPH60RadaxQpClvH5aJ5QDLn5fTntWI3iO7xbQy/YoJXlmjkmlJEQ8v056n61n3WsXM0RuizLv0szmNHZV3eZjIwc/jTUJbESrU1qlqdzbWNu9zHM1vEZU4VygLL9DXaeGtPtjPE32aHKOZFOwcMerD3968qHiS5tb50SKAxQSQQtE7HzZfMA+Zfp+Oa7Lwp4m1MeIdMhlt7M2F3qM2njbu8wFASG9O1XCEjKrVhqkfTPhhdtuv0rpF6Vg6Au2BfpW8nSuyOx5NTclHSiiiqMwpkrrGjO5wqjJNPqhqzE2zKOnehjSuzxz4iXcl9eyyvxngD0HavPXT5jXoXi6EmZuK4yW35PFebV+I+gwqtCyKAHFSIcVKYsHpSbKwOtFbVLRdR0y6s3cos8bRlgMkZGM1gw+C7OG2uraGeSO1u7ZIJ4kUAMy9JB6N69Qa6cLSgEVSm4qyFKlCbvJHN2vhOGAR5mjDJcQz5ht1j3GMkgHHXOajuPB8Upf/THKPdzXbxvGGRjIAMFc84xwT611BpCaPaS7k+wp2tYwtC8Nw6PdW88dw8hhshZgMoGQHL7vrzisfUtA1CTX5DZqyWE95DdzM0iFSUwTgY3A8Yxmu0zSE0KpJO4OhBxUdkctD4Qij1QXr3kksgaZgWQFyJFxhm7gdqhufCMIsBEJZZjFpzWKpwm/wCbcDnnByB7V1jNUTvin7SXcToU9rHG6d4fvrmS/m1iUxvO1uV5VmxEc87QBzVw+G1jujdW148dyLuW6RigZQZAAykdxwOa32emFqrnkzP2MErHPW3ha3tQAlzKT9lltiSBz5jbi35npWhFaRw6fBaMBLHFGqDeAc4GM4q67VXkahyb3BQjHZFa3SGzuknitrclT0aMEH2r03wzqeiajAsbWViJccxtCmQfy5rzKTmqrFkcMhKkcgg4xXPWo+01vZjcFI9kuNHsIrjzF0+1Mbdf3K/4VXl07TckrY2gH/XFf8K5nwd4lv5JTa3shnh2kqz/AHl/HvWnrHijTtPfy3JkmPOyPBI+vpXk1KVRT9mtWZ8qjuS3tvp0ELObK0CgZJMKj+lcfPrGi3KtbzaZmFjhjFGqkj61Fqms3WsPt2+Tbf3B3+ppLKyTlnAxkLz+tehhsC0r1Xr6idnpY1tL0nwfcIGjkmtZP7tzArL+YH9a7zTp/DmmafDBANJmZB98rHkn19q4C4urG1TawVn/ALqjJrn3s576ZnijMasc89a3qUm/tv8AMuGXzrr3Voeyyak2qThI5onY87VcE4rz3xI8kWqTHUoZ1nYfJHjjHbB6EfSqek6LcW0scwmkR0OVKsQQa7y1u7m4tlTV4ra5tB/y0ugF/I9z+H41zRg8NLnWprLAPC2nJprtez+R5s0M10w2RiJPbk/nXSeGvDjSEStiKBeXnfhVHf61r3Op6NbyFdN0tJW/vvkL+uf5VSub+e+wL2fMY6Qp8qD8K256lXZW9T0aU6ko8uHp8l+r3/r1NLUb+G4thpukhlsFOZZiPmmP+H+elV1+VAoGAKgS4jUALgD2p4kDcirhBQVkd+Gw8aEbLd7vuTWUYmuCmATJIq/8BHJ/p+Va3jKAmwwo7L+GCa4b+32sLi5khC7kbHmSfcTHt3PXisnUfF99eMd9zdyZ7hhGPwAFVGCs79TlqYdOblJ7u/8AkVJj/pzA+tV9Fk23Uq54LE/rRBJJcTtM5fcAWPmcgge9UrGQpNu6HOaaR2SduWx3VvGrpziq17pKyglRzWfDqYTAzWnbaqjAZYUWLdRHOzaXPayiS3LxSKchkOMVraV4mvYrqOLWlM1sflaVV+dffjrWt9pglHO2oZra3kHAWpnTjUVpK5w4jB0a2rVn5Gf4st7xJ43kuBcaa/zQyRjCnPrjvUOlXSRxPEvHcVrWcrWcbW5VJ7J/vQSDKn3HoaoX+l2LsZdMmltX/wCeUh3L+BooydJcjWndHlPB1IPl6d/8y210kig+vNZV2QJm9DzUcVtfgld6Nj2p7affzN83ljtwDXSpJj+p1O6MS9QFT7GpY5lsYIUkcl26j+7V+4sFtDvuWLd6zmu7AEmO1Mrn+KQ5FTJ82h0UsLGlFym9X9xoR3OQCpyParEdySRzT/D3hq/1grcK32aBjwgXqP6Vd1/w5d6KVlIaS3PVwPun3qHBo5ZVqanyKVyawO7GTWvGwAHSuWtbvYOtXkvSe9RY0ubbyCq0yxSSRvJEjyRklGZQSueuD2qok5aphuYUAV7iyspY2jls7Z0d/MZWiUhm/vEY5PvUElpalWX7NBtKhCPLHKjov09q0DGT2qJ4z6U7k8qMySxtWn842sBm4PmeWN3HTnHalWCNI2SJBGpyfkGOT1PHerzJxUTCi4KKMDT/AA7Y2Uk0mJLh5U8tjOQw25zjGAOvPSrP2K1jAEdtAoBDDbGBgjofrWi9QSUOTe4lCMdEjG1PSYL6NYy8kCqxb9yQuSe54PPvUtrp1rDBHAlvGY0jEQDKGO30JParxHNPhTLVSb2JcIp3sWLCwtpLqOZreFpk4WQoCyj2PUV6H4W0y18yJvssG5HMinyxlXPVhxwfeuS0mHLjivSvC9vjZxXRTRw12rHomkrtiUVsR9BWbpyYRa00HFdiPInuPoooqiAqnfLujarlRTLlSKGNbnlnii0y7HFcXcW4UmvVPE1sNrHFedaiu1zXm1lZnv4N3iYMseD0qApV2YZNV2FYHaiDZSFalNMakUQsKYwqRjUbUANJxTGNKTULmgBHbFV5H6806RqqSvVIiTFaTmk31UeTmmib3q0YstM9QO1RtL71G0lAhztxVdyScCnMxPSopJPL4XmQ/pS3L2V2O/tKe2LwWZCsww0g6j2FLp9m0jh5Mkt8xJ5zS2lnhCzdTxk1qW/mO5jtEzxjcRwPp/ntVpRhr1ZNKjOvL3USgQ2yAykD0Hc/hREt3eoscSGOPJOe5zWrp+gqD5t0xdz1zWnJPbWaYGBipcmz16ODpUtZe8/wM2w0KOIbpRk+9aTG3tVx8oxWLqPiFVyEIrmb/W5JScGp0Ottvc7CfXIoT8uDism/8RvM+ZJCccAelchJcTSnqaWO3kkPOTRa7M5OEfekbja3z1NPh1kMeprG+wtxn6cmnC2MeOM/Q1XI+xmsbRTtzI6q11EOQM10Fid6ZrhLJsPjPI6iuz0lyY1FRY7I1LlHV9KQh1KFoWfzMKcEGsZ7GxiP+rvJGH8JKqPz5r0AxBk5Gayr63iAJ2jNF7DcFJnE3cjmMxpGsUX90HJP1Pes37prc1UBWIArn7h8ZppmdRW0Qrz470iXrLwDVJmJqSGBpBxTMtbl5dTkB6mrUesOOrGsv7Nzwc/SmND7mnZ9iHWgnZyX3m8usE9TUqaop6mubER7MPxo2yDpz9KRSknsdfBfgnhq1ba9PrmvPo7h0PU1q2OoEYBNNMl2e50l/qGmyuY7h9r9Oaxn0y3edZbN45VDZaInG72qlqa+b++UZI610/g7w1Y+INPJhuJYr2PO8Ifu+nB7fSmtznxM4U4/vFeP5HaeFPE+jAJb3bfYJwMBZhhPwbp+eK6fXEilsnBCvGy/UEV5JrXhfW9LU7ovttuP4kHzAfTr/OsC31++0/8Ac2dzPCpODETlc/7p4pqVtzzJ5fTrLmw8v6/NFvUfKXUJ0thiJW2gfTrU9nGzkVSt0LPzyT3rp9ItAQCRWTZrCNkkSWlocDIq8kIUc1cCBF6VE4pXLsQMB2qtItWmFQyCkFinItV3FW5BVWQUwK79KgerEnSq70CZCetW7WPLCq6jJrV06Lc4q4oym7G/odsSw4r03w5bbVXiuP8AD1ryvFek6Jb7UXiuylE8rETN+0TCirqjioYFwBU46V0o81sKKKKYgpGGRS0UAYGv2++B8DtXlOtQlJW4r2nUI98LDFeX+J7bbIxxXJiIdT1MDV6HETcZqs9W7oYY1Rc1wnsoaelRsacxqMmkUNaozTjTGoAY5qu5qZ6rSnimhMhlNVJjU0rYqpM3WqRlJlWVutQGTmpJWqpM21Gb0FUTFXZMHJqW3VZZ0jklWIN/E3SodJktyoa5kbPptFbxm0GVV8+OZioxxwP0xSZ20cLLmTaTRk30MtsdqYcH+NeaWxtWb5ijux9B/WtqK+0OEgQWjMe285/nWpHcNOoMUCRqfWkp2Ot5fTnLm1t2KFlpElwVNxwg/hHT/wCvW/FHbWMXAUGqsl35EfJrm9X1bqN1K51qnGC5YqyNbVdcCZCNgVyN/q8krEKxNZ9zcPO55pkMTP8AdFNJsxq1oUleTsKzu/MjYHvSR/vH2xoT7mrRs2CqW+taXh6yEspYjgVrGCW55NbHznpDRfiNsNLcjc456CtqDSwAMjoM1tW9quRxwK0IrcHoOprRHBK8tZO5zZ0occVWutOKAEL3rtBbA4OO9Vr21GwcVSM3Y85bMVwO2Sa67QZdyLk1zWsx+XNHjuxra8PNwtc9T4j6DLf4Mfn+Z26/6nNYuotgGthT+4/CsPUj1rNnp0zlNV5Jrm7nqa6HU+prnbo8mkhTXUhjXcwq9L8irEo7Zb39qqW3MoFW2+a8fPTOK2pq7PKx9Vwo+71di7BbF1UgZwefpU0mmnOQODVzR1BTa3VePwrZW33RkY5Wt2zwYo5CewIHvWdNA6McZrsbqEc8c1jXEYD9KjmNeW2qMxraQDlTUe0ocgEEflXYw2yS2avtBO0GqGoaYFDlR3/oKTSZ0UsTUpdbrzKNhOrfJJyD1FW4FuNOulu9JuHhmXoUOD9PcVBoWh3mp/aPseGkhUEIeCxPYH14qC5MyhgQySoSrKwwVI6gispKx62HrU66fL80ep+FviLbXaLZ+IlW3uegmIxG/wBf7p/SqHxA0rTZovttssRcYYMnfn2rk9J8K32taGuoWs8MrFmVomyCpB9ayX+36bMtnc+dEjNgxtyp+nb8qabtqebVwdJ1G6E7Nbr+v+GNawTLiux06MLEK5TTR84rr7I/uhWLLRM55qJulPbrTGoGRNUL1M1QvQBVlqrIKtyVVk70CK0nSoGFWWFR7eaYmRxJkit/SIsuvFZlvFlhXVaFaFnXitYLU56rsjsfDlt93ivQdMh2oOK5vw9Z7VXiuytI9qiu+mjxK87ssoMU+gDiitTlCiiigAooooAjnXchrgvFNtnccV6A4ytcx4htw6Hisqiujow0uWR47qcZWQ1jyV1ut2pDtxXL3EeCa82Ssz6GlO6KjtUbNTpBg1Xc81BsSbqQtUQNBagAc8VUmNTuaqzGmiWVJ3xVGaSp7ljzWbKxyatGMhXfNWNLt/tV7HFjIPJqjurofCJt47tpbmWOMDAG5sH3/pVR3Mqt1B23OzsfDdt9mUlOcVQudOtbRnM52xdD7/Ste48SwxwbLGLzDjHmy/Ig/Dqf0rmJ9TSScuN15c9mx8q/QVbqdicNlU5rnrPlj57/APA+ZUstJAPn3h8uAHKqeC31qabWrcMY7ZdwXjI6Vl+IDcy3EMMlxvdl3Oi9E9BVKQx2cO1fvVhK99T6fCumqadJe7+ZPqepswOTya56V3nfmnuzTycc1p6VYb8FhnvVRjc5sXi1S0W5WsbBpHy2cKMmtyHT1hgUY5rQtLVUtzgfebFTXSgFFrbbY8WUpTlzSd2YGoYQPj+EYrV8MQ7bcHHJrH1A72Uf32zXVaLEIrVM9TQR1NeFcCrsC8E/hVWOrsHJUU0KRY2AbRVa9QeUau9Tn3qrqBxCatGLPNPEQxLB/vNWloIxtrN8RH99b/Vv6VqaEOFrnqfEfRZav3Efn+Z2i/8AHuPpWFqXQ1tqw8j8KwtSPBrOR6dI5PVDyawTCZ3YA9BmtvVT8xrL0x1XU4hJ9xjtP40oiqvQz7RiJ8HqDV1QfPY9iSaZrFs1nfg9icfl/wDWqW2+dGPUqdwrop7ng5i/3SXmdHpi4CSDoflat+AYNY2lKDHtb7rCtm33BcSfeHBrRnlRKeoRYYkdKwbxcHNdNdrn6Vz1+uMio6m3Q0NNbOn/AEX+lTagQIpPr/QVU0s/6Cw9FNS6qcRSfX+gpi6HSfDCzJhknx9+T9B/k1t/EHwgmq27ahYRhdQRfnUceeo9f9odj+Hph/wzt/L0S2JH3hu/M5rt5h8lTLU46daVKpzxPnzwjrsnh7UykjH7BcNiQH+Bumf6H/61df4ut7e8tGlRVJ27lPv1rO+Jnh9Ybx7+BMQTHEygfdb+9+Pf/wCvXPeH9bdEOn3zEgcRsx7elEN+VnoYyCrwWLpbrcm09sMK6iyl+QVx1u/lyFT2OK27S4wBzXO0dKd0b5amsaqRzZHWpg+RSKFY1E9PJqJzQBBJVZ6sSVWegRCRzSom407bmrlnAWYcVSREnYsadbF2HFd/4d0/lMisbQ9PLFTtr0fRLAIF+WuulA83E1ehr6VbBEHFbUYwKht49qjirIHFdiVjyZO7FooopkBRRRQAUUUUAIelZWqRb0NaxqtcpuU0mrlQdmea65Z8txXDajblGPFeu6vZ7weK4PWrHG7iuGrA9nDVuhwsyYqo61sXsBRjxWbIvNcrR6UXcqFaaRVhhxUZWkUQNVeRc5q0wqJxxTRLMq5Tis2ZME1t3C8Gsu4FaIxkUcc1oaFpmpXcrNbxBcngtVI/er1fwLGr2UT4G5lBNXFJ7mU8VPD6wtqUtJ8DTTYk1K4Z/wDYXgVP4jt7HQbULCiG4YYijx1Pr9K6nXNch0mHy0UTXrj5IQenu3oP515vql0v2h7q/m867f8AIegA7ClKSjojpwmGrY6SqYh+4unf+u5iTKbdXnuG3TyHcxNc9dzmaQ81srDPrOpC3Q7U6u3ZRWL9naK7kjk+8jlT+BqYQ5tWehjcbGj+7p7/AJGhp1rncxHQfrXS2EIit2bHSszT8CIDuTW+q7YY0/vEVqeNdvVkqJtSJfQZP+fzqnqDfM+OuMVpAfvD7AD/AD+dY98/3j6mkMxnHm38aDt/n+ldhaD5kUdAK5LTfnv3kPY4FdbYnbGXbvTEjRDchR1rRtB94+nSsy0BY7z+FaqfJFkde31PSmiZbFhTleOgOBVLUT+4Y/Wr6ptjVR2FZ+pf8e7fQ1ZgzzfxF/r7f6t/StTSGKQFh1AJFZXiTi5th/vf0rb8Lw/aLhFP+qiHmyH2HQfif61z1PiPpMtdsPF+v5s6aU+X8noKxtROVNRxXrz64yBjtCbiPr0/QfrTtQ+6ayZ6lM5PVPvGsCVirgqcEHIrf1T7xrn5+SaEZ1TV1S9t762gyGEhT5mxkAjgH+lQ6SDldwwTwaq2UYdgG5APAq/aDEr47NXRSep4WZwappvudLpI/d7e68f5/CtlPmTPcVkWh8uZSOjj9R/k1rRHafY/yrRnmQI5eUI71g6gMgmty5+QmsW+6N6GoZoP0cf6HJ9DUmt8RSfX+gqLRz/oso+tP1//AFUn1/oKa3Jex654Jg8rR7RcdIl/lW/cHANZ/h2PZYRD0UCrd42ENLqeccz4mWOe0ljkAZWBBBrwvVIGiuTCpPnRnKN/eXtXsviG4wj815VeEXF+7gDAO0GidrXO3AVpQm4rZ7kcDOx3PgMRzj1rVtmIAplna78cVqRWWAOK527noRVlZElu5q2rVHHAV7VLsIpFDt9NZs1G2RUZegLhIaiPNDNk0ICxosDZJDHuYV0Wj2RdhxWfp1qXccV33h/Tfu5Fb04XOSvV5UaugadhVJFdtZW4RRxVPTLUIg4rajXAFd0I2R4lWpzMcowKeKQUtaGAUUlLQAUUUUAFFFFABTHGRT6CMigDMvIAwPFcrrGnhlb5a7h0yKzby2DqeKznG50UqnKzx7WdPKk/Ka5i5gKseK9d1nTNwPFcHq+mlGPFcNSnY9ihXTRyLioWrQuYCrHiqEi4rBo7U7kLHmoJDUkhxVWZ8UAyC4bg1l3Dc1buJOtZsrZJq0YyGry4rudH177HpcdvYsolCAPM33Y+O3qf0+tcIGCKznoozW54S0i41qRFJMdop+Yjq3sKpX6DjTpW9pW2Ru2i3ur3LpY7juP726kz+p7n2FY/iLT49P1W5USSSrAqrlz1YjJP617BpdhaaTpzOwWOCBC7Y7Ack15lBBJrviuCF1z5khuJx6DOcfyFS49DswmOlUc6jVoRWxJo2ly2FhHI6ESy4eQkc+w/CuZ8UQCHWpHAwJVEn9D+oNeyataKsO0DgV5r45tf9HtrgDlHMbfjyP5H863jpoeB7WVSq5y3Zk6U2+RFrp1AaZFH8IrltD5uFrqrblpH9On4UmdkdiQttjdvXJrntRk2oxJxgVt3J2wEfhXM6w+Y2H944/pSRT2G6OpLL6nk108T7mWNeg61zmm5Rcjqelb9iCGHrTEdDaKPlHYVfT55VX0+Yj69P61StcBeenf6Vesfmy7fxHd+Hb9MVSM5Fw9/yrM1If6O30NaI5UmqGpD/R2/GqMmeZ+JuLu2/wCBf0q3pesvZ2UloYtiOd7yqvJHpnPbHAqn4m/4/bcf739K1NMtxcW4UgE+4rnqP3j6PLot4eNvP82SeHIne4nuZRhn/T2q/qHQ1dtLZbaDaByetUNROAayZ6kFZHKaqeTWBIfmNbmqnk1z0rfMaEjOpIv6fjfV6xGbpx6ms/TPmkArQsztuS3o5B/Ot6O54+bP91H1Oij/AOPZT/EhrRjfKKc9OKpqNuPRqsWgyhT04/wrSR5NMluvnjPqBn6isG7OQRW+/wDqz/eX+VYF6MMcdKg0J9I/49X+v9ak1wZGPVh/IU3SP+PZvr/WpdXGXT/fH9KpbkS+E9s0cYtF+lR6o+2M1Npg/wBEX6VU1dsIaR5x574ruTFbytnoDXC2Me5hnvXTeOZcRhB/EwH9axtIjy61NVndgY6Nm7p9uFUHFaIQelNgTalTgcVgekhmwCmMoqcionpBYqyrVR1q6/NQsuTTEyptJNXrK2LsOKktrUuw4rqdG0ssV+WtYRuc9Sooon0LTCWUla9E0exCKOKp6NpoQL8tdVawBVHFdtOFjyK9bmZLBHtUVZApFGKUVucTdxaSlNJQIBS0CigAooooAKSlpDQAtFJS0AIaidMjpUpooAyby1DqeK5TWNKDZOK710yKz7u1Dg8VnKFzop1XFnjGraWULHbXK30BjJ4r2jWNKDhsLXBa1o7AsQv6VxzpWPWoYhM88uDjNUJmNdFf6e6k/KaxprYjORWFrHYpXMmYE1VdDWpJD7VA0dNEspBFK4cZHpXY+E9YghZYcCJhwB2P0rlXjxULAg1Sk4mNWmqqsz03xd4kRrRdPjbggSTkeg5VfxPP4e9XfhbpLC3n1W4U+dcn5M9l7V5NbxS3mpwo8pMcrgSFm5/z2r6I0BolsIo4gAqqAAKpK7uGIqRo4eOHh11f9f1sQ6rFlG4rzrxZB5mlXid1G8fgc16lqEeUJrgdcg3vLERw6lfzFVHc8u9nc840ZtsufSustQRak9zjNcfpX3wO5OK7SPi1QetNnpQKt8wVBnoBmuW1Bt00aHtya6PVGwrD8K5eQ+bet6DikimadgMDceg6Vu6YCzA1iW/O1B0HWuk0uPCj1NAGqv3An984/DvWnF8sZ9elZ9r88zP/AAL8q/1P5/yrRj+baPxNUjOROBhAKo6oMWrH61o/wD3NZ+rf8ejfjVmLPLvEZzfw/Q/zrf0Afulrn/EHOoRfQ/zrotAH7pa5anxH0+W/wY/11OgC5SsTVhjNdHFFmOuf1tdpNRY71LU4vVTya52Y/Ma6HVOprm5vvUIxqmno/wDrhV+0ObiUf7Z/nVDRf9eKuWh/0+Zf9s/zralueTmn8KPqddbHzbRT3xUkTbZwB/GvH1FQaY2EKH6ip7lSoDL95DuFayPJgWZ/uBx0IrBvuGI7dRW8GV4eDweR+NYN7nJHcdKzNixo/wDx7N/vf1qbVhgqfRx/SodG/wCPc/7w/nVvVl/ck+jf4VS3IesT2fTv+PVfpWbrb4U1o6Wc2SfSsXxG+2NvpSW55rPKPGE3majGnpk1JoycrWdrknmay/8AsgCtfR8DbWdR6nq4SNqaOgjXin9KSP7opWNZHaNY1C5qQ800IWNCQmyAjNWLe2LsOKhlmCKfs6pPKkixum/G0n19PT61v6fNbrdWaGNjDOCfN4AQ5xgjrnJwfTvWsKbZzVa8YlvSdL3MCRXcaRpgVRxWB4dlmsb6+tNUimkjhl/dXEUTP8pAYKwUEg4OAe+D+Pd6D51xE801u0ETN+5SRSH246sO2Tnj0612Qp2PJrYjmLtpbhAK0EXFIiYqSt0jibuFFFFMkKUUlLQAUUUUAFFFFABQaKKAEoFFFABRQKWgBKYy5p5ooAoXNsHB4rntT0kSA/LXXFc1DLCGHIqHG5rCo4nkmr6Fy2FrjdS0hkJ+WveL3T1kB4rldV0NWDYWuedI9CjiujPELqyZSeKz5LcjtXp2qaEQTha5q80llJ+WudwaO2NVSONkhI7VUliPpXT3FgRnisy4tSvalYtMwjlWBGQQeK9d8Ca19rs4y5+cfK4968suISD0re8D3LW+oSRZwHG4fUVUHrY58TDmjfse3SESw5HpXE66m26zXUaXP5kOCawfESgTZ96paM897Hj+mri9ZP7rkfrXZKflQegrlrGLGqzjH/LVv511HRM+gpyPRpvQyNWk4P1zXPW/3mc9zWtrDkBvYf5/lWbbIcgdqXQt7mtYL0JroYZDFb5T/WudiD3P+c/hWHZoSwAra00efdGTrHD8ie7dz/T86ENm7aoI4lQdAKvW4yCfwqmnAHqea0LcYVfzqkZzJ34UCs3V/wDj1b8a0ZOn5Vm6qf8AR2FWYnl3iD/kIRfQ/wA66Lw99xa57xAP+JhD9D/Ouj8Oj5VrlqfEfT5d/BidjCMQ/hXK6+csa65F/wBHP0rkdd6mpex003eTOI1TvXOT/eNdFqnU1zs/3qEKqaWif68VPA2NTkPbeR+tQaJ/rxUyj/S5j6SE1rS3PLzP+FH1OvtTsZGq7KQR+FULM77cHuKtnJQVozyYDbN827oT80Z/Q1naj1yKsF/s94GP3H+Vqr6gMEqak0LGjf8AHuf94fzrQvk32kn1/pVHRl/0b/gQ/nWtMubaQY6tj9KfUXQ9Q0GTfpsTeqg/pWP4qbbCxqz4Tn3aPb567AP0rN8ZSYt2PtQtzzWjyC7ffqk7Zz81bmltjFc+Vb7SWP8AEc1u6YpOMVlNanrUHaKR0sD5UVLgnpVSNvKZE8uWWRskJGuTgdT+tX3g8+3glibbCzY83B/dvn5dw9M5BHvUqDZpKsokU5FvGHdHYFgu1Bk8+1X7GDzpYfLaNlmUvEBk+YAOee3JrPvNHmnvluYpWhIIhlJbm2kzlN3qhPQ+9ddZaBe3loht7d7a4FwpmQMFNtKCNzoTwVZSTj3+tdEKJw1cX2MJtM3Wh1WGASW4bFzA3DoSQrpjvn065AI610Ol+GbvUYby2aAmylmUx3NwrRSx4ADMEIyTjjPGTXYaZ4Qso7g3V2Dc3bSiUyHKAkAbcqDg4xnkda6qKELjiumMLHnVKrkZ2i6RFp0cgjaSSSRt8ksrbnc4xkn6ACtdExTlXFOrRI527hSiikNMQGiigUALiiiigAooooAKKKKACiiigAxSYpaKAEopTSUALSUUuaAEpCM040lAEbICKqT2quDxV+kIpWGnY5e/0pZAflrmtQ0IEnCfpXpDxgiqc9orZ4qJQTN4Vmjx++0IjOE/Sudv9GYZ+T9K9tutMDZ+WsS+0UNn5awlSOuGJPC77SmUn5T+VQ6RatDqlu2CPmx+fFes3/h/OflrCk0Bo50cJ91gajkszd1lKLRq6M5UAGqXiUnzAa6Cz09oz0qhr1izkcVTjqcKaseXWdkft8z7Ty5P61tS25WE8V0tvoTK24r15qW70lvLAxTlE66dVWPLtXgJfbjqait7YrjiuuvtHd7gfL05pv8AZZQZK8Cp5TVVEYSxyIipEP30pwvt7102l2i28CRqPlUcn1NGmaU5kaeRfmPC+wrbS0KqABSsNTKsabmFaEC5J9KaluRzirscJWLp1FNImcisw4FZ2rL+4atvyTtHHpVDVICYXGKozueS+IVxfw/Q/wA66Lw4PlWsjxRAVvbc47H+dbHhwcKK5qnxH02XP9xH+up2h4tj9K5DXec110h/0f8ACuS1scNUyOqlucNqY+Y1zs4+Y10upL8zVgTp8xqUVURa0X/XCr8cX+muccMxqnpCkTLxXR2lk0gL7ejZrektTx80kvZpeZe0xSoCsPY1pJEcEEVLa2LFUYL161rJYsQDtrRo8mEjnLu1MkRGOR0qjKpmiXcPnXhq7N9OY9FrOn0lkmDhflbrS5SnNFHRbcm36fxD+dbUloTD06t/StHRdJYQ/d7/ANa6BdJJTG3uKfKR7VWMzw27Q2Sxn+HIqDxUrTQ7Rnnit+30topSAvB5qa50hp3jBXuKpQ1OSUkeVT6A5txIqH5G547H/IrX0XRXLLlD+Veq2vh9GiKOnDDBqxp+gLCQCgyKp0ru5UcTZWOL0fRCNbnV0ODbxFM/7z5/p+Yq/rWlC0ZI4iyxXfF0qru8uIEbpfbj5T9Qe1dxPoQnMMsMz29xDnZIoB4PUEHgg4H5Vf03SY7TzHkdp7iXAklkAywHQYHAAyePc1caaRhOu2c7o3hKC0d1Ija2IZQMZMqNziT+9g5weuD+fV29qkSKiDCqMAe1TWlrFaW8cEC7Yo12qMk4HpzU4ArRIwc7jEQCpAAKWiqIDFLSUtABSUuKKAEpaKKACiiigAooooAKKKKACiiigAooooAKSloNACUUUuKAEpaSigBaSiloASmladRigCB4warS2yt2rQxTStKw07GJPYK3as+fSVb+GuoKUxoge1LlLU2YcenjAOKqX+lrJ2rqFiAFI0IJHFLlFzGB/ZKD+Gq9zpKsv3a6sximPCD2puI1UaPPptCUyE7aqSaCHYDbha9Fe1U9qjNkvoKXKWqrOEGjhAAFxjpSnS8DpXbGyXPSmNZL6VLgaKscR/ZpMgGKlkseAAK61bEbs4ppsgWJxS5B+2OV+w8Diqd/p5ZG4rtzZD0qKbTw2flp8ovanhfinQ3kliZVPy5/pUWjafJEwBU8V7FeaIkp5TP4VWi8PRhs7P0rKdG+p34bMXRXKcXNE3k4x2rmNXt3IPFewyaCrDG2qE/hRJeq/pWcqDPRpZtBbnz9fWMjMflNZv8AY00j8Ia+iD4GiY5KD8qtQeCbePBMY/KpWHZVXOIW0PCdH8OTbwShrudL0EoFyhr0qPw1DF92MflV6DRkXHyfpXTCnyni4nGus9TibTQ9qbSvTpWjDo/GNtdtFpqgD5anSwUfw1XIcyrHEro3H3ad/YKtwVruRZKP4akW0X0p8gnWZy2n6KscYG3vWvHpihfu1sx26gdKmEY9KfKZuozDbTV8xTt7VMlgu5Tjoa1jGOOKUIM0+UhybIIrdVHSpPJGc4qbApaoVxiqB2pwFLRQITFLRQetABRS4ooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoNFFABRRRQAGkpaQ0AFFFFACikNLRQAlcrq+ua2PFE2kaFplhdeRZw3csl1dtD/rHlUKAqNn/AFRPbrXV1y1l/wAlQ1n/ALA9j/6Pu6AIvtvjb/oB6F/4NJP/AIzSfbfG3/QD0L/waSf/ABmuupaAOR+2+Nv+gHoX/g0k/wDjNH23xv8A9APQv/BpJ/8AGa66g0Acl9t8b/8AQD0L/wAGkn/xmk+2+Nv+gHoX/g0k/wDjNdd3oNAHI/bfG3/QD0L/AMGkn/xmj7Z42/6Aehf+DST/AOM11opaAOP+2eNf+gHoX/g0k/8AjNBu/Gv/AEA9C/8ABnJ/8Zrr6KAOPN141/6AWhf+DST/AOM0gufGmP8AkB6F/wCDST/4zXZYoxQFzjftXjT/AKAehf8Agzk/+M0hufGn/QC0L/wZyf8AxmuzwKMUDucS03jM/wDMC0L/AMGkn/xmkEvjMf8AMD0L/wAGkn/xmu2ooC5xXneM/wDoBaF/4NJP/jNL5/jP/oBaF/4NJP8A4zXaYpMUWC7ONE/jQf8AMC0L/wAGkn/xmj7R40/6AWhf+DST/wCM12dFAXOL8/xn/wBAPQ//AAZyf/GaUXHjQf8AMC0L/wAGcn/xmuzxSYoEceLrxqP+YHoX/g0k/wDjNL9r8a/9APQv/BpJ/wDGa7CigDkPtnjX/oB6F/4NJP8A4zS/bPG3/QD0L/waSf8AxmuuooA5IXvjb/oB6F/4NJP/AIzS/bfG/wD0A9C/8Gkn/wAZrrKUUAcj9t8b/wDQD0L/AMGkn/xml+2+N/8AoB6F/wCDST/4zXWmigDkftvjf/oB6F/4NJP/AIzS/bfG/wD0A9C/8Gkn/wAZrrKWgDkftvjf/oB6F/4NJP8A4zR9u8b/APQD0L/waSf/ABmuuxRQBheDNZn17RBeXdtHa3CzzW8kUchkUNHIyHDEDIO3PQVu1yXwx/5Fy5/7Cd//AOlUtdbQAUUUUAFFFFABmgUlLQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAlKKKKACg0UUAJXL2X/JUNZ/7A1j/6Pu66iuXsv+Soaz/2BrH/ANH3dAHUUUtJigAooooAWkoooA8K+M/iXxDo3i6WVdQ1GPwvaWKySjQ7m1W5t5SSS8scoLMu3GAMD360a7rXjGDxppGgaZrMsumeLI4bm0v5ERJrFY1DXAVMdWXBAPQtjtXrWr+EvD2s3yXuraJpt7doAFmuLZHcAdBkir8+mWVxe2t5NaQSXdqGEEzIC8QYYbaeoyPSgD501zx148tNZ+IFjpUl1d263UtrY3IiDLpnkoskjOdvRkY43Z+Zao3HjPxpqV3pdrpuqeIZb2Xwnb6hDFpdtDL5l4zEbpty8RnjJGK+l49I06NL5I7G2Vb5i10BGAJyRgl/72RxzTLDQ9LsLhLix060t544BarJFEqssIORGCB90Ht0oA8J+IHxN17RPF2kQtfCGHQ7W1n16CCEyJcSSsokjDAELtTc45FdPr8GtSfFvRdMsfGetRaVq1rc35jh+zlY9hTaqExn5CGPXJ969PbQtLaPUEbTrQpqBzeAxLi44x8/Hzccc1JHpGnxT2k8dlbLNaRGC3cRgNFGcAop7DgcD0oA+e9Q+IfjSLRr7y4br7NH4sNiur+dDhYvPC+R5f3unGcfjV7whrvinxB8SPEFlPrGrrp1vq9zZRtBeWcccKAHaPKdTK5GRgrx09DXc+KPFvgTQLu90fUdPM0drKl/f/ZtMeeG0kc7llmZVIVj1z171Be678PtN8bGODQvtXiABLw3On6Q9wwEvKyGRFOM565oA53wkNeute+IFpqPjfWza6C4t7d2+zrnfFu3sfKxuB6dB7Vg6F4w8Qal4Z+G1leeKrmyTxJLdvqOsN5QkiMY+SBGK7ULdsgnJ79K9b8X6p4O8NXdvY+ILe0hbxNP5DBrbct1INoHmkDH8QGWrn9Q8SfDKx0PxJpk1jYtpWgXES6hbR6fviSaVtilVC4ZsjBI6YoA6myiZPAt1CPFU1+USVV1dGhEq4JxlgpQsv3Scduma8MtPFvjm68CfD670LxDPfa5q1xeT3Ec4jZZfJXcLfCqMAhPrl+uMY9Wm8Y+DbDwnb2s2iX9tpF1cGwh01tFlQyuV3lVg2ZIIyc4xnNM0LxD8OIbPSLnRbSygWXVDY26RWBikgvHXDKyFQY2KqASQOAO1AHmF18Q/F3iXwrHd+GNTmsL+/8AF/8AZ1sk8a/uo/squIGBHQSZyetR3PxQ8Sa14a8R6jYXd9YSrrun2UVv+7jktg6YmiDOu0fOG+ZunU8V67deIvAtheSwy2luk8OvRWrbbLpqMqZV8gfeK/x/rWjqkPg9vEi+Gr/S7GTUNXVtQaF7QMk5j4LucYLDPfmgDyPxL4l8TaZaeDbdtU8TZvp783aWctleXjrHGjIFZF8sgcnGM4J9ql0f4g+IdE8M+BvF/iTWPt2h3ZubTUhGqHaTua3Zto4kG3a3QZ4616bcXngXwv4r0Dw59j0+y1e5Mk2nxRWoAQsNrMCBhC23HbO3FdJJ4Y0OTTZ9Pk0iwawnlM8tuYFMbyE5LFcYJyBzQB4T4x8ZeL9H+HPhawXV54vGGrxzanPMIBI8MSqzpFsCnAJMaZx61q+MPEuq65o/w/8AEPh/xNqWm2/iK8trG4tbYQlIiwbzCu5Cd4YFeSR8vSvbhplkNRGoC0gF8IvIFx5Y3iPOdm7rjPaqkfhvRYra2t4tKsUgtp/tMEawqFilyTvUY4bJPI9aAPLbjUtY0j4y/wBir4l1PULS08ONqQs5Ghzc3KN5YRsID8w+bAwc8jjisTwn4p1tD8PdXPjCXWLrxHdCHUNKYQmOJWViTGqqGTyyADkn3r2xvDWiNrY1htJsTqwOReGBfNBxt+/jPTj6UzT/AAp4f03VJNS0/RdOttQkzvuIbdFkOevIGeaAPnDwd8R/G4Hg211zUZpo9e1iOS1vBEo8yBZZIprd+MZBVGGOcP1r6pFZMfhvRY7exgTSrFYLGQzWqCBdsDkklkGPlOSTkVr9qACiiigAxRRRQAUUUUAcl8Mf+Rcuf+wnf/8ApVLXW1yXwx/5Fy5/7Cd//wClUtdbQAUUUUAGKKKKAAUUUUAFFFFABRRRQAUUUUAFFFFABQKKBQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVy1l/yVDWv+wNY/8Ao+7rqa5ey/5KhrX/AGBrH/0fd0AdRiiiigAoxRRQAlFLRQAlFLikxQAuaBSUooAKDRRQB5H4j8E+Ko9S8ZR+Gn0aXTfFSATyXzSLLaMYvKcqFBDjbyASMGk0L4QwWvjptT1GV7jTrbTbOzs/Lu5YZPMgABZwhUMDgcHI9q9dooA85+Kvw9PjvV/DfnvGum2JuhdfMRJiSIKrR8EblYA89MCuH1f4I36eH/Gmk6Ld27xawuneRLdyt5jvA7PM8pC/eYsTkevavfu9FAHir/D7xJBpOgf2XYaLZ3ulax/aIt21G5nikXyinLyAsDk9BxxUV18KvEEkc2uG90x/FMuuQ601uodLT90pRYgcFuhJLY5Pavb6KAPDdV+Gfim/0ya+aTSF1248TW+vPbiV/s6JDHtEe/buJOBk4HWtbVvDnju78aaD4qitvDw1Cxs57SW2a6l8oh2yCG2Z6D0r1zFFAHhnif4W+KvEmrat4huNXsbPWjNaS6fbxL5kMf2cZUGQruXLNISB1zzXt1uZDBGZ1VZio3hTkBsc4PpmkubqC2Cm4mjiDdN7AZ+lENzDMP3Tq30pXV7DsyXrS4ooNMQGikooAXNApMUtAAKKKKACiiigAooooA5L4Y/8i5c/9hO//wDSqWutrkvhj/yLlz/2E7//ANKpa62gAooooAKKKKACiiigAooooAKKKKACiiigAooooAKSlpooAdRQKKACiiigAooooAKKKKACiiigAooooAK5ey/5KhrX/YGsf/R93XUVy9l/yVDWv+wNY/8Ao+7oA6iiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKQsAMkgCqU+r6fAH8y9twUGWHmAkfgOaTaW4WuXq5XxB4jaKSS007Hmqdskx5Cn0Udz+g96kvPFtoIZRaRzyShTsJjwpbHGckHGa4xgywsE5cA4z3Nefi8XZctN7nRSo3d5IuWdpe6ncu1uklxKOHmkbgexY/yH5V1ui6JcWuHurnLf3IxwPxPX8hVKx8R6fYWkVtbWd35ca4BIQEnuT83U9atx+LbFv8AWRXUfuUDfyJpUYUIayld+o5uo9EtDogMDFFUbHVrG+O22uo3f+5nDfkeavV6KaaujnatuFFFFMQUUUUAFFFFACDrS0neloAKKKKAOS+GP/IuXP8A2E7/AP8ASqWutrkvhj/yLlz/ANhO/wD/AEqlrraACiiigAooooAKKKKACiiigAooooAKKKKACiiigApop1NoAcKKQUtABRRRQAGiiigAooooAKKKKACiiigArl7L/kqGtf8AYGsf/R93XUVy9l/yVDWv+wNY/wDo+7oA6iiiigAooooAKKKKACiiigAooooAKKbJIkaF5HVFHVmOAKzpNf0pDj7fbsf9ht/8s1Lko7saTexp0Vmx67pT9NQtV9nkCn8jWdqfim1hDJp5F1L2ZT+7H/Au/wCH6VMq0IrmbGoSbskb1xPDbRGS4lSKMdWdsCufufFtqku2C3uJ0HVwAoP0BIJ/SuVvry51CVZL2UyFfurgBU+g/wD11DXm1cwk3amtDphh19oHvp9STfeTSSkn5kckBT6begpoRQBhQMdOOlOxRXnyk5O7OlJLYhu5DDbSSAZKrkA+tYdszNeROWJcuMsevXmt6ePzYZIz0ZSv5iubUkhWBIPBBHataKumiJ7nUZpOM1z8l3cSDDTNj/Z4/lUG0Zzjn170Kg3uHOjpiobGe3IPoa6vwnrMrz/Yb2UyFhmF2+9x1Unv6j6GuG0idpY3R2LFCME9cH/9VadrIYL21lU4KTIR/wB9AH9CadCpKjUQqkVOJ6lRQKK+gPPCiiigAooooAQ9aWkaloAKKKKAOS+GP/IuXP8A2E7/AP8ASqWutrkvhj/yLlz/ANhO/wD/AEqlrraACiiigAooooAKKKKACiiigAooooAKKKKACiiigAptOppoAWlpopwoAKKKKACiiigAooooAKKKKACiiigArl7L/kqGtf8AYGsf/R93XUVy9l/yVDWv+wNY/wDo+7oA6iiiigAooooAKKKKACigkAZJwKx9Q8Q6faRsUnW4l7RwncSfcjgfjUynGCvJjSb2NO4uIraF5biRY41GSzHAFclqfiuaRmTTUVI+nnSL8x9wvb8fyrn9X1ae+uFa6bexP7qCMZCn0A6k+/X6dK2dC8LTXQW41cvFGeVtlOGP+8e30HPv2rz5YipXly0dF3OhU401eZgyzSX1yBI017cdQMGQj6Dt+GKuNpepLCZWsJ1RRkkleB9M5r0Ozs7eyi8u1gjhT0RcVz3jW/KRR2ELYMo3S4POzoB+Jz+RqamDjCDnUk2ONZyfLFHJKQygjoeRVPUrp7ZUEYBZyeT0GKuio5okmXbIgYdea8xWvqdTMUX10Gz5ufYqMfyqzBqp6XEf/Ak/wqWTS4W/1bOh9jkfrWXPEYZXjYglT1HeuhKE9EjN80TdiuoJfuSoT6ZwfyqO/uxBCTGyGXIwp5z+FYZAPUA0gABwq8noAOtHsEne4c5dl1Kd0KgIhIwWXr+HpVMDAq9b6bLIAZm8pf7o5b/AfrVz+zbfZja2f7285o54Q0Qcre5i0VoyaUwP7qUEejj+o/woi0piczSAL/dTv+NX7aIuRj9EQ7ZZOzEKPw//AF1Jqd19nlskH3nnT8gwJ/pV1FWNAqgKijp2FVb+xS8MLlykkTblI5HbqPwrm5ry5maW0sewikyM471wNz4l1SWMqJYIF7tFH835sSP0qbw5c3sl6HjSe4VvvSMSV/76PH4fpXsrGwlJRimzidFpXZ3NFAorsMQooooAQjilFIelC9KAFooooA5L4Y/8i5c/9hO//wDSqWutrkvhj/yLlz/2E7//ANKpa62gAooooAKKKKACiiigAooooAKKKKACiiigAooooAKSlpKAEpaKKAFooFFABRRRQAUUUUAFFFFABRRRQAVy9l/yVDWv+wNY/wDo+7rqK5ey/wCSoa1/2BrH/wBH3dAHUUUUUAFFFFABTJZFijaSRgqKCzMegA70+ua8bXLLaQWicC4Yl/dVxx+JIrOrNU4OT6FRjzOxh61qkurysFZ0sh9yPpv92/w/rWTJiMcCrDHYvFUrhnciOJd0jEKq+pPAH514FScqkry3O+MVFWR13gTSoltn1KVQ9xK7LGT/AAKDjj6kH8MV11VdMtFsdPt7VDkRIEz6kDk/jVqvfo01TgonBOXM2wrzfxDL5niXUkY5aJo1A9F8tSP1Jr0ivHvF9y9t471Jo+QRFuU9/wB2tcuYfwl6muH+IuUVDbXCXCbozx3B6j61NXinaVtQvIbG1ee4dURQSSxwPz7CuN0nxJpWvzTnTNRt7uWM5kWJslfw9O2elXvidodz4g8KXlhaSeXJLGVDds5BGfY4wfrXiHgH4W63Bqktzql3caTGiFY5LK4Akds+oz8vrnrXdhqcHByb1MKkpc1kj3Wrelbftoz12HH14/8Ar1w3g3WNQOqah4f190l1KxCyR3Crt+0Qno+PXscV3WkxNJdCQfcjzz6kjGKKy5YtMcNWbdNkJVGZVLEAkAd/anUhIAyeAO5rhNijpupwXy/Idkg6o3X/AOvV2SRY1LSMFUdycCuJaSOTVrkxYMZkJH51o7QcHAJHQ1XKFy5qN99oQxQgiI/eY8bvb6VmNc3MAAhmdV9M5FWRGWPSrdvpjXAIAycZrSML6Ilux6tZeHtMhVH+zLK2Ad0xL/z4rYCgAAAADsKZbc28Z/2R/KpK+gjGMV7qsec23uFFFFUIKKKKAA0gpaBQAUUUUAcl8Mf+Rcuf+wnf/wDpVLXW1yXwx/5Fy5/7Cd//AOlUtdbQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFIaWg0AJRRRQAUtJQKAFooooAKKKKACiiigAooooAK5ey/5KhrX/YGsf8A0fd11FcvZf8AJUNa/wCwNY/+j7ugDqKKKKACiiigArkfHJxdWB/2Jf5pXU3E8dvE0kpwo6kAn9BXB+I9TXU72MxIywQqQpYYLE4ycdhwP1rjxs4qk4t6s2oRblcyLibAPOAOpNdH4R0GU3CahfI0apzDGwwSf7xHb2H4+lVvCFtDdayzTAN5Ee9FI43Zxn8P6131c+CwyklVkaVqjXuoK5qy1uS418WeP3fmyJ/3yD/hXS1wfh8bvF8uO0lw3/j2P61115NSgl1ZjTSadzvK8a8cqf8AhN9QPqsf/oC17LXlfjSzaTxReTAcEIP/ABxajGq9P5lUHaRzKlkffGxRvUVo2+pjhblcH++oyPxHUfrVOSEqelRkGvHaO06COaOUZjkR/wDdINRvaQSMWaJdx6kcVglATkjn1qxZSSrdQqsj4ZsFSxIxiptbYZyurWcEPxp0ERRj9/pk6yjJOQrZGfxr0XMcKfwog/ACvMkmbVPi5q97Ax8jSLOPTw4/56uS7AfQAiuqKlmy+Wb1Y5Na1U3yp9iIdTYn1KCPhCZW/wBjp+fSs25uZrkESHCf3F6fj61GFJqZIC3aoUSrnOWSk6jMPRq6OGAtjg1U0/Tz/aVxx0YfyFdZaWDHGFrWNNshysULWyyRxXY+HtLXqy0mmaSSwLLxXUWtuIUAAr0cPQtqzmqVL6FhBtUAdhilooruMAooooAKKKKACiiigAooooA5L4Y/8i5c/wDYTv8A/wBKpa62uS+GP/IuXP8A2E7/AP8ASqWutoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigANJS0lABRRRQAoopKWgAooooAKKKKACiiigArl7L/kqGtf9gax/9H3ddRXL2X/JUNa/7A1j/wCj7ugDqKKKKACiiigCvfQNc27RK+zdxnGa4fxHpMWmS2pSWSR5A5YseONvQfj3zXoFcN4yuPO1ZYQcrBGAfZm5I/LbXFjox9m5Pc3oN81iXwFAWvb65P3UVYgfc8n+S/nXaVwui+IrHRNHkF2soZXaR2G0LjsSxIHQD8q4vW/jrYGaS28PW0+rXC8FNNt2uyPq4wg/NqMPUhCkkncVSMpSbPbq4bwmA3im4b/ZuD/5FWvKZ/H/AMSNTO6y8PCyiP3Xv9QSM/ikYDD8am8Qav4n0+20mbQI7WS+eIm6WS4aIHOCdrA+oPWs6uIjKcPJ90XCm0mfRNYesaWlw8kuMsxz+gH9K8Gj+JPjm1P+meFLuQD+O01hJf8Ax01q2nxt1CEbdQ8NeJYsdWl0zzE/NCK1eIjNWa/J/qQqbWqZ2moaQUc4U1kS6eR2rPT44+FZfl1B/s0ncTQzRH8mjx+tJN8XPArKWGqQf99r/jn9K550ovb8maqbW5YeyYdqxfEutW/hbSrnVbv5jAu2GLvNM3CoP6+3NU9S+KWn3oMXhfTdR1mfoFsrZ9uf9qRlAUe4BqPwz4S1XWtbg1vxckc1/Cd1hpMDbobPP8bH+J/VjwPfgDndJJ6/8Fl87exN4G8Oz6PoUUN6TJqdy7Xt/Ie88nb8BxXTpYse1dbbaGYowGBZzyzY6n1q3Ho5/u1r9XlJ3luT7RLRHIxWHtV63sCSAFrrIdHA6ir8OmImPlFbRwrIdU5bR9Ezd3DsuAWBH/fIrp7XTETGRWjDbrH0AqcDFdcKKijGU2yKKJUAwKfIyxxs7HCqCSfQU6ub8W37i3Nnbq7M4/eugJ2L6cdz/KivVVGm5sKcHUkoo5q8vp9Qu5LhpZFUn92oYjaO2Perum+JL60bbdbbqEfg4/Hv+NZQjDIoLEgDqpxmlWNUBCjr75r5WOIrQlzxlqey6UGuVrQ9E0zUbfUoPNtmyBwyngqfQirleXxXVzYM0tlK0Tkc4AIP1BrtfDetpqkASUql2g+dP73uP88V7uCzGNe1OekvwfoedXwrp+9HY26KKK9M5AooooAKKKKAOS+GP/IuXP8A2E7/AP8ASqWutrkvhj/yLlz/ANhO/wD/AEqlrraACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAEopaSgAoFFFAC0UCigAooooAKKKKACuXsv8AkqGtf9gax/8AR93XUVy1kf8Ai6Gs/wDYHsf/AEfd0AdTRRmigAooooADxXkHifXbXTrTUdb1GXy7RN0zN1O3PygepxgAV6rqsph0y7lXqkLsPwUmvnD4voLi38MaXJ/x63usW8Uy9mQZOD7cCvPxvvSjB7HRQ0TkV9I8L6p8SLu31DxMsyabOd9joiSFECYyJJyOpI5x2/Sva9B8AWOn2yQy7EhUcW9qgijH5cn9Kp+EZIovEK+ayoGgdEycDdlMAfgDXoWaMLThVhzSXy6IKsnF2Rz+paRpWm6TdzQ2FuGSJiGKBjnHHJ96yfAcUf2m+VlUlYoQMjtl/wD61W/G1/8AJHp8ZGXxJL6hQflH4kH8qwPDt8bLxDbljiKb9y3/AAIjB/76x+ZqalSEcRGK2X6jjFum2d/Pp1lcDE9pbyA/3oway7nwjo83KW7QN6wuV/Tp+lb9Fd8qcZfEjnUmtmcZdeB1fIhvnK/3Z4g/8sVn/wDCvmD5U6aT6/ZsGvQ6KxeEpPoX7afc4+z8FhcC7vCUH8ECbB+Zz+mK6Ox0y0sYfKtYVjTqcckn1J6mrtFaU6FOn8KFKcpbsj8lfSlEajtT6K0sQIFA7UtFFMAooooAK4+/YnU7xs/8tcfkoH9K7CuS1aMxarcBs4ciRfpgD+YNedmSfs0/M6sJbnZjX8Ox/tC42HhwOx9fxqlFKXjBPBNa9ynn280K4LMuMZ79qxEYHGOB2r52qrO56kNVYc53ZzUCTvbXMc1s+J0bKkVKBvc4GRSiPHKqPesdb3RemzO007xVZ3CIt0GtpTwdwyufr/jW7BcQ3C7oJo5V9UYN/KvK1OZWU8dMA06GOWGbzYZ5I39UYr/KvXo5vUjpUjf8DingYvWLser0V5/aeItRslw7LcoP+eo5H4j+ua6/RNWh1a182L5XU4dD1U16uGx9LEPljo+zOKrhp0ld7GjRRRXaYHJfDH/kXLn/ALCd/wD+lUtdbXJfDH/kXLn/ALCd/wD+lUtdbQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAGKSlooASloxRQAUUUUAFFFFAAa5ay/5KhrP/AGBrH/0fd11JrlbP/kp+s/8AYHsf/R93QB1NFJRQAtLmm0ZoApa/zoeoAdfs8n/oJr57+M8Eq+FbfVbZC8ukXsN/gDkqrYb9Dn8K+idTTzdNuo/78Tr+YNeW3McVzZyRXCq8EqFXVuhUjkH8K8zHS5KkJHTQV4tFjQbOfxDphv8ATBBPasFKbmx5gKhuO3Qjr61ei1bV9K+WQzRoONl3EWX8G4/Q4rzDwxq/iX4Qyy6a2k3ur+FpG861MSFp4FP8JTqQP7wz7+g6C+/aB0G5sprf+xtaWWRCmGtHIGRj05pQoxSvCTTHKbb95XR1DySXU81xcsGlkbcxAwPQADPQCszUWMZ8xPvKMj6jkVyFr8WvCgZIb24vdPZuFN5aSRg/jgj866VtQs9SsRdadcwXdswJWSFw6nj1FcM4zT5pI3i4vRHtKHKgjoaWmQgrEoPUACn19EecFFFFABRRRQAUUUUAFFFFABRRRQAVz/if/j4s/wDdk/mtdBWJ4nTMFtJ3WTaT7EH+oFcuNV6Ev66m1B2qI4HUrs6Z4gExDGKWJd4H1Iz9Rj9TWube0vIxJHjD874m6/0rH8ZKscdtcMQqLuVmJwB0Iz+TVxnhPxHFq9s19o73KW4kKJI8ZQS47gHqvvXjex9pC57SipJWdmd/c2clsC0ZMkfqByPqP61FERt+8D602x8RRMqrdoY36F15X6+o/Wtia2hnGXUBj0deCP8AGuOdDlemhLco6SRlyJGR82DTN6hcE9Kiuop4p9sq7R2PZvpUUHnXEphigkklzgBFzmuZt3slqWrWvclaVccmn6VqE9hei4ttoUH5lJxvHpVyHwlq826R1ih44R5OT+WaYvhvVhKIzan/AHt67f51ssPiYNTUGn6EOrRknFyR6Hpl9FqFmlxAflbqD1U9watVm6Bpg0rT1t929yd7t6sfT8hWlX11JzcE6m/U8OfKpPl2OS+GP/IuXP8A2E7/AP8ASqWutrkvhj/yLlz/ANhO/wD/AEqlrra0JCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooADXK2f/JT9Z/7A9j/AOj7uuqNcrZf8lQ1n/sD2P8A6Pu6AOnNJTqKAEooxRigBk5AgkJ6BTXlIXfHbxnkOyIfxIFeqXaM9rMq/eZCB9cVxlv4duPPtyRgRyI35EH+lefjacpyjZHRRkop3OxvLK2vYfJu7eOaPsrrnHuPSs2Lwvo0bZFire0js4/Ikitqiu1wjLVowUmtmeV+ILC3069OmXywvbXBb7MkwBEq4yVwepA6/n3rhLr4Yw/bLjUvBk17ol4gHm/YkD27E9A8J4I9h064rvdck/t/XbzV8BtP0qb+zbF+zykE3Lj1GQkfsY39a7PwNGF0BHx80sjuT6/MQP0Arzlh7V3CLsrXOn2nuczR45pnxX8W+EQsPjjQ1vtOTj+09M3SKB6sOSPxr0/wr8TfCnieEPpmrQM3Uo5wy/Udvxro77RrC+LNcWyGRhguvyt+Y5rzvxH8E/DerTNcJbRR3JO4SqpikB9Q8ZU/mDXXarDz/r+upj7kj1CC5huF3QTRyr6owP8AKpc18+3nwi8XaY+7w94s1JAv3UuDHeKPbL7CP1qv5Hxj0ngf2XqMa+qXMbn/AL4+UUe3kt4/19wci6M961PWLPTcC4l/eEZEaDcxH07fjWLJ4wTP7mxlYeruq/yzXiX/AAk3j2J2a58EwXbk/PJBq0eSf+BZNOPjPxSn+t+HuoD/AHL6J/5CuSpiazfuWS9V/mbRpQW9z22HxfCSBPZzoPVGD4/ka3dO1O01BCbSZXI+8vRl+oPIr51HjbxM/EXw/wBUJ7b7uNB+opo8S/ECWRXs/B1rYSD7slxqqMR+CYNOniqqfv2t6r/MJUoP4T6YozXz3awfGjXkUrrWmafCejWkDSED/ekwD+Bq/D8JPGmoc6/8RdZkDdRbS+T/AOOgEfrXaqvNqkYOFt2e5s6r95gPqaja6gX700Q+rivGB+z/AKfJzfeItau27ma5kP8AJxT/APhnrw9/z/6j/wCBE3/xynzz/l/L/MVl3PYWv7RRlrqAD3kH+Nc14w8WeG7DS5v7R17TbYqN6h7hckjnGM5rhB+z14aPEt3qEi+jXM3/AMcq9p/wC8E2kgc2JlYc/P8AP+r7jUz5pxcXHf8AruVG0XdM4Hxn46HjLRNQ0XwPpd1qwmiaObUWUw21uCOTvI+Y4zwP1rH8GXHiXTzYaLqOgxrb20fktexXK7GVRhSE65PH517lFp8FpaPpyRBII90IQDGF5A/TFcjFYvBrcFtNyVkUg/3gDnP6V5EKqinBLY9igr+85anQWWhWkUaefGJpurFiSM+w6YrXRHkJWGOSQjghFJxUtjALq9hgYkK2WbB5wO38q62GKOGJY4kVEXoqjAFPDYV4hc0noc1fEuLtuzj5tNvbmFoltHBbozkAKfXrmui0LTBpdl5O7e7MXduxJ9PyFaWBRXpUMFToy51qziqV5VFyvYKMCiiusxCiiigDkvhj/wAi5c/9hO//APSqWutrkvhj/wAi5c/9hO//APSqWutoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArlrL/kqGs/8AYHsf/R93XU1y9l/yVDWv+wNY/wDo+7oA6eiloxQAmKTFOxRigBMUmKXFLigBuKwPG+pXGm6DIumsg1W8dbOxD9POfhWI7hRlz7Ka6HFcXYD/AISTx5c3x+bTdB3Wtt6SXTL+9f8A4ApCD3Z6AG6zpNvoPgvTNLs9xgtWSMM3LOQrZZj3JOST6k1t+Df+Rasv91v/AEI1W8dqTpEWBn9+v/oLVZ8F/wDItWftuH/j5rlX+8P0/U1f8NeptUUuKMV1GQlFLRQBha14as9TczDdb3J/5ax/xf7w7/zrmbnwjqsTkQTQTJ67ip/Ij+teh4oxXPUwtOo7tamkaso6I8s1bwz4jj0q6k0+KCS8SNmijkk4dgMhePXp+NbHgzQrDVtIsdYeY3UF1Es0ceNqgEZw3ckdCOOR0ru8Vx/hWNtC8T6zoJ4sZidUsPYSMfPjHssnzewmA7VMMHSg72uOVabOuVAqhVAAAwAB0pcUtFdRkFFFFABRRRQBg+IbIgm8iGdoxKo7gfxfh/L6VgSW0Ms8UzxgyR52N6V3jqGUhhkEYNcW8bQu0T/fiOxv6H8RzXjZhRUJe0j1O/C1G1yvoaHh2MNqLv3jjx/30f8A7E10tc94Yz9quyBxtQE+h+bj9a6Gu3AK1BfM58S/3jCiiiuwwCiiigAooooA5L4Y/wDIuXP/AGE7/wD9Kpa62uS+GP8AyLlz/wBhO/8A/SqWutoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArl7L/AJKhrX/YGsf/AEfd11FcvZf8lQ1r/sDWP/o+7oA6iiiigArF8SeKNH8NC2/tm8EEl0xS3hSN5ZZiBk7I0BZsDrgcd62q82+L/hK58US6O9ppJvHszK6XUGptY3Nq7BQDGwVgQQDkH0FAHcaRrenavp6Xun3SS2zqWDEFCACQcqwBGCCOR2q19stt6p9oh3t91d4yeM8fhzXzp4q8DeKBbeCbC/1J7rXtVjm0XV7iMM+bNn8wsz4GSigjJxktWv4n+D13qXifWb+3sbDypdT0yWyYyYaO1hiCTJ7ZAAx3wKAPb7q7RrGR7S5thIyMInkYFNwB64PIB64rP8NWdj4c0Gw05LuJsL/rZHAa4kY5d/csxJ/GvC9c8CX2i6t4c04aFbalp8niTULq3sA2IBbPANiudpCDIPBGM1BrPwh8Y3Hg3SdD8vS7kW2nTRh96eZBO8pdVEjozeWqkD5NpyOuKAPb/EHinw5bxaxHqOoRZ0aJbm+iUFnhQqSDtAycgHpmtfRbixbS4pLGaNrXb5gbONob5ufTg968W1X4W6xLd+MJIdN06afW9FgtYLxpgHguEhKSZyufnJGWB7c1X1P4P64mneJLPQRZ2Ntf2+mFYEl2pPJBnz1b5SBuz1IOe4xS5Ve/Ud9LHtt94h0mwlsI7vULeNr+Qw22XyJXAJIBHHQGnafrljfRXskbyRR2ly9rK1xE0I3rjO3eBuXnhhkHsa8Qj+E1/Fa6TL/Ylrd/ZNZe+ksby6iYPE8W1lUpEqIN+DtAxxmrV18M9f8A7Ta7uLCw1awHiXUdUk0ue42pcQzqgiY5UruUqTgjvTEe7oyuoZCGUjIIOQaWszwxaGx0CxtTYwaeYogv2SCTekP+yrYGQPpWnQAUUVm+JNc07w3ol1q+tXSWun2q7pZWBOOcAADkkkgADkk0AaVch8RYpbK2sfEdorNcaLKZpFQZMlq2FnXHf5cOPeMU/QvHmlaqLkzQalpIt4lndtWtHtFMZOAwZ8AjPvWwdd0aSxjuTqmntZzFlSX7QhjfA5AOcHAzmgDRgmjuII5oHWSKRQ6OpyGBGQRT6y213Rrawtrh9T06Gzm+WCU3CLHJ7Ic4P4Vi6n4/0ax1C+s/39zLaWMeosYArI8LvsUqxYAnP6UAddRVJtW09dRTT3vrVdQddy2xmUSkeoTOcfhTLXW9Lu7z7Ja6lZT3WC3kx3CM+AcE7Qc8HigDQooooAKp3unwXnMilZMYEiHDD/H8auUVMoqatJXQ02ndFextI7OARRZxnJY9WPqasUUU4xUVZA227sKKKKYgooooAKKKKAOS+GP/ACLlz/2E7/8A9Kpa62uS+GP/ACLlz/2E7/8A9Kpa62gAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACuXsv+Soa1/wBgax/9H3ddRXL2X/JUNa/7A1j/AOj7ugDqKKKKACiiigAqK5Mq28hgVWmCkornALY4BPYVLQaAPC/C3xT8VP4R8OXV9o9jqWpa1qU1jbiK58kHZ5nLZTC4KY75HPXiuhi+KNwLq9trjSYo57XxBaaG6i4z/rtuX+7/AA7jx3x1rsbHwT4bsJYZLPRrSF4bg3cZRMbJSCC6jscE9PWmXHgTwvc66dZn0SyfVDMlx9pMfz+YmCr/AFGBz7UAcFpHxa1LUNesrKfQ4Lewvr2/06C6S73uJbYE7ihUAAgetHwD+Iuo+NLNLK+VZ57GzSS8vZWCSSyu77QkYUDYFXlumePevRYfCOgQSW8kWlWqPbzy3MRCfcllGJHHu3el0jwloOj3dvc6XpVraXEFubWOSJNpWIsW2fTcScetAG5RRRQAUUUUAFcl8U/CLeNvBl1o8V0LS4Z454JWXcokjYMu4d1OMH611tFAHiH/AAgPxAuo/Es91rNmkupJCIbJrua6gjZZQ8hUSqRHuGQMKdvHpVXw/wDBjUbVrCPVW0u5s4vEUmry2zlpVaJoAmz5kAZtwzyAP5V7zRQB8v8AiX4e6p4PtNKaOyg1eVIdSgjs106W7giWaTejJtHySYYDnA4PPFdM3wn13UPDUsTTWltPdeGLLSfLlZsxzRSLI27AIxgY4zzXvVFAHimo/CjVrjxtc3qT6YbG41yHWjqDhvtsQRQPs68Y2cYBzwD0qTwp8JrzRPEnhfVs6as+nahqVzeSxKRJPHcBhEu7bltuehPHavZ6KACiiigAooooAKKKKACiiigAooooAKKKKAOS+GP/ACLlz/2E7/8A9Kpa62uS+GP/ACLlz/2E7/8A9Kpa62gAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACuWsv+Soa1/wBgax/9H3ddTXM614Vk1DXX1ay1/V9JuZLaO1kFkLdlkRGdlyJYn5BkboRQB01Fcj/wieq/9D34m/792H/yNR/wieq/9D34m/792H/yNQB11Fcj/wAInqv/AEPfib/v3Yf/ACNR/wAInqv/AEPfib/v3Yf/ACNQB11Fcj/wieq/9D34m/792H/yNR/wieq/9D34m/792H/yNQB11Fcj/wAInqv/AEPfib/v3Yf/ACNR/wAInqv/AEPfib/v3Yf/ACNQB11Fcj/wieq/9D34m/792H/yNR/wieq/9D34m/792H/yNQB11Fcj/wAInqv/AEPfib/v3Yf/ACNR/wAInqv/AEPfib/v3Yf/ACNQB11Fcj/wieq/9D34m/792H/yNR/wieq/9D34m/792H/yNQB11Fcj/wAInqv/AEPfib/v3Yf/ACNR/wAInqv/AEPfib/v3Yf/ACNQB11Fcj/wieq/9D34m/792H/yNR/wieq/9D34m/792H/yNQB11Fcj/wAInqv/AEPfib/v3Yf/ACNR/wAInqv/AEPfib/v3Yf/ACNQB11Fcj/wieq/9D34m/792H/yNR/wieq/9D34m/792H/yNQB11Fcj/wAInqv/AEPfib/v3Yf/ACNR/wAInqv/AEPfib/v3Yf/ACNQB11Fcj/wieq/9D34m/792H/yNR/wieq/9D34m/792H/yNQB11Fcj/wAInqv/AEPfib/v3Yf/ACNR/wAInqv/AEPfib/v3Yf/ACNQB11Fcj/wieq/9D34m/792H/yNR/wieq/9D34m/792H/yNQB11Fcj/wAInqv/AEPfib/v3Yf/ACNR/wAInqv/AEPfib/v3Yf/ACNQB11Fcj/wieq/9D34m/792H/yNR/wieq/9D34m/792H/yNQAvwx/5Fy5/7Cd//wClUtdbWT4X0OLw9pC2ENzc3YEskzT3JTzHeRy7E7FVerHoBWtQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAf/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The innervation of the adrenal glands is via visceral afferent fibers arising from the celiac, aorticorenal, and renal ganglia.These fibers connect with the posterior vagus nerve, phrenic nerve, and greater and lesser splanchnic nerves.",
"    <br>",
"     The nerve fibers provide sensory or indirect vasomotor innervation as they traverse the adrenal cortex, and terminate in the medulla as preganglionic sympathetic fibers.",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_23_11639=[""].join("\n");
var outline_f11_23_11639=null;
var title_f11_23_11640="Atropine: Drug information";
var content_f11_23_11640=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"43\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Atropine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?16/49/17173?source=see_link\">",
"    see \"Atropine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/13/25816?source=see_link\">",
"    see \"Atropine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F137934\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      AtroPen&reg;;",
"     </li>",
"     <li>",
"      Atropine Care&trade;;",
"     </li>",
"     <li>",
"      Isopto&reg; Atropine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F137935\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Dioptic's Atropine Solution;",
"     </li>",
"     <li>",
"      Isopto&reg; Atropine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F137978\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Anticholinergic Agent;",
"     </li>",
"     <li>",
"      Anticholinergic Agent, Ophthalmic;",
"     </li>",
"     <li>",
"      Antidote;",
"     </li>",
"     <li>",
"      Antispasmodic Agent, Gastrointestinal;",
"     </li>",
"     <li>",
"      Ophthalmic Agent, Mydriatic",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F137939\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Doses &lt;0.5 mg have been associated with paradoxical bradycardia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Inhibit salivation and secretions (preanesthesia):",
"     </b>",
"     <i>",
"      I.M., I.V., SubQ:",
"     </i>",
"     0.4-0.6 mg 30-60 minutes preop and repeat every 4-6 hours as needed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Bradycardia (Note:",
"     </b>",
"     Atropine may be ineffective in heart transplant recipients):",
"     <i>",
"      I.V.:",
"     </i>",
"     0.5 mg every 3-5 minutes, not to exceed a total of 3 mg or 0.04 mg/kg (ACLS, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Neuromuscular blockade reversal:",
"     </b>",
"     <i>",
"      I.V.:",
"     </i>",
"     25-30 mcg/kg 30-60 seconds before neostigmine or 7-10 mcg/kg 30-60 seconds before edrophonium",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Organophosphate or carbamate insecticide or nerve agent poisoning: Note:",
"     </b>",
"     The dose of atropine required varies considerably with the severity of poisoning. The total amount of atropine used for carbamate poisoning is usually less than with organophosphate insecticide or nerve agent poisoning. Severely poisoned patients may exhibit significant tolerance to atropine; &ge;2 times the suggested doses may be needed. Titrate to pulmonary status (decreased bronchial secretions); consider administration of atropine via continuous I.V. infusion in patients requiring large doses of atropine. Once patient is stable for a period of time, the dose/dosing frequency may be decreased. Pralidoxime is a component of the management of organophosphate insecticide and nerve agent toxicity; refer to Pralidoxime monograph for the specific route and dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      I.V., I.M. (unlabeled dose):",
"     </i>",
"     Initial: 1-6 mg (ATSDR, 2011; Roberts, 2007); repeat every 3-5 minutes as needed, doubling the dose if previous dose did not induce atropinization (Eddleston, 2004b; Roberts, 2007). Maintain atropinization by administering repeat doses as needed for &ge;2-12 hours based on recurrence of symptoms (Reigart, 1999).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      I.V. Infusion (unlabeled dose):",
"     </i>",
"     Following atropinization, administer 10% to 20% of the total loading dose required to induce atropinization as a continuous I.V. infusion per hour; adjust as needed to maintain adequate atropinization without atropine toxicity (Eddleston, 2004b; Roberts, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      I.M. (AtroPen&reg;):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Mild symptoms (&ge;2 mild symptoms): Administer 2 mg as soon as an exposure is known or strongly suspected. If severe symptoms develop after the first dose, 2 additional doses should be repeated in rapid succession  10 minutes after the first dose; do not administer more than 3 doses. If profound anticholinergic effects occur in the absence of excessive bronchial secretions, further doses of atropine should be withheld.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Severe symptoms (&ge;1 severe symptoms): Immediately administer",
"     <b>",
"      three",
"     </b>",
"     2 mg doses in rapid succession.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Symptoms of insecticide or nerve agent poisoning, as provided by manufacturer in the AtroPen&reg; product labeling, to guide therapy:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Mild symptoms: Blurred vision, bradycardia, breathing difficulties, chest tightness, coughing, drooling, miosis, muscular twitching, nausea, runny nose, salivation increased, stomach cramps, tachycardia, teary eyes, tremor, vomiting, or wheezing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Severe symptoms: Breathing difficulties (severe), confused/strange behavior, defecation (involuntary), muscular twitching/generalized weakness (severe), respiratory secretions (severe), seizure, unconsciousness, urination (involuntary)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Mydriasis, cycloplegia (preprocedure):",
"     </b>",
"     <i>",
"      Ophthalmic",
"     </i>",
"     (1% solution): Instill 1-2 drops 1 hour before the procedure.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Uveitis:",
"     </b>",
"     <i>",
"      Ophthalmic:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% solution: Instill 1-2 drops up to 4 times/day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ointment: Apply a small amount in the conjunctival sac up to 3 times/day. Compress the lacrimal sac by digital pressure for 1-3 minutes after instillation.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F137960\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/13/25816?source=see_link\">",
"      see \"Atropine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Doses &lt;0.1 mg have been associated with paradoxical bradycardia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Inhibit salivation and secretions (preanesthesia):",
"     </b>",
"     <i>",
"      I.M., I.V., SubQ:",
"     </i>",
"     Infants and Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Children &lt;5 kg:",
"     </i>",
"     0.02 mg/kg/dose 30-60 minutes preop then every 4-6 hours as needed. Use of a minimum dosage of 0.1 mg in neonates &lt;5 kg will result in dosages &gt;0.02 mg/kg. There is no documented minimum dosage in this age group.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Children &gt;5 kg:",
"     </i>",
"     0.01-0.02 mg/kg/dose to a maximum 0.4 mg/dose 30-60 minutes preop; minimum dose: 0.1 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Alternate dosing:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     3-7 kg (7-16 lb): 0.1 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     8-11 kg (17-24 lb): 0.15 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     11-18 kg (24-40 lb): 0.2 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     18-29 kg (40-65 lb): 0.3 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &gt;30 kg (&gt;65 lb): 0.4 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Bradycardia:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      I.V., I.O.:",
"     </i>",
"     Infants and Children: 0.02 mg/kg, minimum dose recommended by PALS: 0.1 mg; however, use of a minimum dosage of 0.1 mg in patients &lt;5 kg will result in dosages &gt;0.02 mg/kg and is not recommended (Barrington, 2011); there is no documented minimum dosage in this age group; maximum single dose: 0.5 mg; may repeat once in 3-5 minutes; maximum total dose: 1 mg (PALS, 2010).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endotracheal: Infants and Children: 0.04-0.06 mg/kg; may repeat once if needed (PALS, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Organophosphate or carbamate insecticide or nerve agent poisoning: Note:",
"     </b>",
"     The dose of atropine required varies considerably with the severity of poisoning. The total amount of atropine used for carbamate poisoning is usually less than with organophosphate insecticide or nerve agent poisoning. Severely poisoned patients may exhibit significant tolerance to atropine; &ge;2 times the suggested doses may be needed. Titrate to pulmonary status (decreased bronchial secretions); consider administration of atropine via continuous I.V. infusion in patients requiring large doses of atropine.  Once patient is stable for a period of time, the dose/dosing frequency may be decreased. Pralidoxime is a component of the management of organophosphate insecticide and nerve agent toxicity; refer to Pralidoxime monograph for the specific route and dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      I.V., I.M. (unlabeled dose):",
"     </i>",
"     Initial: 0.05-0.1 mg/kg; repeat every 5-10 minutes as needed, doubling the dose if previous dose does not induce atropinization (Hegenbarth, 2008; Rotenberg, 2003). Maintain atropinization by administering repeat doses as needed for &ge;2-12 hours based on recurrence of symptoms (Reigart, 1999).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      I.V. infusion (unlabeled dose):",
"     </i>",
"     Following atropinization, administer 10% to 20% of the total loading dose required to induce atropinization as a continuous I.V. infusion per hour; adjust as needed to maintain adequate atropinization without atropine toxicity  (Eddleston, 2004b; Roberts, 2007).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      I.M. (AtroPen&reg;):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Mild symptoms (&ge;2 mild symptoms): Administer the weight-based dose listed below as soon as an exposure is known or strongly suspected. If severe symptoms develop after the first dose, 2 additional doses should be repeated in rapid succession 10 minutes after the first dose; do not administer more than 3 doses. If profound anticholinergic effects occur in the absence of excessive bronchial secretions, further doses of atropine should be withheld.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Severe symptoms (&ge;1 severe symptoms): Immediately administer",
"     <b>",
"      three",
"     </b>",
"     weight-based doses in rapid succession.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Weight-based dosing:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &lt;6.8 kg (15 lb): 0.25 mg/dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     6.8-18 kg (15-40 lb): 0.5 mg/dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     18-41 kg (40-90 lb): 1 mg/dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &gt;41 kg (&gt;90 lb): 2 mg/dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     <i>",
"      Symptoms of insecticide or nerve agent poisoning, as provided by manufacturer in the AtroPen&reg; product labeling, to guide therapy:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Mild symptoms: Blurred vision, bradycardia, breathing difficulties, chest tightness, coughing, drooling, miosis, muscular twitching, nausea, runny nose, salivation increased, stomach cramps, tachycardia, teary eyes, tremor, vomiting, or wheezing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Severe symptoms: Breathing difficulties (severe), confused/strange behavior, defecation (involuntary), muscular twitching/generalized weakness (severe), respiratory secretions (severe), seizure, unconsciousness, urination (involuntary);",
"     <b>",
"      Note:",
"     </b>",
"     Infants may become drowsy or unconscious with muscle floppiness as opposed to muscle twitching.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Endotracheal (unlabeled route):",
"     </i>",
"     Increase the dose by 2-3 times the usual I.V. dose. Mix with 3-5 mL of normal saline and administer. Flush with 3-5 mL of NS and follow with 5 assisted manual ventilations (Rotenberg, 2003).",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F137940\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15673226\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15673227\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F137911\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as sulfate: 0.05 mg/mL (5 mL); 0.1 mg/mL (5 mL, 10 mL); 0.4 mg/mL (20 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     AtroPen&reg;: 0.25 mg/0.3 mL (0.3 mL); 0.5 mg/0.7 mL (0.7 mL); 1 mg/0.7 mL (0.7 mL); 2 mg/0.7 mL (0.7 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as sulfate [preservative free]: 0.4 mg/0.5 mL (0.5 mL [DSC]); 0.4 mg/mL (1 mL); 1 mg/mL (1 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ointment, ophthalmic, as sulfate: 1% (3.5 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, ophthalmic, as sulfate [drops]: 1% (2 mL [DSC], 5 mL, 15 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Atropine Care&trade;: 1% (2 mL, 5 mL, 15 mL) [contains benzalkonium chloride]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Isopto&reg; Atropine: 1% (5 mL, 15 mL) [contains benzalkonium chloride]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F137895\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block accres drugH1Div\" id=\"F11217108\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Prescribing and Access Restrictions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The AtroPen&reg; formulation is available for use primarily by the Department of Defense.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F137915\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.M.: AtroPen&reg;: Administer to the outer thigh. Firmly grasp the autoinjector with the green tip (0.5 mg, 1 mg, and 2 mg autoinjector) or black tip (0.25 mg autoinjector) pointed down; remove the yellow safety release (0.5 mg, 1 mg, and 2 mg autoinjector) or gray safety release (0.25 autoinjector). Jab the green tip at a 90&deg; angle against the outer thigh; may be administered through clothing as long as pockets at the injection site are empty. In thin patients or patients &lt;6.8 kg (15 lb), bunch up the thigh prior to injection.  Hold the autoinjector in place for 10 seconds following the injection; remove the autoinjector and massage the injection site. After administration, the needle will be visible; if the needle is not visible, repeat the above steps. After use, bend the needle against a hard surface (needle does not retract) to avoid accidental injury.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V.: Administer undiluted by rapid I.V. injection; slow injection may result in paradoxical bradycardia. In bradycardia, atropine administration should not delay treatment with external pacing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endotracheal: Dilute in NS or sterile water. Absorption may be greater with sterile water. Stop compressions (if using for cardiac arrest), spray the drug quickly down the tube. Follow immediately with several quick insufflations and continue chest compressions.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F137985\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Stable in NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Amiodarone, argatroban, bivalirudin, doripenem, eptifibatide, etomidate, famotidine, fenoldopam, fentanyl, heparin, hydrocortisone sodium succinate, inamrinone, meropenem, methadone, morphine, nafcillin, pantoprazole, potassium chloride, sufentanil, tirofiban, vitamin B complex with C.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Thiopental.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Propofol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Butorphanol, chlorpromazine, cimetidine, dimenhydrinate, diphenhydramine, droperidol, fentanyl, glycopyrrolate, heparin, hydromorphone, hydroxyzine, hydroxyzine with meperidine, meperidine, meperidine with promethazine, metoclopramide, midazolam, milrinone, morphine, nalbuphine, ondansetron, pentazocine, prochlorperazine, promethazine, ranitidine, scopolamine, sufentanil.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Pantoprazole.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Pentobarbital.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F137914\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection: Preoperative medication to inhibit salivation and secretions; treatment of symptomatic sinus bradycardia, AV block (nodal level); antidote for anticholinesterase poisoning (carbamate insecticides, nerve agents, organophosphate insecticides); adjuvant use with anticholinesterases (eg, edrophonium, neostigmine) to decrease their side effects during reversal of neuromuscular blockade",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Use is no longer recommended in the management of asystole or pulseless electrical activity (PEA) (ACLS, 2010).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ophthalmic: Produce mydriasis and cycloplegia for examination of the retina and optic disc and accurate measurement of refractive errors; produce papillary dilation in inflammatory conditions (eg, uveitis)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F13930952\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - varies based on comorbidity; Strength of recommendation - varies based on comorbidity)",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F137976\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Severity and frequency of adverse reactions are dose related and vary greatly; listed reactions are limited to significant and/or life-threatening.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Cardiovascular: Arrhythmia, flushing, hypotension, palpitation, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Ataxia, coma, delirium, disorientation, dizziness, drowsiness, excitement, fever, hallucinations, headache, insomnia, nervousness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Anhidrosis, urticaria, rash, scarlatiniform rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Bloating, constipation, delayed gastric emptying, loss of taste, nausea, paralytic ileus, vomiting, xerostomia, dry throat, nasal dryness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Urinary hesitancy, urinary retention",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Angle-closure glaucoma, blurred vision, cycloplegia, dry eyes, mydriasis, ocular tension increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Dyspnea, laryngospasm, pulmonary edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylaxis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F137918\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to atropine or any component of the formulation; narrow-angle glaucoma; adhesions between the iris and lens (ophthalmic product); pyloric stenosis; prostatic hypertrophy",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     No contraindications exist in the treatment of life-threatening organophosphate or carbamate insecticide or nerve agent poisoning.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F137899\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperthermia: In the presence of a high environmental temperature, heat prostration can occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Psychosis: Can occur in sensitive individuals or following use of excessive doses.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Urinary retention: Avoid use if possible in patients with obstructive uropathy or in other conditions resulting in urinary retention; use is contraindicated in patients with prostatic hypertrophy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anticholinesterase poisoning: Atropine reverses the muscarinic but not the nicotinic effects associated with anticholinesterase toxicity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Arrhythmias: Avoid relying on atropine for effective treatment of type II second-degree or third-degree AV block (with or without a new wide QRS complex). Asystole or bradycardic PEA: Although no evidence exists for significant detrimental effects, routine use is unlikely to have a therapeutic benefit and is no longer recommended (ACLS, 2010).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Autonomic neuropathy: Use with caution in patients with autonomic neuropathy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with myocardial ischemia, HF, tachyarrhythmias (including sinus tachycardia), and/or hypertension; treatment-related blood pressure increases and tachycardia may lead to ischemia, precipitate an MI, or increase arrhythmogenic potential.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastrointestinal disease: Avoid use in patients with paralytic ileus, intestinal atony of the elderly or debilitated patient, severe ulcerative colitis, and toxic megacolon complicating ulcerative colitis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment; effects of atropine may be prolonged in severe hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hiatal hernia: Use with caution in patients with hiatal hernia associated with reflux esophagitis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperthyroidism: Use with caution in patients with hyperthyroidism.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myasthenia gravis: In patients with myasthenia gravis, use atropine with extreme caution when used to treat side effects of acetylcholinesterase inhibition or avoid; may precipitate a myasthenic crisis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; effects of atropine may be prolonged in severe renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: May be inappropriate in older adults depending on comorbidities (eg, dementia, delirium) due to its potent anticholinergic effects (Beers Criteria).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull;	Heart transplant recipients: Atropine will likely be ineffective in treatment of bradycardia due to lack of vagal innervation of the transplanted heart. Cholinergic reinnervation may occur over time (years), so atropine may be used cautiously; however, some may experience paradoxical slowing of the heart rate and high-degree AV block upon administration  (ACLS, 2010; Bernheim, 2004).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Children may be more sensitive to the anticholinergic effects of atropine. Use with caution in children with spastic paralysis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; AtroPen&reg;: There are no absolute contraindications for the use of atropine in severe and life-threatening organophosphate or carbamate insecticide or nerve agent poisonings; however, in mild poisonings, use caution in those patients where the use of atropine would be otherwise contraindicated. Formulation for use by trained personnel only.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Anticholinesterase poisoning: Clinical symptoms consistent with highly-suspected organophosphate or carbamate insecticides or nerve agent poisoning should be treated with antidote immediately; administration should not be delayed for confirmatory laboratory tests. Signs of atropinization include flushing, mydriasis, tachycardia, and dryness of the mouth or nose.  Monitor effects closely when administering subsequent injections as necessary. The presence of these effects is not indicative of the success of therapy; inappropriate use of mydriasis as an indicator of successful treatment has resulted in atropine toxicity. Reversal of bronchial secretions is the preferred indicator of success.  Adjunct treatment with a cholinesterase reactivator (eg, pralidoxime) may be required in patients with toxicity secondary to organophosphorus insecticides or nerve agents. Treatment should always include proper evacuation and decontamination procedures; medical personnel should protect themselves from inadvertent contamination. Antidotal administration is intended only for initial management; definitive and more extensive medical care is required following administration. Individuals should not rely solely on antidote for treatment, as other supportive measures (eg, artificial respiration) may still be required.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298794\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F137904\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AbobotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: Anticholinergic Agents may enhance the tachycardic effect of Cannabinoids.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirabegron: Anticholinergic Agents may enhance the therapeutic effect of Mirabegron. This may result in acute urinary retention.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OnabotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium Chloride: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride.  Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RimabotulinumtoxinB: Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Secretin: Anticholinergic Agents may diminish the therapeutic effect of Secretin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topiramate: Anticholinergic Agents may enhance the adverse/toxic effect of Topiramate. Specifically, the risk of oligohidrosis and hyperthermia may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F137906\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B/C (manufacturer specific) (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F137921\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted. Atropine has been found to cross the human placenta.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F137943\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use caution (AAP rates &ldquo;compatible&rdquo;; AAP 2001 update pending)",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F137922\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Trace amounts of atropine are excreted into breast milk. Anticholinergic agents may suppress lactation.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F137920\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Device",
"     </b>",
"     (AtroPen Intramuscular)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.25 mg/0.3 mL (0.3 mL): $30.14",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5 mg/0.7 mL (0.7 mL): $25.24",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg/0.7 mL (0.7 mL): $25.24",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg/0.7 mL (0.7 mL): $25.24",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ointment",
"     </b>",
"     (Atropine Sulfate Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% (3.5 g): $19.90",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Atropine Sulfate Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.05 mg/mL (5 mL): $15.95",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.1 mg/mL (5 mL): $2.92",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.4 mg/mL (1 mL): $1.73",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.8 mg/mL (0.5 mL): $1.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg/mL (1 mL): $1.90",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Atropine Sulfate Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% (5 mL): $16.82",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Isopto Atropine Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% (5 mL): $39.18",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F137908\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Heart rate, blood pressure, pulse, mental status; intravenous administration requires a cardiac monitor",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     <i>",
"      Organophosphate or carbamate insecticide or nerve agent poisoning:",
"     </i>",
"     Heart rate, blood pressure, respiratory status, oxygenation secretions. Maintain atropinization with repeated dosing as indicated by clinical status. Crackles in lung bases, or continuation of cholinergic signs, may be signs of inadequate dosing. Pulmonary improvement may not parallel other signs of atropinization. Monitor for signs and symptoms of atropine toxicity (eg, fever, muscle fasciculations, delirium); if toxicity occurs, discontinue atropine and monitor closely.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F137923\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Antol (TW);",
"     </li>",
"     <li>",
"      Atrop (SG);",
"     </li>",
"     <li>",
"      Atropin \"Dak\" (DK);",
"     </li>",
"     <li>",
"      Atropin (DE, FI, HR);",
"     </li>",
"     <li>",
"      Atropin Dispersa (LU);",
"     </li>",
"     <li>",
"      Atropin Minims (NO);",
"     </li>",
"     <li>",
"      Atropina (IT);",
"     </li>",
"     <li>",
"      Atropina Braun (ES);",
"     </li>",
"     <li>",
"      Atropina Llorens (ES);",
"     </li>",
"     <li>",
"      Atropina Sulfato Serra (ES);",
"     </li>",
"     <li>",
"      Atropine (GR);",
"     </li>",
"     <li>",
"      Atropine Martinet (FR);",
"     </li>",
"     <li>",
"      Atropine Sulfate (IL);",
"     </li>",
"     <li>",
"      Atropine Sulfate Tablets (GB);",
"     </li>",
"     <li>",
"      Atropini sulfas (HR);",
"     </li>",
"     <li>",
"      Atropinsulfat Braun (LU);",
"     </li>",
"     <li>",
"      Atropinsulfat Lannacher (AT);",
"     </li>",
"     <li>",
"      Atropinsulfatloesung Fresenius (LU);",
"     </li>",
"     <li>",
"      Atropinum Sulfuricum (HU, PL);",
"     </li>",
"     <li>",
"      Atropinum Sulfuricum Nycomed (AT);",
"     </li>",
"     <li>",
"      Atropocil (PT);",
"     </li>",
"     <li>",
"      Atropt (AU, NZ);",
"     </li>",
"     <li>",
"      Atrosol (TR);",
"     </li>",
"     <li>",
"      Atrospan (IL);",
"     </li>",
"     <li>",
"      Bellafit N (CH);",
"     </li>",
"     <li>",
"      Bellapan (PL);",
"     </li>",
"     <li>",
"      Bellpino-Artin (IN);",
"     </li>",
"     <li>",
"      Colircusi Atropina (ES);",
"     </li>",
"     <li>",
"      Colirio Ocul Atropina (ES);",
"     </li>",
"     <li>",
"      Isopto (GB);",
"     </li>",
"     <li>",
"      Isopto Atropin (SE);",
"     </li>",
"     <li>",
"      Isopto Atropina (AR, CO, PE);",
"     </li>",
"     <li>",
"      Isopto Atropine (AE, BE, BF, BH, BJ, CI, CY, EG, ET, GH, GM, GN, IE, IQ, IR, JO, KE, KP, KW, LB, LR, LY, MA, ML, MR, MU, MW, MY, NE, NG, OM, PH, PK, QA, SA, SC, SD, SL, SN, SY, TH, TN, TZ, UG, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Minims Atropine (AT);",
"     </li>",
"     <li>",
"      Minims Atropine Sulfaat (NL);",
"     </li>",
"     <li>",
"      Minims Atropine Sulfate (AE, BH, CY, EG, GB, HK, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Minims Atropine Sulphate (FI);",
"     </li>",
"     <li>",
"      Minims-Atropine (IE);",
"     </li>",
"     <li>",
"      Minims-Atropinsulfat (AT);",
"     </li>",
"     <li>",
"      Ocutropine (KP);",
"     </li>",
"     <li>",
"      Oft Cusi Atropina (ES);",
"     </li>",
"     <li>",
"      Oftan Atropin (FI);",
"     </li>",
"     <li>",
"      Orbatropin (PE);",
"     </li>",
"     <li>",
"      Redotex (MX);",
"     </li>",
"     <li>",
"      Stellatropine (LU);",
"     </li>",
"     <li>",
"      Sulfate d'Atropine-Chauvin (LU)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F137898\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blocks the action of acetylcholine at parasympathetic sites in smooth muscle, secretory glands, and the CNS; increases cardiac output, dries secretions. Atropine reverses the muscarinic effects of cholinergic poisoning due to agents with acetylcholinesterase inhibitor activity by acting as a competitive antagonist of acetylcholine at muscarinic receptors. The primary goal in cholinergic poisonings is reversal of bronchorrhea and bronchoconstriction. Atropine has no effect on the nicotinic receptors responsible for muscle weakness, fasciculations, and paralysis.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F137917\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: I.M., I.V.: Rapid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: I.M.: Rapid and well absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Widely throughout the body; crosses blood-brain barrier",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic via enzymatic hydrolysis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 2-3 hours; Children &lt;2 years of age: 7 hours; Elderly 65-75 years of age: 10 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: I.M.: 3 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (30% to 50% as unchanged drug and metabolites)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Agency for Toxic Substances and Disease Registry (ATSDR), &ldquo;Nerve Agents,&rdquo; 2011. Available at",
"      <a href=\"file://www.atsdr.cdc.gov/MHMI/mmg166.pdf\" target=\"_blank\">",
"       file://www.atsdr.cdc.gov/MHMI/mmg166.pdf",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/23/11640/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/23/11640/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Barrington KJ, \"The Myth of a Minimum Dose for Atropine,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2011, 127(4):783-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/23/11640/abstract-text/21382950/pubmed\" id=\"21382950\" target=\"_blank\">",
"        21382950",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bernheim A, Fatio R, Kiowski W, et al, &ldquo;Atropine Often Results in Complete Atrioventricular Block or Sinus Arrest After Cardiac Transplantation: An Unpredictable and Dose-Independent Phenomenon,&rdquo;",
"      <i>",
"       Transplantation",
"      </i>",
"      , 2004, 77(8):1181-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/23/11640/abstract-text/15114081/pubmed\" id=\"15114081\" target=\"_blank\">",
"        15114081",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dix J, Weber RJ, Frye RF, et al, &ldquo;Stability of Atropine Sulfate Prepared for Mass Chemical Terrorism,&rdquo;",
"      <i>",
"       J Toxicol Clin Toxicol",
"      </i>",
"      , 2003, 41(6):771-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/23/11640/abstract-text/14677786/pubmed\" id=\"14677786\" target=\"_blank\">",
"        14677786",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Eddleston M, Buckley NA, Checketts H, et al, &ldquo;Speed of Initial Atropinisation in Significant Organophosphorus Pesticide Poisoning - A Systematic Comparison of Recommended Regimens,&rdquo;",
"      <i>",
"       J Toxicol Clin Toxicol",
"      </i>",
"      , 2004a, 42(6):865-75.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/23/11640/abstract-text/15533026/pubmed\" id=\"15533026\" target=\"_blank\">",
"        15533026",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Eddleston M, Dawson A, Karalliedde L, et al, &ldquo;Early Management After Self-Poisoning with an Organophosphorus or Carbamate Pesticide &ndash; A Treatment Protocol for Junior Doctors,&rdquo;",
"      <i>",
"       Crit Care",
"      </i>",
"      , 2004b, 8(6):R391-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/23/11640/abstract-text/15566582/pubmed\" id=\"15566582\" target=\"_blank\">",
"        15566582",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Eisenberg MS and Mengert TJ, &ldquo;Cardiac Resuscitation,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2001, 344(17):1304-13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/23/11640/abstract-text/11320390/pubmed\" id=\"11320390\" target=\"_blank\">",
"        11320390",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Field JM, Hazinski MF, Sayre MR, et al, &ldquo;Part 1: Executive Summary: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2010, 122 (Suppl 3):640-56.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hegenbarth MA, &ldquo;Preparing for Pediatric Emergencies: Drugs to Consider,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2008, 121(2):433-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/23/11640/abstract-text/18245435/pubmed\" id=\"18245435\" target=\"_blank\">",
"        18245435",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kanto J, Virtanen R, Iisalo E, et al, \"Placental Transfer and Pharmacokinetics of Atropine After a Single Maternal Intravenous and Intramuscular Administration,\"",
"      <i>",
"       Acta Anaesthesiol Scand",
"      </i>",
"      , 1981, 25(2):85-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/23/11640/abstract-text/7324829/pubmed\" id=\"7324829\" target=\"_blank\">",
"        7324829",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kleinman ME, Chameides L, Schexnayder SM, et al, &ldquo;Part 14: Pediatric Advanced Life Support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2010, 122(18 Suppl 3):876-908.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/23/11640/abstract-text/20956230/pubmed\" id=\"20956230\" target=\"_blank\">",
"        20956230",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mokhlesi B, Leikin JB, Murray P, et al, &ldquo;Adult Toxicology in Critical Care: Part II: Specific Poisonings,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2003, 123(3):897-922.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/23/11640/abstract-text/12628894/pubmed\" id=\"12628894\" target=\"_blank\">",
"        12628894",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Reigart JR and Roberts JR, &ldquo;Recognition and Management of Pesticide Poisonings,&rdquo; U.S. Environmental Protection Agency, Washington, D.C., 5th edition, 1999: 34-47. Available at",
"      <a href=\"file://www.epa.gov/oppfead1/safety/healthcare/handbook/handbook.htm\" target=\"_blank\">",
"       file://www.epa.gov/oppfead1/safety/healthcare/handbook/handbook.htm",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Roberts DM and Aaron CK, &ldquo;Management of Acute Organophosphorus Pesticide Poisoning,&rdquo;",
"      <i>",
"       BMJ",
"      </i>",
"      , 2007, 334(7594):629-34.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/23/11640/abstract-text/17379909/pubmed\" id=\"17379909\" target=\"_blank\">",
"        17379909",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rotenberg JS and Newmark J, \"Nerve Agent Attacks on Children: Diagnosis and Management,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2003, 112(3 Pt 1):648-58.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/23/11640/abstract-text/12949297/pubmed\" id=\"12949297\" target=\"_blank\">",
"        12949297",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8983 Version 45.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-118.195.65.244-FC54B750F8-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_23_11640=[""].join("\n");
var outline_f11_23_11640=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137934\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137935\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137978\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137939\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137960\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137940\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15673226\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15673227\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137911\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137895\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11217108\">",
"      Prescribing and Access Restrictions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137915\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137985\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137914\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13930952\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137976\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137918\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137899\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298794\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137904\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137906\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137921\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137943\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137922\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137920\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137908\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137923\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137898\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137917\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8983\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8983|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?16/49/17173?source=related_link\">",
"      Atropine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/13/25816?source=related_link\">",
"      Atropine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_23_11641="Differential diagnosis of the orthopedic manifestations of child abuse";
var content_f11_23_11641=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Differential diagnosis of the orthopedic manifestations of child abuse",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/23/11641/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/23/11641/contributors\">",
"     Susan A Scherl, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/23/11641/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/23/11641/contributors\">",
"     William Phillips, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/23/11641/contributors\">",
"     Daniel M Lindberg, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/23/11641/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/23/11641/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/23/11641/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;When evaluating the child who is suspected of being physically abused, it is important to remember that findings that appear to be inflicted may result from other causes. The differential diagnosis of child abuse varies depending upon the clinical manifestations. In some cases, the manifestations of abuse are so characteristic that there is no differential diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/23/11641/abstract/1\">",
"     1",
"    </a>",
"    ]. Other cases are less clear. In these cases, familiarity with the conditions that can simulate child abuse can facilitate arrival at the correct diagnosis, initiation of appropriate therapy, and avoidance of the consequences of an unnecessary report of suspected child abuse.",
"   </p>",
"   <p>",
"    The differential diagnosis of the orthopedic manifestations of child abuse will be discussed here. An overview of the orthopedic manifestations of child abuse and the differential diagnosis of other clinical manifestations of child abuse are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/30/13802?source=see_link\">",
"     \"Orthopedic aspects of child abuse\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/27/23990?source=see_link\">",
"     \"Differential diagnosis of suspected child abuse\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1405830\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC CONSIDERATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major considerations in the differential diagnosis of a child with potentially inflicted orthopedic trauma include accidental injury, normal variants, birth trauma, metabolic bone disease, skeletal dysplasia (including osteogenesis imperfecta [OI]), infection, drug toxicity, and congenital insensitivity to pain [",
"    <a class=\"abstract\" href=\"UTD.htm?11/23/11641/abstract/2-5\">",
"     2-5",
"    </a>",
"    ]. A careful history and physical examination, in conjunction with additional laboratory tests or radiographic studies, if indicated, usually can lead to the proper diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/23/11641/abstract/4,6\">",
"     4,6",
"    </a>",
"    ]. Radiographic review with a pediatric radiologist is often a key step in differentiating normal bony variants or bone disease from inflicted injury.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ACCIDENTAL TRAUMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unintentional injury is a major consideration in all children who present with orthopedic trauma. This is particularly true in children who present with isolated linear parietal skull fractures or diaphyseal long-bone fractures, because these fractures are common in both intentional and unintentional injury [",
"    <a class=\"abstract\" href=\"UTD.htm?11/23/11641/abstract/7-10\">",
"     7-10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/30/13802?source=see_link&amp;anchor=H13#H13\">",
"     \"Orthopedic aspects of child abuse\", section on 'Fracture patterns'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Even injuries that are highly suggestive of child abuse, such as femoral fractures in infants, may be caused in unusual accidents [",
"    <a class=\"abstract\" href=\"UTD.htm?11/23/11641/abstract/11\">",
"     11",
"    </a>",
"    ]. Stairway injuries and falls from the arms of caretakers are important sources of accidental skull and long-bone fractures [",
"    <a class=\"abstract\" href=\"UTD.htm?11/23/11641/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]. The child's injuries must be viewed in the context of the child's age and the purported mechanism of injury [",
"    <a class=\"abstract\" href=\"UTD.htm?11/23/11641/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     NORMAL VARIANTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The radiographic appearance of some normal variants can mimic the metaphyseal or diaphyseal findings of child abuse.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Metaphyseal variants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Normal metaphyseal variants that have radiographic appearance similar to classic metaphyseal lesions (CMLs) include step-off, beak, proximal tibial cortical irregularity, and spur [",
"    <a class=\"abstract\" href=\"UTD.htm?11/23/11641/abstract/17\">",
"     17",
"    </a>",
"    ]. They may be unilateral or bilateral. These normal variants are contour changes but are in close continuity with normal bone and with the cortex. In contrast, in CMLs, a discrete fracture fragment is separated by a radiolucency from the remainder of the metaphysis. High-detail radiographs in several projections may be necessary to demonstrate the fracture fragment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/30/13802?source=see_link&amp;anchor=H15#H15\">",
"     \"Orthopedic aspects of child abuse\", section on 'Long-bone fractures'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A step-off is an acute angulation (almost 90&ordm;) in the extreme portion of the metaphysis adjacent to the physis that is seen in the distal femur, radius, and ulna, and the proximal tibia and fibula (",
"      <a class=\"graphic graphic_figure graphicRef67603 \" href=\"UTD.htm?10/41/10898\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      A beak is a medial projection that may be seen on the proximal humerus and tibia (",
"      <a class=\"graphic graphic_figure graphicRef67603 \" href=\"UTD.htm?10/41/10898\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Proximal tibial cortical irregularity consists of an area of focal cortical irregularity in the medial aspect of the proximal tibial metaphysis, suggesting focal periosteal new bone formation (",
"      <a class=\"graphic graphic_figure graphicRef67603 \" href=\"UTD.htm?10/41/10898\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      A spur is a discrete longitudinal projection of bone that is continuous with the cortex and extends beyond the metaphyseal margin. It may be seen on the lateral aspect of the distal femur and distal radius, the medial aspect of the distal ulna, and the metacarpals and metatarsals (",
"      <a class=\"graphic graphic_figure graphicRef67603 \" href=\"UTD.htm?10/41/10898\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Diaphyseal variants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symmetric, uniform, diaphyseal periosteal elevation involving the humerus, femora, or tibiae may be seen as a manifestation of physiologic new bone formation in infants between two and eight months of age [",
"    <a class=\"abstract\" href=\"UTD.htm?11/23/11641/abstract/4,18,19\">",
"     4,18,19",
"    </a>",
"    ]. The physiologic new bone is typically most obvious on the medial aspect of the bone; it is smooth, lamellar, and confined to the diaphysis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/23/11641/abstract/4\">",
"     4",
"    </a>",
"    ]. In contrast, periosteal changes from inflicted trauma are asymmetric, heterogeneous, extend to the metaphysis, and produce abnormal uptake in radionuclide bone scans [",
"    <a class=\"abstract\" href=\"UTD.htm?11/23/11641/abstract/4,20\">",
"     4,20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     BIRTH TRAUMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clavicle or humerus can be fractured during the birth process. In one study, in which 9106 newborns were prospectively screened for clavicle fractures, the prevalence was 1 in 213 live births (0.5 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/23/11641/abstract/21\">",
"     21",
"    </a>",
"    ]. All fractures occurred during vaginal deliveries, and none of the infants were in breech presentation. Risk factors for newborn clavicle fractures included large birth weight (average birth weight 3.8 kg versus 3.4 kg among infants with and without clavicle fractures, respectively), shoulder dystocia, mechanically assisted delivery, and prolonged gestation. In these infants, fracture callus usually is visible or palpable within the first two weeks of life [",
"    <a class=\"abstract\" href=\"UTD.htm?11/23/11641/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/21/24922?source=see_link&amp;anchor=H27#H27\">",
"     \"Assessment of the newborn infant\", section on 'Clavicles'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Rib fractures also can occur in the setting of a difficult delivery, although this is a rare occurrence. A 2008 case series and review of the literature identified a total of 13 cases [",
"    <a class=\"abstract\" href=\"UTD.htm?11/23/11641/abstract/23\">",
"     23",
"    </a>",
"    ]. Common features included macrosomia and difficult delivery. Shoulder dystocia occurred in seven cases and ipsilateral clavicle fracture in six.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     METABOLIC BONE DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Metabolic bone disease is one of the major considerations in the differential diagnosis of child abuse.",
"   </p>",
"   <p>",
"    Similar to victims of child abuse, children with metabolic bone disease may have periosteal new bone formation or sustain pathologic fractures after seemingly trivial trauma. In contrast to the degree of trauma in children with inflicted injuries, trauma in children with metabolic bone disease actually is trivial. Metabolic bone disease can usually be distinguished from inflicted injury after a complete examination and appropriate laboratory and radiographic studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Rickets",
"    </span>",
"    &nbsp;&mdash;&nbsp;Metaphyseal fractures and periosteal new bone formation may be seen in both rickets and physical abuse [",
"    <a class=\"abstract\" href=\"UTD.htm?11/23/11641/abstract/24\">",
"     24",
"    </a>",
"    ]. Rickets can be caused by deficient intake, poor absorption, or increased excretion of calcium, phosphate, or vitamin D&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef67378 \" href=\"UTD.htm?11/53/12124\">",
"     table 1",
"    </a>",
"    ). Premature infants, particularly those with birth weights less than 1500 g, and breast-fed or infants with inadequate intake of vitamin D are at risk for rickets. Premature infants also are at increased risk for abuse [",
"    <a class=\"abstract\" href=\"UTD.htm?11/23/11641/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/37/28248?source=see_link&amp;anchor=H3#H3\">",
"     \"Etiology and treatment of calcipenic rickets in children\", section on 'Vitamin D deficiency'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The characteristic radiographic and laboratory findings of rickets can usually distinguish this disease from physical abuse. Characteristic radiographic findings of rickets include osteopenia, metaphyseal cupping (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef80989 \" href=\"UTD.htm?40/15/41206\">",
"     image 1",
"    </a>",
"    ), physeal widening, enlargement of the costochondral junction (\"rachitic rosary\", (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef81446 \" href=\"UTD.htm?19/21/19807\">",
"     image 2",
"    </a>",
"    )), and Looser zones (pseudofractures, (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef52768 \" href=\"UTD.htm?7/43/7862\">",
"     image 3",
"    </a>",
"    )). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/21/26967?source=see_link&amp;anchor=H2256742#H2256742\">",
"     \"Overview of rickets in children\", section on 'Radiographic findings'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The characteristic laboratory abnormality in rickets is a markedly elevated alkaline phosphatase. Other biochemical findings vary depending upon the type of rickets, and may include decreased calcium or phosphate concentrations. These findings usually are not present in children who have been physically abused (unless there is concomitant nutritional neglect) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/23/11641/abstract/27\">",
"     27",
"    </a>",
"    ]. Rickets is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/21/26967?source=see_link\">",
"     \"Overview of rickets in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Vitamin C deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vitamin C deficiency (ascorbic acid deficiency, scurvy), may present with bone pain and periosteal reaction. Radiographic findings include large periosteal calcium deposits secondary to subperiosteal hemorrhage and central epiphyseal lucency. Infants and children with ascorbic acid deficiency typically present with irritability, pseudoparalysis (secondary to pain), failure to thrive, and gingival hemorrhage. The prominence of hair follicles on the thighs and buttocks (",
"    <a class=\"graphic graphic_picture graphicRef64172 \" href=\"UTD.htm?33/17/34067\">",
"     picture 1",
"    </a>",
"    ) and the eruption of coiled, fragmented hair with a characteristic corkscrew appearance are specific features of vitamin C deficiency.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Copper deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Copper deficiency may be caused by dietary deficiency or a recessive X-linked disorder of copper metabolism (Menkes disease, kinky hair disease). It is associated with metabolic bone disease that may result in pathologic fractures. However, similar to rickets, copper deficiency has characteristic clinical, laboratory, and radiographic features that can distinguish it from physical abuse.",
"   </p>",
"   <p>",
"    Predisposing factors for nutritional copper deficiency include low birth weight (&lt;2500 g), prolonged parenteral nutrition, malnutrition, and peritoneal dialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/23/11641/abstract/28\">",
"     28",
"    </a>",
"    ]. Nutritional copper deficiency has not been reported among full-term breast-fed infants, nor among full-term infants ingesting a formula containing at least &lt;40",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    of copper. Clinical features of nutritional copper deficiency include [",
"    <a class=\"abstract\" href=\"UTD.htm?11/23/11641/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Failure to thrive",
"     </li>",
"     <li>",
"      Psychomotor retardation",
"     </li>",
"     <li>",
"      Hypotonia",
"     </li>",
"     <li>",
"      Hypopigmentation",
"     </li>",
"     <li>",
"      Prominent scalp veins in palpable periosteal depressions",
"     </li>",
"     <li>",
"      Hepatomegaly",
"     </li>",
"     <li>",
"      Sideroblastic anemia",
"     </li>",
"     <li>",
"      Neutropenia (usually less than",
"      <span class=\"nowrap\">",
"       1000/microL)",
"      </span>",
"     </li>",
"     <li>",
"      Radiologic changes of osteoporosis (blurring and cupping of metaphyses, sickle-shaped metaphyseal spur formation, fractures)",
"     </li>",
"     <li>",
"      Plasma copper concentration usually &lt;40",
"      <span class=\"nowrap\">",
"       mcg/dL",
"      </span>",
"     </li>",
"     <li>",
"      Plasma ceruloplasmin concentration &lt;13",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Menkes disease is a rare X-linked recessive disorder of copper metabolism. The clinical features of Menkes disease are similar to those of nutritional copper deficiency, except that patients with Menkes disease have neither sideroblastic anemia nor neutropenia, and have increased, rather than decreased, muscle tone. Patients with Menkes disease have the following additional clinical features [",
"    <a class=\"abstract\" href=\"UTD.htm?11/23/11641/abstract/30\">",
"     30",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Intrauterine growth retardation",
"     </li>",
"     <li>",
"      Microcephaly",
"     </li>",
"     <li>",
"      Intracranial hemorrhage",
"     </li>",
"     <li>",
"      Seizures",
"     </li>",
"     <li>",
"      Focal cerebral and cerebellar degeneration",
"     </li>",
"     <li>",
"      Steely, kinky, sparse hair (twisted with partial breaks on magnification)",
"     </li>",
"     <li>",
"      Wormian bones (small, irregular bones along the cranial sutures)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Features that distinguish copper deficiency from physical abuse include the characteristic metaphyseal changes (cupping, fraying, and sickle-shaped metaphyseal spurs) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/23/11641/abstract/28,31\">",
"     28,31",
"    </a>",
"    ]. In addition, children with copper deficiency usually have delayed bone age [",
"    <a class=\"abstract\" href=\"UTD.htm?11/23/11641/abstract/31\">",
"     31",
"    </a>",
"    ], and symmetric skeletal findings involving the entire skeleton. The skeletal changes are particularly evident in the most rapidly growing bone ends (eg, the wrists, knees, proximal femora and humeri, and costochondral junctions).",
"   </p>",
"   <p>",
"    If the copper deficiency is severe enough to cause fractures, the other clinical manifestations (as described above) should be present [",
"    <a class=\"abstract\" href=\"UTD.htm?11/23/11641/abstract/28\">",
"     28",
"    </a>",
"    ]. Nutritional copper deficiency is neither associated with skull fracture or cerebral hemorrhage, nor with rib fractures in full-term infants. Furthermore, nutritional copper deficiency is unlikely if the child lacks a predisposing factor and has normal-appearing bones on skeletal survey [",
"    <a class=\"abstract\" href=\"UTD.htm?11/23/11641/abstract/28\">",
"     28",
"    </a>",
"    ]. Serum copper and ceruloplasmin concentrations can be measured, if indicated by the clinical constellation, to confirm or refute the diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Other conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pathologic fractures also occur in several inherited syndromes. Some of these are associated with renal disease (eg, primary hyperoxaluria, autosomal dominant distal renal tubular acidosis, Lowe oculocerebrorenal syndrome). Others are associated with skeletal abnormalities (eg, McCune-Albright syndrome, mucolipidosis II [I-cell disease], Gaucher disease, hyperimmunoglobulin E syndrome [Job syndrome]) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/23/11641/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. The additional clinical manifestations of these disorders can usually distinguish them from physical abuse. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/55/12154?source=see_link\">",
"     \"Primary hyperoxaluria\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/32/10759?source=see_link\">",
"     \"Overview of renal tubular acidosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/11/9402?source=see_link\">",
"     \"Gaucher disease: Pathogenesis, clinical manifestations, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/25/32153?source=see_link&amp;anchor=H8#H8\">",
"     \"Hyperimmunoglobulin E syndrome\", section on 'Skeletal abnormalities'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SKELETAL DYSPLASIA",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Osteogenesis imperfecta",
"    </span>",
"    &nbsp;&mdash;&nbsp;OI is an inherited disorder of collagen formation that results in \"brittle\" bones that are prone to repeated fracture, often with minimal trauma. The clinical features, diagnosis, and management of OI are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/9/38040?source=see_link\">",
"     \"Osteogenesis imperfecta: Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/36/26185?source=see_link\">",
"     \"Osteogenesis imperfecta: Management and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Similar to children with inflicted trauma, children with severe forms of OI have multiple fractures in various stages of healing. They also may have metaphyseal, rib, and skull fractures. Although OI is a well recognized cause of fractures that occur with minimal or no witnessed trauma, OI is a rare disorder and consequently is seldom the cause of such fractures. This was illustrated in a study of 39 infants (up to 12 months of age) who had rib fractures [",
"    <a class=\"abstract\" href=\"UTD.htm?11/23/11641/abstract/34\">",
"     34",
"    </a>",
"    ]. Final diagnoses were child abuse (82 percent), accidental injuries (8 percent), birth trauma (one case), and, finally, bone fragility (8 percent, of whom one had OI, one had rickets, and one was born prematurely).",
"   </p>",
"   <p>",
"    The differentiation between OI and child abuse can be difficult, and relies heavily on careful clinical evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?11/23/11641/abstract/35\">",
"     35",
"    </a>",
"    ]. The diagnosis of OI is usually clear when associated characteristic manifestations are present [",
"    <a class=\"abstract\" href=\"UTD.htm?11/23/11641/abstract/36\">",
"     36",
"    </a>",
"    ]. These include a positive family history, scoliosis, long-bone deformity, growth retardation, hearing loss, dentinogenesis imperfecta (",
"    <a class=\"graphic graphic_picture graphicRef68896 \" href=\"UTD.htm?35/46/36576\">",
"     picture 2",
"    </a>",
"    ), osteopenia, wormian bones, and possibly blue sclerae (",
"    <a class=\"graphic graphic_picture graphicRef51775 \" href=\"UTD.htm?0/63/1014\">",
"     picture 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?11/23/11641/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. Osteopenia (perhaps mild) and wormian bones are almost always present, even in patients with mild disease who may lack other characteristic features. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/9/38040?source=see_link\">",
"     \"Osteogenesis imperfecta: Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/27/440?source=see_link&amp;anchor=H22#H22\">",
"     \"Developmental defects of the teeth\", section on 'Dentinogenesis imperfecta'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, the characteristic features of OI are not universally present, and when this is so, the differentiation from child abuse may be difficult. To further complicate the issue, children with OI are not immune to inflicted trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?11/23/11641/abstract/39\">",
"     39",
"    </a>",
"    ]. Patients with mild OI usually do not begin to have fractures until they begin toddling or walking [",
"    <a class=\"abstract\" href=\"UTD.htm?11/23/11641/abstract/40\">",
"     40",
"    </a>",
"    ]. The fractures typically occur in the diaphyses of long bones; metaphyseal corner fractures, posterior rib, and skull fractures are not characteristic of mild OI [",
"    <a class=\"abstract\" href=\"UTD.htm?11/23/11641/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinical features highly suggestive of inflicted trauma include a history that is inconsistent with the child's injuries; lack of or delay in seeking medical care; retinal hemorrhages; subdural hematoma; and characteristic patterns of bruising [",
"    <a class=\"abstract\" href=\"UTD.htm?11/23/11641/abstract/38\">",
"     38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/54/26473?source=see_link\">",
"     \"Physical abuse in children: Epidemiology and clinical manifestations\"",
"    </a>",
"    .) However, retinal hemorrhages and subdural hematoma also can occur in children with OI [",
"    <a class=\"abstract\" href=\"UTD.htm?11/23/11641/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. In unclear cases, nonaccidental injury is assumed to be the cause of inexplicable fractures because of the potential threat to the child's life of a missed diagnosis of inflicted injury [",
"    <a class=\"abstract\" href=\"UTD.htm?11/23/11641/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is no definitive lab test for OI. As in child abuse, the diagnosis of OI is largely clinical, and is based mainly on a careful history and physical examination. Analysis of type I collagen genes (which requires skin biopsy for fibroblast culture) and DNA testing of white blood cells for mutations in COL1A1 and COL1A2 can be helpful. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/9/38040?source=see_link&amp;anchor=H12#H12\">",
"     \"Osteogenesis imperfecta: Clinical features and diagnosis\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Genetic consultation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    testing for OI should be considered in children who present with fractures suggestive of abuse if:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      There are no other signs of abuse (eg, bruises or head injury).",
"     </li>",
"     <li>",
"      The fracture site is consistent with the history but the mechanism of injury seems too minor to have caused fracture.",
"     </li>",
"     <li>",
"      The child has sustained fractures in different environments.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The safety of the child should be ensured until the results of the evaluation are complete.",
"   </p>",
"   <p>",
"    DEXA scanning or CT evaluation for bone mineral density may have a role as an adjunct in diagnosis of OI since virtually all adults, and most children [",
"    <a class=\"abstract\" href=\"UTD.htm?11/23/11641/abstract/44,45\">",
"     44,45",
"    </a>",
"    ], with OI have osteoporosis. Bone mineral studies may also prove helpful in the differentiation of child abuse and mild OI [",
"    <a class=\"abstract\" href=\"UTD.htm?11/23/11641/abstract/44,46\">",
"     44,46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Infantile cortical hyperostosis (Caffey disease)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infantile cortical hyperostosis (Caffey disease, Caffey-Silverman disease) is characterized by fever (sometimes as high as 40&ordm;C [104&ordm;F]), irritability, subperiosteal bone hyperplasia, and swelling of overlying soft tissues [",
"    <a class=\"abstract\" href=\"UTD.htm?11/23/11641/abstract/47-51\">",
"     47-51",
"    </a>",
"    ]. The bone changes typically begin before six months of age and resolve by two years [",
"    <a class=\"abstract\" href=\"UTD.htm?11/23/11641/abstract/47,49,52,53\">",
"     47,49,52,53",
"    </a>",
"    ]. Leukocytosis, elevated ESR, and elevated alkaline phosphatase are common laboratory findings [",
"    <a class=\"abstract\" href=\"UTD.htm?11/23/11641/abstract/54\">",
"     54",
"    </a>",
"    ]. These clinical features in conjunction with radiologic demonstration of periosteal involvement establish the diagnosis.",
"   </p>",
"   <p>",
"    Radiographic manifestations include cortical diaphyseal periosteal new bone formation, typically of the mandible, long bones, clavicles, scapulae, and ribs, although any bone may be involved. The mandible is involved in 95 percent of cases, and mandibular involvement is useful in differentiating Caffey disease from child abuse. Periosteal reaction of a single bone (except the mandible) is suggestive of trauma (inflicted or otherwise) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/23/11641/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Infantile cortical hyperostosis is transmitted as an autosomal dominant trait with incomplete penetrance [",
"    <a class=\"abstract\" href=\"UTD.htm?11/23/11641/abstract/53,55-57\">",
"     53,55-57",
"    </a>",
"    ]. It has been linked to a mutation in the gene encoding the alpha 1 chain of type I collagen (COL1A1) on chromosome 17q21 [",
"    <a class=\"abstract\" href=\"UTD.htm?11/23/11641/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     INFECTION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Congenital syphilis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The skeletal changes of congenital syphilis usually involve the metaphysis and diaphysis of the long bones [",
"    <a class=\"abstract\" href=\"UTD.htm?11/23/11641/abstract/58\">",
"     58",
"    </a>",
"    ]. Metaphyseal lesions appear as irregular bands of decreased mineralization or focal circumscribed areas of metaphyseal and cortical bone destruction [",
"    <a class=\"abstract\" href=\"UTD.htm?11/23/11641/abstract/59\">",
"     59",
"    </a>",
"    ]. The lesions are usually, but not always, symmetric [",
"    <a class=\"abstract\" href=\"UTD.htm?11/23/11641/abstract/60\">",
"     60",
"    </a>",
"    ]. Wimberger sign (destruction of the medial aspect of the proximal tibial metaphysis) is characteristic, but not pathognomonic [",
"    <a class=\"abstract\" href=\"UTD.htm?11/23/11641/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]. The lesions can manifest as pseudoparalysis (refusal to move an affected limb) and may result in pathologic fractures.",
"   </p>",
"   <p>",
"    Clinical manifestations of congenital syphilis in children younger than two years of age can help to differentiate it from physical abuse. These include cutaneous lesions, hepatosplenomegaly, jaundice, anemia, and snuffles. Laboratory abnormalities may include leukocytosis, monocytosis, and a Coombs-negative hemolytic anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?11/23/11641/abstract/63,64\">",
"     63,64",
"    </a>",
"    ]. Serum Venereal Disease Research Laboratory (VDRL) test or rapid plasma reagin (RPR) titers four times higher than maternal titers confirm the diagnosis. Congenital syphilis is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/31/17914?source=see_link\">",
"     \"Congenital syphilis: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Osteomyelitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with acute osteomyelitis may present with a warm, swollen, tender extremity. Similar findings may be present in a child with repeated or severe injury and extensive subperiosteal bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?11/23/11641/abstract/4\">",
"     4",
"    </a>",
"    ]. In contrast to the abused child whose radiograph may demonstrate extensive periosteal reaction, bone changes are not usually present in early acute osteomyelitis. However, bone changes often are present in late acute, subacute, and chronic osteomyelitis. In addition, children with osteomyelitis usually have increased acute-phase reactants (erythrocyte sedimentation rate [ESR] and C-reactive protein [CRP]), and may have an increase or left shift in the white blood cell count. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/32/33289?source=see_link\">",
"     \"Evaluation and diagnosis of hematogenous osteomyelitis in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     TOXICITY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Vitamin A",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic overingestion of vitamin A may cause thick periosteal reaction of the tubular bones, widening of the cranial sutures, premature physeal closure, muscle tenderness, bone tenderness and hypercalcemia, and pathologic fracture [",
"    <a class=\"abstract\" href=\"UTD.htm?11/23/11641/abstract/1,65,66\">",
"     1,65,66",
"    </a>",
"    ]. Elevation of serum vitamin A concentration is diagnostic [",
"    <a class=\"abstract\" href=\"UTD.htm?11/23/11641/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Methotrexate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skeletal manifestations of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/32/13833?source=see_link\">",
"     methotrexate",
"    </a>",
"    osteopathy include osteopenia, particularly of the lower extremities, dense provisional zones of calcification, growth arrest lines, and pathologic fractures [",
"    <a class=\"abstract\" href=\"UTD.htm?11/23/11641/abstract/67-70\">",
"     67-70",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Prostaglandin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reversible, symmetrical periostitis of the long bones, associated with limb pain and swelling, has been observed in children treated with prostaglandins for cyanotic congenital heart disease [",
"    <a class=\"abstract\" href=\"UTD.htm?11/23/11641/abstract/1,71\">",
"     1,71",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Interleukin-11",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reversible periostitis of the clavicle, humerus, forearm, and lower-extremity long bone also has been reported among children treated with interleukin-11 for thrombocytopenia [",
"    <a class=\"abstract\" href=\"UTD.htm?11/23/11641/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     INSENSITIVITY TO PAIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Insensitivity to pain can predispose patients to recurrent injury that can mimic inflicted trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?11/23/11641/abstract/73\">",
"     73",
"    </a>",
"    ]. Insensitivity to pain may be a manifestation of hereditary sensory autonomic neuropathy or other disorders with sensory deficits (eg, myelodysplasia, cerebral palsy). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/33/29209?source=see_link\">",
"     \"Clinical features of cerebral palsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Congenital",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital insensitivity to pain, also known as hereditary sensory autonomic neuropathy (HSAN) type 4, is a rare, autosomal recessive disorder. Because these children do not feel pain, they are prone to repetitive injury that may be difficult to differentiate from abuse. Careful clinical history and neurosensory examination can make the diagnosis. Patients with HSAN are unable to sense pain and often temperature, but all other sensation (light touch, deep touch, proprioception) remains intact [",
"    <a class=\"abstract\" href=\"UTD.htm?11/23/11641/abstract/63\">",
"     63",
"    </a>",
"    ]. Congenital insensitivity to pain is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/27/23990?source=see_link&amp;anchor=H12#H12\">",
"     \"Differential diagnosis of suspected child abuse\", section on 'Congenital insensitivity to pain'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/16/43272?source=see_link\">",
"     \"Hereditary sensory and autonomic neuropathies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     OTHER",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other conditions that may be associated with extremity pain periosteal reaction, pathologic fractures, or cortical deficits include childhood cancers (eg, leukemia, primary bone tumors, metastatic neuroblastoma) and placement of intraosseous vascular catheters [",
"    <a class=\"abstract\" href=\"UTD.htm?11/23/11641/abstract/1,74\">",
"     1,74",
"    </a>",
"    ]. These conditions can be distinguished from physical abuse by history and associated clinical features. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/58/4009?source=see_link\">",
"     \"Overview of the presentation and classification of acute lymphoblastic leukemia in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1405891\">",
"    <span class=\"h1\">",
"     CHILD PROTECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Suspected child abuse should prompt involvement of an experienced child protection team (eg, social worker, nurse, child abuse subspecialist), if available. In many parts of the world (including the US, UK, and Australia), a mandatory report to appropriate governmental authorities is also required for cases of suspected abuse. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/5/35927?source=see_link&amp;anchor=H3#H3\">",
"     \"Child abuse: Social and medicolegal issues\", section on 'Reporting suspected abuse'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1405659\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The major considerations in the differential diagnosis of a child with potentially inflicted orthopedic trauma include the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Accidental injury (see",
"      <a class=\"local\" href=\"#H2\">",
"       'Accidental trauma'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Normal bony variants (see",
"      <a class=\"local\" href=\"#H3\">",
"       'Normal variants'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Birth trauma (see",
"      <a class=\"local\" href=\"#H6\">",
"       'Birth trauma'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Metabolic bone disease (see",
"      <a class=\"local\" href=\"#H7\">",
"       'Metabolic bone disease'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Skeletal dysplasia (including osteogenesis imperfecta [OI]) (see",
"      <a class=\"local\" href=\"#H12\">",
"       'Skeletal dysplasia'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Bone infection (see",
"      <a class=\"local\" href=\"#H15\">",
"       'Infection'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Drug toxicity (see",
"      <a class=\"local\" href=\"#H18\">",
"       'Toxicity'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Congenital insensitivity to pain (see",
"      <a class=\"local\" href=\"#H23\">",
"       'Insensitivity to pain'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A careful history and physical examination, in conjunction with additional laboratory tests or radiographic studies, if indicated, usually indicates the proper diagnosis. Radiographic review with a pediatric radiologist is often a key step in differentiating normal bony variants or bone disease from inflicted injury. (See",
"      <a class=\"local\" href=\"#H1405830\">",
"       'Diagnostic considerations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Suspected abuse should prompt involvement of a child abuse team, if available and reporting to appropriate government authorities as required by law. (See",
"      <a class=\"local\" href=\"#H1405891\">",
"       'Child protection'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11641/abstract/1\">",
"      Radkowski, M, Merten, DF, Leonidas, JC. The abused child: Criteria for the radiologic diagnosis. Radiographics 1983; 3:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11641/abstract/2\">",
"      Cramer KE. Orthopedic aspects of child abuse. Pediatr Clin North Am 1996; 43:1035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11641/abstract/3\">",
"      Kocher MS, Kasser JR. Orthopaedic aspects of child abuse. J Am Acad Orthop Surg 2000; 8:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11641/abstract/4\">",
"      Carty HM. Fractures caused by child abuse. J Bone Joint Surg Br 1993; 75:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11641/abstract/5\">",
"      Merten DF, Carpenter BL. Radiologic imaging of inflicted injury in the child abuse syndrome. Pediatr Clin North Am 1990; 37:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11641/abstract/6\">",
"      Bishop N, Sprigg A, Dalton A. Unexplained fractures in infancy: looking for fragile bones. Arch Dis Child 2007; 92:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11641/abstract/7\">",
"      Scherl SA, Miller L, Lively N, et al. Accidental and nonaccidental femur fractures in children. Clin Orthop Relat Res 2000; :96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11641/abstract/8\">",
"      Loder RT, Bookout C. Fracture patterns in battered children. J Orthop Trauma 1991; 5:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11641/abstract/9\">",
"      King J, Diefendorf D, Apthorp J, et al. Analysis of 429 fractures in 189 battered children. J Pediatr Orthop 1988; 8:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11641/abstract/10\">",
"      Schwend RM, Werth C, Johnston A. Femur shaft fractures in toddlers and young children: rarely from child abuse. J Pediatr Orthop 2000; 20:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11641/abstract/11\">",
"      Grant P, Mata MB, Tidwell M. Femur fracture in infants: a possible accidental etiology. Pediatrics 2001; 108:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11641/abstract/12\">",
"      Tarantino CA, Dowd MD, Murdock TC. Short vertical falls in infants. Pediatr Emerg Care 1999; 15:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11641/abstract/13\">",
"      Chiaviello CT, Christoph RA, Bond GR. Stairway-related injuries in children. Pediatrics 1994; 94:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11641/abstract/14\">",
"      Joffe M, Ludwig S. Stairway injuries in children. Pediatrics 1988; 82:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11641/abstract/15\">",
"      Nimkin K, Kleinman PK. Imaging of child abuse. Radiol Clin North Am 2001; 39:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11641/abstract/16\">",
"      Shaw BA, Murphy KM, Shaw A, et al. Humerus shaft fractures in young children: accident or abuse? J Pediatr Orthop 1997; 17:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11641/abstract/17\">",
"      Kleinman PK, Belanger PL, Karellas A, Spevak MR. Normal metaphyseal radiologic variants not to be confused with findings of infant abuse. AJR Am J Roentgenol 1991; 156:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11641/abstract/18\">",
"      Plunkett J, Plunkett M. Physiologic periosteal changes in infancy. Am J Forensic Med Pathol 2000; 21:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11641/abstract/19\">",
"      de Silva P, Evans-Jones G, Wright A, Henderson R. Physiological periostitis; a potential pitfall. Arch Dis Child 2003; 88:1124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11641/abstract/20\">",
"      Conway JJ, Collins M, Tanz RR, et al. The role of bone scintigraphy in detecting child abuse. Semin Nucl Med 1993; 23:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11641/abstract/21\">",
"      McBride MT, Hennrikus WL, Mologne TS. Newborn clavicle fractures. Orthopedics 1998; 21:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11641/abstract/22\">",
"      Cumming WA. Neonatal skeletal fractures. Birth trauma or child abuse? J Can Assoc Radiol 1979; 30:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11641/abstract/23\">",
"      van Rijn RR, Bilo RA, Robben SG. Birth-related mid-posterior rib fractures in neonates: a report of three cases (and a possible fourth case) and a review of the literature. Pediatr Radiol 2009; 39:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11641/abstract/24\">",
"      Paterson CR. Vitamin D deficiency rickets simulating child abuse. J Pediatr Orthop 1981; 1:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11641/abstract/25\">",
"      Elmer E, Gregg GS. Developmental characteristics of abused children. Pediatrics 1967; 40:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11641/abstract/26\">",
"      Klein M, Stern L. Low birth weight and the battered child syndrome. Am J Dis Child 1971; 122:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11641/abstract/27\">",
"      Zeiss J, Wycliffe ND, Cullen BJ, et al. Radiological case of the month. Simulated child abuse in drug-induced rickets. Am J Dis Child 1988; 142:1367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11641/abstract/28\">",
"      Shaw JC. Copper deficiency and non-accidental injury. Arch Dis Child 1988; 63:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11641/abstract/29\">",
"      Cordano A. Clinical manifestations of nutritional copper deficiency in infants and children. Am J Clin Nutr 1998; 67:1012S.",
"     </a>",
"    </li>",
"    <li>",
"     Menkes disease. In: OMIM&trade; Online Mendelian Inheritance in Man, McKusick, VA (Ed), Johns Hopkins University, Baltimore, MD. Available at: www.ncbi.nlm.nih.gov:80/entrez/dispomim.cgi?id=309400 (Accessed on March 20, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11641/abstract/31\">",
"      Gr&uuml;nebaum M, Horodniceanu C, Steinherz R. The radiographic manifestations of bone changes in copper deficiency. Pediatr Radiol 1980; 9:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11641/abstract/32\">",
"      Walsh J, Reardon W. Job syndrome masquerading as non-accidental injury. Arch Dis Child 2008; 93:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11641/abstract/33\">",
"      Kirchner SG, Sivit CJ, Wright PF. Hyperimmunoglobulinemia E syndrome: association with osteoporosis and recurrent fractures. Radiology 1985; 156:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11641/abstract/34\">",
"      Bulloch B, Schubert CJ, Brophy PD, et al. Cause and clinical characteristics of rib fractures in infants. Pediatrics 2000; 105:E48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11641/abstract/35\">",
"      Rauch F, Glorieux FH. Osteogenesis imperfecta. Lancet 2004; 363:1377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11641/abstract/36\">",
"      Astley R. Metaphyseal fractures in osteogenesis imperfecta. Br J Radiol 1979; 52:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11641/abstract/37\">",
"      Cremin B, Goodman H, Spranger J, Beighton P. Wormian bones in osteogenesis imperfecta and other disorders. Skeletal Radiol 1982; 8:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11641/abstract/38\">",
"      Ablin DS, Greenspan A, Reinhart M, Grix A. Differentiation of child abuse from osteogenesis imperfecta. AJR Am J Roentgenol 1990; 154:1035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11641/abstract/39\">",
"      Knight DJ, Bennet GC. Nonaccidental injury in osteogenesis imperfecta: a case report. J Pediatr Orthop 1990; 10:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11641/abstract/40\">",
"      Carty H. Brittle or battered. Arch Dis Child 1988; 63:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11641/abstract/41\">",
"      Groninger A, Schaper J, Messing-Juenger M, et al. Subdural hematoma as clinical presentation of osteogenesis imperfecta. Pediatr Neurol 2005; 32:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11641/abstract/42\">",
"      Ganesh A, Jenny C, Geyer J, et al. Retinal hemorrhages in type I osteogenesis imperfecta after minor trauma. Ophthalmology 2004; 111:1428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11641/abstract/43\">",
"      Gahagan S, Rimsza ME. Child abuse or osteogenesis imperfecta: how can we tell? Pediatrics 1991; 88:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11641/abstract/44\">",
"      Miller ME, Hangartner TN. Bone density measurements by computed tomography in osteogenesis imperfecta type I. Osteoporos Int 1999; 9:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11641/abstract/45\">",
"      Lund AM, M&oslash;lgaard C, M&uuml;ller J, Skovby F. Bone mineral content and collagen defects in osteogenesis imperfecta. Acta Paediatr 1999; 88:1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11641/abstract/46\">",
"      Moore MS, Minch CM, Kruse RW, et al. The role of dual energy x-ray absorptiometry in aiding the diagnosis of pediatric osteogenesis imperfecta. Am J Orthop (Belle Mead NJ) 1998; 27:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11641/abstract/47\">",
"      CAFFEY J. Infantile cortical hyperostosis; a review of the clinical and radiographic features. Proc R Soc Med 1957; 50:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11641/abstract/48\">",
"      Staheli LT, Church CC, Ward BH. Infantile cortical hyperostosis (Caffey's disease). Sixteen cases with a late follow-up of eight. JAMA 1968; 203:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11641/abstract/49\">",
"      Bernstein RM, Zaleske DJ. Familial aspects of Caffey's disease. Am J Orthop (Belle Mead NJ) 1995; 24:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11641/abstract/50\">",
"      Pazzaglia UE, Byers PD, Beluffi G, et al. Pathology of infantile cortical hyperostosis (Caffey's disease). Report of a case. J Bone Joint Surg Am 1985; 67:1417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11641/abstract/51\">",
"      Finsterbush A, Rang M. Infantile cortical hyperostosis. Follow-up of 29 cases. Acta Orthop Scand 1975; 46:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11641/abstract/52\">",
"      Caffey, J, Silverman, W. Infantile cortical hyperostosis, preliminary report of a new syndrome. Am J Roentgen 1945; 54:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11641/abstract/53\">",
"      Glorieux FH. Caffey disease: an unlikely collagenopathy. J Clin Invest 2005; 115:1142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11641/abstract/54\">",
"      Gensure RC, M&auml;kitie O, Barclay C, et al. A novel COL1A1 mutation in infantile cortical hyperostosis (Caffey disease) expands the spectrum of collagen-related disorders. J Clin Invest 2005; 115:1250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11641/abstract/55\">",
"      GERRARD JW, HOLMAN GH, GORMAN AA, MORROW IH. Familial infantile cortical hyperostosis. J Pediatr 1961; 59:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11641/abstract/56\">",
"      Maclachlan AK, Gerrard JW, Houston CS, Ives EJ. Familial infantile cortical hyperostosis in a large Canadian family. Can Med Assoc J 1984; 130:1172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11641/abstract/57\">",
"      VAN BUSKIRK FW, TAMPAS JP, PETERSON OS Jr. Infantile cortical hyperostosis; an inquiry into its familial aspects. Am J Roentgenol Radium Ther Nucl Med 1961; 85:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11641/abstract/58\">",
"      Connors JM, Schubert C, Shapiro R. Syphilis or abuse: making the diagnosis and understanding the implications. Pediatr Emerg Care 1998; 14:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11641/abstract/59\">",
"      Brion LP, Manuli M, Rai B, et al. Long-bone radiographic abnormalities as a sign of active congenital syphilis in asymptomatic newborns. Pediatrics 1991; 88:1037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11641/abstract/60\">",
"      Chipps BE, Swischuk LE, Voelter WW. Single bone involvement in congenital syphilis. Pediatr Radiol 1976; 5:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11641/abstract/61\">",
"      Giacola GP. Radiological case of the month. Congenital syphilis. Am J Dis Child 1991; 145:1045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11641/abstract/62\">",
"      Ghadouane M, Benjelloun BS, Elharim-Roudies L, et al. Skeletal lesions in early congenital syphilis (a review of 86 cases). Rev Rhum Engl Ed 1995; 62:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11641/abstract/63\">",
"      Stewart GM, Rosenberg NM. Conditions mistaken for child abuse: Part I. Pediatr Emerg Care 1996; 12:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11641/abstract/64\">",
"      KEMPE CH, SILVERMAN FN, STEELE BF, et al. The battered-child syndrome. JAMA 1962; 181:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11641/abstract/65\">",
"      Halkier-S&oslash;rensen L, Laurberg G, Andresen J. Bone changes in children on long-term treatment with etretinate. J Am Acad Dermatol 1987; 16:999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11641/abstract/66\">",
"      Prendiville J, Bingham EA, Burrows D. Premature epiphyseal closure--a complication of etretinate therapy in children. J Am Acad Dermatol 1986; 15:1259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11641/abstract/67\">",
"      Roebuck DJ. Skeletal complications in pediatric oncology patients. Radiographics 1999; 19:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11641/abstract/68\">",
"      Meister B, Gassner I, Streif W, et al. Methotrexate osteopathy in infants with tumors of the central nervous system. Med Pediatr Oncol 1994; 23:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11641/abstract/69\">",
"      Schwartz AM, Leonidas JC. Methotrexate osteopathy. Skeletal Radiol 1984; 11:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11641/abstract/70\">",
"      Stanisavljevic S, Babcock AL. Fractures in children treated with methotrexate for leukemia. Clin Orthop Relat Res 1977; :139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11641/abstract/71\">",
"      Letts M, Pang E, Simons J. Prostaglandin-induced neonatal periostitis. J Pediatr Orthop 1994; 14:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11641/abstract/72\">",
"      Milman E, Berdon WE, Garvin JH, et al. Periostitis secondary to interleukin-11 (Oprelvekin, Neumega). Treatment for thrombocytopenia in pediatric patients. Pediatr Radiol 2003; 33:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11641/abstract/73\">",
"      Sathiaseelan S, Rayar U. The mystery of the broken bones. CMAJ 2003; 169:1189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11641/abstract/74\">",
"      Harty MP, Kao SC. Intraosseous vascular access defect: fracture mimic in the skeletal survey for child abuse. Pediatr Radiol 2002; 32:188.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6614 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-89.32.226.102-5846377118-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_23_11641=[""].join("\n");
var outline_f11_23_11641=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1405659\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1405830\">",
"      DIAGNOSTIC CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ACCIDENTAL TRAUMA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      NORMAL VARIANTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Metaphyseal variants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Diaphyseal variants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      BIRTH TRAUMA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      METABOLIC BONE DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Rickets",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Vitamin C deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Copper deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Other conditions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SKELETAL DYSPLASIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Osteogenesis imperfecta",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Infantile cortical hyperostosis (Caffey disease)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      INFECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Congenital syphilis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Osteomyelitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      TOXICITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Vitamin A",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Methotrexate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Prostaglandin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Interleukin-11",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      INSENSITIVITY TO PAIN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Congenital",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      OTHER",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1405891\">",
"      CHILD PROTECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1405659\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6614\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6614|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?40/15/41206\" title=\"diagnostic image 1\">",
"      Rickets wrist",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?19/21/19807\" title=\"diagnostic image 2\">",
"      Rachitic Rosary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?7/43/7862\" title=\"diagnostic image 3\">",
"      Pseudofractures in osteomalacia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6614|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?10/41/10898\" title=\"figure 1\">",
"      Metaphyseal variants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6614|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/17/34067\" title=\"picture 1\">",
"      Perifollicular abnormality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?35/46/36576\" title=\"picture 2\">",
"      Dentinogenesis imperfecta",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/63/1014\" title=\"picture 3\">",
"      Blue sclerae",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6614|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/53/12124\" title=\"table 1\">",
"      Etiology of rickets",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/21/24922?source=related_link\">",
"      Assessment of the newborn infant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/5/35927?source=related_link\">",
"      Child abuse: Social and medicolegal issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/33/29209?source=related_link\">",
"      Clinical features of cerebral palsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/31/17914?source=related_link\">",
"      Congenital syphilis: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/27/440?source=related_link\">",
"      Developmental defects of the teeth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/27/23990?source=related_link\">",
"      Differential diagnosis of suspected child abuse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/37/28248?source=related_link\">",
"      Etiology and treatment of calcipenic rickets in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/32/33289?source=related_link\">",
"      Evaluation and diagnosis of hematogenous osteomyelitis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/11/9402?source=related_link\">",
"      Gaucher disease: Pathogenesis, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/16/43272?source=related_link\">",
"      Hereditary sensory and autonomic neuropathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/25/32153?source=related_link\">",
"      Hyperimmunoglobulin E syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/30/13802?source=related_link\">",
"      Orthopedic aspects of child abuse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/9/38040?source=related_link\">",
"      Osteogenesis imperfecta: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/36/26185?source=related_link\">",
"      Osteogenesis imperfecta: Management and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/32/10759?source=related_link\">",
"      Overview of renal tubular acidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/21/26967?source=related_link\">",
"      Overview of rickets in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/58/4009?source=related_link\">",
"      Overview of the presentation and classification of acute lymphoblastic leukemia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/54/26473?source=related_link\">",
"      Physical abuse in children: Epidemiology and clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/55/12154?source=related_link\">",
"      Primary hyperoxaluria",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_23_11642="Acute asthma exacerbations in children: Inpatient management";
var content_f11_23_11642=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Acute asthma exacerbations in children: Inpatient management",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/23/11642/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/23/11642/contributors\">",
"     Mark Dovey, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/23/11642/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/23/11642/contributors\">",
"     Robert A Wood, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/23/11642/contributors\">",
"     Gregory Redding, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/23/11642/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/23/11642/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/23/11642/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;More than 6 million children in the United States have asthma, which accounts for more than 200,000 hospitalizations each year [",
"    <a class=\"abstract\" href=\"UTD.htm?11/23/11642/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Although exacerbations are common, most can be managed successfully at home. Children with severe exacerbations or those who fail to improve with outpatient therapy need to be admitted to the hospital.",
"   </p>",
"   <p>",
"    Inpatient management of acute asthma exacerbation in children will be discussed here. Outpatient and intensive care unit (ICU) management are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/16/33034?source=see_link\">",
"     \"Acute asthma exacerbations in children: Outpatient management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/44/22218?source=see_link\">",
"     \"Acute severe asthma exacerbations in children: Intensive care unit management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most children who require admission for asthma are initially treated in the emergency department (ED); some are admitted directly from clinicians' offices. Outpatient management of asthma exacerbation is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/16/33034?source=see_link\">",
"     \"Acute asthma exacerbations in children: Outpatient management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Criteria for admission",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children who require beta 2-agonist therapy more often than every two to three hours, have not improved after administration of systemic glucocorticoids, or who require supplemental oxygen need to be admitted to the hospital. Other factors that may necessitate hospitalization include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A history of rapid progression of severity in past exacerbations",
"     </li>",
"     <li>",
"      Poor adherence with outpatient medication regimen",
"     </li>",
"     <li>",
"      Inadequate access to medical care",
"     </li>",
"     <li>",
"      Poor social support system at home",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Management approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inpatient treatment is typically a continuation of therapies and monitoring that have been started in the ED (",
"    <a class=\"graphic graphic_algorithm graphicRef80100 \" href=\"UTD.htm?25/62/26600\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/23/11642/abstract/3\">",
"     3",
"    </a>",
"    ]. Before arrival to the inpatient unit, patients usually have received several",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/54/39782?source=see_link\">",
"     albuterol",
"    </a>",
"    treatments (with or without",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/12/35008?source=see_link\">",
"     ipratropium",
"    </a>",
"    bromide), systemic glucocorticoids, and when necessary, supplemental oxygen.",
"   </p>",
"   <p>",
"    Communication between the providers in the ED and those caring for the patient in the hospital is essential to ensure that treatments ordered in the ED are not missed or duplicated during the transfer of care.",
"   </p>",
"   <p>",
"    Inpatient therapy consists of [",
"    <a class=\"abstract\" href=\"UTD.htm?11/23/11642/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Inhaled beta 2-agonists, administered continuously or every two to four hours, depending upon the patient's degree of illness. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Short-acting beta 2-agonists'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Systemic glucocorticoids. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Glucocorticoids'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Supplemental oxygen as necessary to maintain oxygen saturation &ge;92 percent. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Supplemental oxygen'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Asthma education. (See",
"      <a class=\"local\" href=\"#H38\">",
"       'Discharge education'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Initiation or adjustment of controller agents, based upon classification of severity",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      control (",
"      <a class=\"graphic graphic_table graphicRef80908 graphicRef71181 \" href=\"UTD.htm?28/58/29614\">",
"       table 1A-B",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef76669 graphicRef67459 \" href=\"UTD.htm?22/39/23160\">",
"       figure 1A-B",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef78322 graphicRef64986 \" href=\"UTD.htm?29/50/30510\">",
"       table 2A-B",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37354?source=see_link\">",
"       \"Chronic asthma in children younger than 12 years: Controller medications\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Planning for discharge begins at the time of admission. The patient's and family's understanding of asthma, including signs and symptoms, triggers, medications, and self-monitoring should be assessed so that appropriate education can be provided [",
"    <a class=\"abstract\" href=\"UTD.htm?11/23/11642/abstract/4\">",
"     4",
"    </a>",
"    ]. For patients newly diagnosed with asthma, it is important to anticipate the need for medication equipment, such as a nebulizer or spacer, so that it can be delivered to the family and they can learn how to use it before the child is discharged. (See",
"    <a class=\"local\" href=\"#H37\">",
"     'Discharge medications'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     STANDARD THERAPIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Expert guidelines state that standard asthma treatment should include short-acting beta 2-agonists, systemic glucocorticoids, and supplemental oxygen [",
"    <a class=\"abstract\" href=\"UTD.htm?11/23/11642/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Short-acting beta 2-agonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend that children who are admitted to the hospital with acute asthma exacerbation receive therapy with inhaled short-acting beta 2-agonists (SABA, eg",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/54/39782?source=see_link\">",
"     albuterol",
"    </a>",
"    , salbutamol) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/23/11642/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inhaled beta 2-agonists, most commonly",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/54/39782?source=see_link\">",
"     albuterol",
"    </a>",
"    , can be administered continuously or intermittently (via nebulizer or metered dose-inhaler (MDI) with spacer) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/23/11642/abstract/8-14\">",
"     8-14",
"    </a>",
"    ]. Children with moderate exacerbations usually require inhaled SABA every one to three hours. At our institution, children who require inhaled SABA more often than every three hours receive continuous administration. However, some hospitals only permit continuous administration in the ICU. Delivery systems for SABA are discussed separately. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Continuous therapy'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/42/30376?source=see_link\">",
"     \"Use of medication nebulizers in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/57/36760?source=see_link\">",
"     \"The use of inhaler devices in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    All nebulized treatments should be given with oxygen (generally at a flow rate of 6 to 8",
"    <span class=\"nowrap\">",
"     L/min)",
"    </span>",
"    rather than with compressed air. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/24/27014?source=see_link\">",
"     \"Continuous oxygen delivery systems for infants, children, and adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;The National Asthma Education and Prevention Program (NAEPP) has published doses for common medications used during asthma exacerbation (",
"    <a class=\"graphic graphic_table graphicRef58783 \" href=\"UTD.htm?32/24/33165\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/23/11642/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Weight-based dosing of inhaled medications may not be appropriate for young children because of the low deposition of medication in the lungs [",
"    <a class=\"abstract\" href=\"UTD.htm?11/23/11642/abstract/3,9\">",
"     3,9",
"    </a>",
"    ]. Standard doses, such as 2.5 mg of nebulized",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/54/39782?source=see_link\">",
"     albuterol",
"    </a>",
"    for children who weigh less than 30 kg and 5 mg for children who weigh more than 30 kg, may be used [",
"    <a class=\"abstract\" href=\"UTD.htm?11/23/11642/abstract/3\">",
"     3",
"    </a>",
"    ]. Common MDI doses for albuterol in children range from four to eight puffs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Frequency",
"    </span>",
"    &nbsp;&mdash;&nbsp;The frequency of treatments depends upon the patient's asthma severity or asthma score as determined by the clinician.",
"   </p>",
"   <p>",
"    Patients must be evaluated upon admission, every one to two hours while on beta 2-agonist continuous therapy, and before and after intermittent treatments to determine their response to therapy. This evaluation should include an assessment of:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Respiratory rate",
"     </li>",
"     <li>",
"      Accessory muscle use",
"     </li>",
"     <li>",
"      Air exchange",
"     </li>",
"     <li>",
"      Wheezing",
"     </li>",
"     <li>",
"      Inspiratory to expiratory ratio",
"     </li>",
"     <li>",
"      Pulse oximetry",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with lack of response or worsening of these parameters need more frequent treatments. Patients who are stable but not significantly improved should continue on the same frequency of treatments. Patients with clear improvement of the above parameters should have the interval between their treatments increased. In addition to the regularly scheduled beta 2-agonist treatment, \"as needed\" treatments should be available for episodes of acute bronchospasm or worsening respiratory distress.",
"   </p>",
"   <p>",
"    Some institutions have established multidisciplinary protocols (clinical pathways or care paths) for increasing or decreasing the frequency of inhaled SABA treatments based on asthma scores or other methods of assessment performed largely by respiratory therapists",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    nurses [",
"    <a class=\"abstract\" href=\"UTD.htm?11/23/11642/abstract/3,15,16\">",
"     3,15,16",
"    </a>",
"    ]. The effect of such protocols has been evaluated in a systematic review [",
"    <a class=\"abstract\" href=\"UTD.htm?11/23/11642/abstract/17\">",
"     17",
"    </a>",
"    ]. The systematic review found that the use of clinical pathways appeared to be effective in reducing length of stay and hospital costs associated with pediatric asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?11/23/11642/abstract/4,17\">",
"     4,17",
"    </a>",
"    ]. However, they were less effective in reducing readmission rates or affecting clinical outcomes, such as increasing asthma education, and the use of controller medications, spacers, or peak flow meters [",
"    <a class=\"abstract\" href=\"UTD.htm?11/23/11642/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one such system [",
"    <a class=\"abstract\" href=\"UTD.htm?11/23/11642/abstract/3\">",
"     3",
"    </a>",
"    ], the aerosol frequency is determined by the clinician for the first four hours. After that, the respiratory therapist or nurse evaluates the child's respiratory status before the scheduled treatment, using the following scoring system:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Respiratory rate &mdash; 1 point for tachypnea (defined by RR &gt;50 breaths per minute (BPM) in an infant, RR&gt;40 BPM in a child, and RR&gt;20 BPM in an adolescent).",
"     </li>",
"     <li>",
"      Accessory muscle use &mdash; 1 point for suprasternal, subcostal, or intercostal retractions; 2 points for neck or abdominal muscle use.",
"     </li>",
"     <li>",
"      Air exchange &mdash; 1 point for localized decrease in breath sounds; 2 points for multiple areas of decrease.",
"     </li>",
"     <li>",
"      Wheeze &mdash; 0 points for no wheezing or end-expiratory wheeze; 1 point for wheezing during all of expiration; 2 points for wheezing during all of expiration and during inspiration.",
"     </li>",
"     <li>",
"      Inspiratory:Expiratory ratio &mdash; 0 points for &le;1:2; 1 point for &ge;1:3.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      If the score is &ge;2, the treatment is given. The interval between treatments does not change and the patient is reassessed before the next scheduled treatment.",
"     </li>",
"     <li>",
"      If the score is &lt;2, the treatment is not given, the clinical status is documented, and the child is reassessed one hour later. At reassessment, if the score is &ge;2, the treatment is given and the interval changed accordingly; if the score is &lt;2, the child is reassessed one hour later.",
"     </li>",
"     <li>",
"      If the child requires \"as needed\" treatments between regularly scheduled treatments, the interval between treatments is changed accordingly (eg, if the as-needed treatment is administered two hours after the last treatment in a child receiving treatments every three hours, the interval is changed to every two hours).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Continuous therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest that patients who have poor improvement after several",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/54/39782?source=see_link\">",
"     albuterol",
"    </a>",
"    treatments or who require treatments more frequently than every three hours be treated with continuous albuterol nebulization. However, intermittent treatments every two hours may be better for younger patients who are unable to tolerate continuous therapy. Such patients must be monitored closely for worsening hypoxemia. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Monitoring'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Continuous nebulized",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/54/39782?source=see_link\">",
"     albuterol",
"    </a>",
"    has been studied extensively in adults and found to be as efficacious as intermittent nebulization [",
"    <a class=\"abstract\" href=\"UTD.htm?11/23/11642/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. Continuous nebulized albuterol also appears to be safe and effective in children [",
"    <a class=\"abstract\" href=\"UTD.htm?11/23/11642/abstract/10-14\">",
"     10-14",
"    </a>",
"    ]. Results from one small randomized trial suggest that continuous nebulization of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/52/18245?source=see_link\">",
"     levalbuterol",
"    </a>",
"    (levosalbutamol), which consists of only the R-enantiomer of albuterol, is no more effective than traditional albuterol, a racemic mixture of the R- and S-enantiomers [",
"    <a class=\"abstract\" href=\"UTD.htm?11/23/11642/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Continuous nebulized",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/54/39782?source=see_link\">",
"     albuterol",
"    </a>",
"    is typically given at a dose of 0.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per hour for children and 10 to 15 mg per hour for adults (",
"    <a class=\"graphic graphic_table graphicRef58783 \" href=\"UTD.htm?32/24/33165\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/23/11642/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/42/30376?source=see_link&amp;anchor=H1352583#H1352583\">",
"     \"Use of medication nebulizers in children\", section on 'Continuous nebulization'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Children receiving continuous nebulized",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/54/39782?source=see_link\">",
"     albuterol",
"    </a>",
"    therapy who have increasing fatigue, increasing work of breathing, carbon dioxide retention, or worsening hypoxemia may need to be transferred to the ICU for closer monitoring and more aggressive treatment. (See",
"    <a class=\"local\" href=\"#H32\">",
"     'Failure to respond'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/44/22218?source=see_link\">",
"     \"Acute severe asthma exacerbations in children: Intensive care unit management\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Children receiving continuous nebulized",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/54/39782?source=see_link\">",
"     albuterol",
"    </a>",
"    may be switched to intermittent therapy every two to three hours when they have improving asthma parameters or score as outlined above.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Adverse effects &mdash; Potential adverse effects of continuous nebulized SABA therapy include transient decreases in serum potassium, magnesium, and phosphate [",
"      <a class=\"abstract\" href=\"UTD.htm?11/23/11642/abstract/4\">",
"       4",
"      </a>",
"      ]. These decreases are rarely of clinical importance in children. However, we suggest measuring serum electrolytes daily in patients receiving continuous",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/54/39782?source=see_link\">",
"       albuterol",
"      </a>",
"      who have been taking diuretics regularly, in patients who have coexistent cardiovascular disease, and in patients with known predilection to electrolyte disturbances. (See",
"      <a class=\"local\" href=\"#H31\">",
"       'Laboratory'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/17/5402?source=see_link&amp;anchor=H17666854#H17666854\">",
"       \"Causes of hypokalemia\", section on 'Elevated beta-adrenergic activity'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The treatment of hypokalemia is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/2/9258?source=see_link\">",
"     \"Clinical manifestations and treatment of hypokalemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Glucocorticoids",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Systemic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic glucocorticoids are an important component of the management of asthma exacerbations due to their ability to decrease airway inflammation and secretions [",
"    <a class=\"abstract\" href=\"UTD.htm?11/23/11642/abstract/22\">",
"     22",
"    </a>",
"    ]. We recommend systemic glucocorticoids for children with acute asthma exacerbation who require hospitalization.",
"   </p>",
"   <p>",
"    In the rare cases in which glucocorticoids are contraindicated (eg, hypersensitivity reaction, varicella infection, herpes simplex keratitis), the severity of bronchospasm must be weighed against the reason for contraindication.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dose and duration &mdash; Glucocorticoids may be given as",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"       prednisone",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/30/35296?source=see_link\">",
"       prednisolone",
"      </a>",
"      , or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/63/17401?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      . Dosing varies from institution to institution, but is typically 1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      every 12 hours for a total of five days (with a maximum dose of 60 mg per day) [",
"      <a class=\"abstract\" href=\"UTD.htm?11/23/11642/abstract/4\">",
"       4",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      A longer course (eg, 7 to 10 days) may be indicated for patients who have a severe exacerbation that is slow to respond to treatment or patients who have had more than one exacerbation requiring oral glucocorticoids in the previous two months [",
"      <a class=\"abstract\" href=\"UTD.htm?11/23/11642/abstract/4\">",
"       4",
"      </a>",
"      ]. Greater than 10 days may be necessary for patients whose control regimen includes oral glucocorticoids.",
"      <br/>",
"      <br/>",
"      We suggest that systemic glucocorticoid therapy be tapered in patients who require a course longer than 10 days [",
"      <a class=\"abstract\" href=\"UTD.htm?11/23/11642/abstract/4\">",
"       4",
"      </a>",
"      ]. Glucocorticoid therapy may be tapered in a number of ways; we suggest decreasing the dose by 50 percent every two to three days (ie, 2",
"      <span class=\"nowrap\">",
"       mg/kg/day",
"      </span>",
"      for days 1 to 10, 1",
"      <span class=\"nowrap\">",
"       mg/kg/day",
"      </span>",
"      for days 11 to 12, 0.5",
"      <span class=\"nowrap\">",
"       mg/kg/day",
"      </span>",
"      for days 13 to 14, and 0.25",
"      <span class=\"nowrap\">",
"       mg/kg/day",
"      </span>",
"      for days 15 to 16). A more gradual taper may be indicated for patients on chronic oral glucocorticoid therapy.",
"     </li>",
"     <li>",
"      Route &mdash; Oral administration is preferred to intravenous administration since it is less invasive and equally efficacious [",
"      <a class=\"abstract\" href=\"UTD.htm?11/23/11642/abstract/4,23\">",
"       4,23",
"      </a>",
"      ]. If the patient cannot tolerate oral glucocorticoids (eg, gastrointestinal impairment or repeated spitting of doses), glucocorticoids can be given intravenously.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Inhaled",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inhaled glucocorticoids are not as effective as systemic glucocorticoids for severe asthma exacerbations and should not be used as a substitute for systemic glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?11/23/11642/abstract/4,24,25\">",
"     4,24,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Simply doubling the dose of inhaled glucocorticoids does not appear to be effective in reducing the severity or preventing the progression of acute exacerbations [",
"    <a class=\"abstract\" href=\"UTD.htm?11/23/11642/abstract/4,26-29\">",
"     4,26-29",
"    </a>",
"    ]. However, several studies in adults suggest there may be some benefit from multiple high doses of inhaled glucocorticoids (eg, 9000 mcg of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/63/37872?source=see_link\">",
"     fluticasone",
"    </a>",
"    over three hours) in patients with acute asthma exacerbation when administered in the ED [",
"    <a class=\"abstract\" href=\"UTD.htm?11/23/11642/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. The data in children are inconsistent, perhaps related to different dosing regimens or levels of severity [",
"    <a class=\"abstract\" href=\"UTD.htm?11/23/11642/abstract/4,24,25,32\">",
"     4,24,25,32",
"    </a>",
"    ]. Administration of multiple high doses of inhaled glucocorticoids may be a useful strategy for patients in whom systemic glucocorticoids are contraindicated (eg, past adverse reactions). However, additional information regarding optimal dosing and indications is needed [",
"    <a class=\"abstract\" href=\"UTD.htm?11/23/11642/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Supplemental oxygen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with acute asthma have ventilation-perfusion",
"    <span class=\"nowrap\">",
"     (V/Q)",
"    </span>",
"    mismatch, which may lead to hypoxemia. Beta 2-agonists may worsen this mismatch by causing increased blood flow in areas of the lung that are poorly ventilated. Oxyhemoglobin saturation may decrease by &ge;5 percent in the first 30 minutes after an",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/54/39782?source=see_link\">",
"     albuterol",
"    </a>",
"    treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?11/23/11642/abstract/33\">",
"     33",
"    </a>",
"    ]. In addition, chronic or intermittent hypoxia (oxygen saturation 90 to 94 percent) may be associated with long-term cognitive and behavioral effects [",
"    <a class=\"abstract\" href=\"UTD.htm?11/23/11642/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Supplemental oxygen (humidified) should be provided by nasal cannula or face mask as needed to maintain an oxygen saturation of &ge;92 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?11/23/11642/abstract/35\">",
"     35",
"    </a>",
"    ]. All nebulized medications should be delivered with oxygen, generally at a flow rate of 6 to 8",
"    <span class=\"nowrap\">",
"     L/min.",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/24/27014?source=see_link\">",
"     \"Continuous oxygen delivery systems for infants, children, and adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although the administration of supplemental oxygen to adult patients with chronic lung disease may worsen underlying hypercarbia, this is not a concern in children with uncomplicated asthma exacerbations. Children with underlying lung disease (eg, bronchopulmonary dysplasia, cystic fibrosis, obstructive sleep apnea) should be monitored closely for hypercarbia while receiving supplemental oxygen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Monitoring and management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients receiving supplemental oxygen therapy should be monitored with continuous pulse oximetry [",
"    <a class=\"abstract\" href=\"UTD.htm?11/23/11642/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Oxygen saturation should be noted at the time of each patient assessment by the nurse, respiratory therapist, or clinician. Small children should be placed on infant flow meters to allow accurate weaning below 1",
"    <span class=\"nowrap\">",
"     L/min",
"    </span>",
"    of flow.",
"   </p>",
"   <p>",
"    Depending upon the oxygen saturation, we suggest the oxygen flow rate be adjusted as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?11/23/11642/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      &ge;94 percent &mdash; Decrease the flow rate by",
"      <span class=\"nowrap\">",
"       1/4",
"      </span>",
"      <span class=\"nowrap\">",
"       L/minute",
"      </span>",
"      for children who weigh &lt;15 kg and by",
"      <span class=\"nowrap\">",
"       1/2",
"      </span>",
"      <span class=\"nowrap\">",
"       L/minute",
"      </span>",
"      for children who weigh &ge;15 kg",
"     </li>",
"     <li>",
"      &le;90 percent &mdash; Increase the flow rate to achieve a saturation of 91 to 94 percent",
"     </li>",
"     <li>",
"      91 to 94 percent &mdash; Continue the same flow rate",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Oxygen saturation should be rechecked 5 to 10 minutes after changes to the oxygen flow rate. Changes to the oxygen flow rate should be documented appropriately.",
"   </p>",
"   <p>",
"    Once patients are no longer receiving supplemental oxygen therapy, oximetry should be monitored 5 to 10 minutes after discontinuation, just before the next SABA treatment, and while the child is sleeping for the first sleep period after discontinuation [",
"    <a class=\"abstract\" href=\"UTD.htm?11/23/11642/abstract/3\">",
"     3",
"    </a>",
"    ]. If the oxygen saturation remains &ge;92 percent during these, pulse oximetry can be discontinued.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     THERAPIES RESERVED FOR SPECIAL CIRCUMSTANCES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Systemic beta agonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;The addition of systemic to inhaled beta 2-agonists has been used with some success to treat severe asthma exacerbations [",
"    <a class=\"abstract\" href=\"UTD.htm?11/23/11642/abstract/36\">",
"     36",
"    </a>",
"    ]. However, there is no evidence to support the isolated use of intravenous beta 2-agonists [",
"    <a class=\"abstract\" href=\"UTD.htm?11/23/11642/abstract/37\">",
"     37",
"    </a>",
"    ]. Systemic beta 2-agonists typically are used in the ED or ICU setting since they require a higher level of monitoring than is available on regular nursing units. (See",
"    <a class=\"local\" href=\"#H32\">",
"     'Failure to respond'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/16/33034?source=see_link\">",
"     \"Acute asthma exacerbations in children: Outpatient management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/44/22218?source=see_link\">",
"     \"Acute severe asthma exacerbations in children: Intensive care unit management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Ipratropium bromide",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the addition of inhaled",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/12/35008?source=see_link\">",
"     ipratropium",
"    </a>",
"    bromide to inhaled beta agonist therapy has proven effective in the emergency department setting, studies of its use during hospital admissions have not revealed added benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?11/23/11642/abstract/6,38\">",
"     6,38",
"    </a>",
"    ]. Thus, ipratropium bromide is not recommended as standard therapy during hospitalizations for asthma exacerbations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Methylxanthines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravenous",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/47/9975?source=see_link\">",
"     aminophylline",
"    </a>",
"    improves lung function (FEV1) within six hours of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?11/23/11642/abstract/39\">",
"     39",
"    </a>",
"    ]. However, it has little effect on clinical scores, frequency of use of nebulized short acting beta 2-agonists (SABAs), mechanical ventilation rates, or length of hospital stay when added to standard therapy (SABAs and glucocorticoids) for acute asthma exacerbation in children who are not critically ill [",
"    <a class=\"abstract\" href=\"UTD.htm?11/23/11642/abstract/39-43\">",
"     39-43",
"    </a>",
"    ]. In addition, it is associated with a high incidence of side effects [",
"    <a class=\"abstract\" href=\"UTD.htm?11/23/11642/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. The 2007 NAEPP guidelines do not recommend methylxanthines (eg, aminophylline,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?23/49/24344?source=see_link\">",
"     theophylline",
"    </a>",
"    ) for treatment of acute asthma exacerbations [",
"    <a class=\"abstract\" href=\"UTD.htm?11/23/11642/abstract/44\">",
"     44",
"    </a>",
"    ]. However, intravenous bronchodilators (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/51/25397?source=see_link\">",
"     terbutaline",
"    </a>",
"    , aminophylline) may be helpful in treating critically ill children with status asthmaticus [",
"    <a class=\"abstract\" href=\"UTD.htm?11/23/11642/abstract/45\">",
"     45",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/44/22218?source=see_link&amp;anchor=H7#H7\">",
"     \"Acute severe asthma exacerbations in children: Intensive care unit management\", section on 'Pharmacotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Leukotriene receptor antagonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leukotriene receptor antagonists (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/26/1446?source=see_link\">",
"     montelukast",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/22/41316?source=see_link\">",
"     zafirlukast",
"    </a>",
"    ) have not been sufficiently studied in acute asthma exacerbations in children to make recommendations regarding their use during hospitalization.",
"   </p>",
"   <p>",
"    In patients taking leukotriene receptor antagonists (LRTA) for long-term asthma control, LRTA need not be continued while receiving systemic glucocorticoids during hospitalization for acute asthma exacerbation. LRTA may be restarted at the time of discharge.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Routine antibiotic administration has no benefit in acute asthma exacerbations [",
"    <a class=\"abstract\" href=\"UTD.htm?11/23/11642/abstract/46\">",
"     46",
"    </a>",
"    ]. However, antibiotics may be necessary to treat comorbid infections (eg, bacterial pneumonia, bacterial sinusitis) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/23/11642/abstract/44\">",
"     44",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/48/25354?source=see_link&amp;anchor=H12#H12\">",
"     \"Inpatient treatment of pneumonia in children\", section on 'Empiric therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/58/42921?source=see_link&amp;anchor=H3#H3\">",
"     \"Acute bacterial rhinosinusitis in children: Microbiology and treatment\", section on 'Empiric antibiotic therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Magnesium sulfate",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is some evidence that",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/29/34262?source=see_link\">",
"     magnesium sulfate",
"    </a>",
"    , when used in addition to standard therapy in the ED, can safely improve spirometric indices during severe asthma exacerbations [",
"    <a class=\"abstract\" href=\"UTD.htm?11/23/11642/abstract/47-51\">",
"     47-51",
"    </a>",
"    ]. However, none of these studies involved hospitalized children. Many institutions restrict the use of magnesium sulfate for patients with asthma to the ED or ICU. We suggest that the use of magnesium sulfate be reserved for inpatients with severe asthma who are being transferred to the ICU. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/16/33034?source=see_link\">",
"     \"Acute asthma exacerbations in children: Outpatient management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/44/22218?source=see_link\">",
"     \"Acute severe asthma exacerbations in children: Intensive care unit management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Chest PT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chest physical therapy is not recommended for inpatient treatment of asthma exacerbations. It is not beneficial and may subject the patient to unnecessary stress [",
"    <a class=\"abstract\" href=\"UTD.htm?11/23/11642/abstract/44,52\">",
"     44,52",
"    </a>",
"    ]. An exception may be made for children with asthma exacerbation complicated by atelectasis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/5/34903?source=see_link&amp;anchor=H14#H14\">",
"     \"Atelectasis in children\", section on 'Chest physiotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     MONITORING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical status and response to therapy must be monitored frequently during treatment for acute asthma exacerbation [",
"    <a class=\"abstract\" href=\"UTD.htm?11/23/11642/abstract/44\">",
"     44",
"    </a>",
"    ]. A variety of tools are used for this purpose in children, each of which has advantages and disadvantages [",
"    <a class=\"abstract\" href=\"UTD.htm?11/23/11642/abstract/44,53-61\">",
"     44,53-61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Clinical assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vital signs and pulse oximetry should be assessed immediately upon arrival to the inpatient unit. These values should be compared with those obtained in the ED to determine whether the patient is improving or worsening.",
"   </p>",
"   <p>",
"    Monitoring protocols vary from institution to institution. Patients typically are assessed every 15 minutes to every four hours, depending upon clinical status.",
"   </p>",
"   <p>",
"    Patients who are receiving continuous",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/54/39782?source=see_link\">",
"     albuterol",
"    </a>",
"    and supplemental oxygen should be placed on cardiopulmonary monitors and receive continuous monitoring of oxygen saturation. Such monitoring should be continued until the patient is tolerating interval treatments every three hours. The frequency of monitoring vital signs and oxyhemoglobin saturation can be decreased as the patient improves and inhalation treatments are spaced to every four hours. However, at minimum, vital signs and oxygen saturation should be monitored every four hours.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Asthma scores",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several scoring systems have been developed to standardize and facilitate assessment of asthma severity in children [",
"    <a class=\"abstract\" href=\"UTD.htm?11/23/11642/abstract/56-60,62,63\">",
"     56-60,62,63",
"    </a>",
"    ]. These scores also can be used to evaluate the response to treatment and guide changes in the frequency of bronchodilator administration. However, they must be used with caution in preschool-aged children [",
"    <a class=\"abstract\" href=\"UTD.htm?11/23/11642/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the asthma assessment score published as part of the Cincinnati Children's Hospital Medical Center clinical practice guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?11/23/11642/abstract/63\">",
"     63",
"    </a>",
"    ], the score is the sum of numeric ratings for five parameters: respiratory rate, accessory muscle use, air exchange, wheeze, and inspiratory:expiratory ratio. Bronchodilator is administered for a score of 2 or more. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Frequency'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Pulmonary function",
"    </span>",
"    &nbsp;&mdash;&nbsp;The NAEPP guidelines suggest that monitoring of pulmonary function (eg, forced expiratory volume in one second (FEV1) or peak expiratory flow rate (PEFR)) during acute asthma exacerbations can help determine the severity of the exacerbation and guide therapeutic decisions, particularly for adults [",
"    <a class=\"abstract\" href=\"UTD.htm?11/23/11642/abstract/44\">",
"     44",
"    </a>",
"    ]. The guidelines suggest that FEV1 or PEFR be measured on admission, 15 to 20 minutes after bronchodilator therapy during the acute phase of hospitalization, and at least daily thereafter until discharge in patients older than 5 years [",
"    <a class=\"abstract\" href=\"UTD.htm?11/23/11642/abstract/44\">",
"     44",
"    </a>",
"    ]. For children, FEV1 and PEFR may be unobtainable",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    of limited value during an exacerbation [",
"    <a class=\"abstract\" href=\"UTD.htm?11/23/11642/abstract/44,55\">",
"     44,55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Spirometry",
"    </span>",
"    &nbsp;&mdash;&nbsp;The NAEPP guidelines suggest that, if it is readily available, spirometry (specifically FEV1) is preferable to PEFR in the monitoring of response to therapy for acute asthma exacerbation [",
"    <a class=\"abstract\" href=\"UTD.htm?11/23/11642/abstract/44\">",
"     44",
"    </a>",
"    ]. Spirometry is better able to distinguish between poor effort, restrictive ventilatory disorder, and obstructive ventilatory disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?11/23/11642/abstract/44\">",
"     44",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/27/29112?source=see_link&amp;anchor=H2#H2\">",
"     \"Overview of pulmonary function testing in children\", section on 'Spirometry'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Children younger than five years typically cannot perform spirometry, and older patients who are inexperienced with the testing may require several attempts before useful data can be obtained. In addition, many patients may not be able to cooperate with spirometry during the acute phase of their exacerbation. Other limitations that may preclude the use of monitoring of FEV1 during hospitalization for asthma exacerbation include expense and the need for specialized equipment and staff.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Peak flow",
"    </span>",
"    &nbsp;&mdash;&nbsp;The NAEPP guidelines suggest that monitoring of pulmonary function during acute asthma exacerbations can help determine the severity of the exacerbation and guide therapeutic decisions [",
"    <a class=\"abstract\" href=\"UTD.htm?11/23/11642/abstract/44\">",
"     44",
"    </a>",
"    ]. Either PEFR or FEV1 can be used, but the NAEPP expert panel suggests that if spirometry is readily available, it is preferable to PEFR monitoring. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/53/854?source=see_link\">",
"     \"Peak expiratory flow rate monitoring in asthma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because measurement of PEFR is dependent on effort and technique, patients require education and frequent reviews of technique [",
"    <a class=\"abstract\" href=\"UTD.htm?11/23/11642/abstract/44\">",
"     44",
"    </a>",
"    ]. Additional limitations to PEFR monitoring include the lack of correlation with other asthma outcome measures (eg, treatment failure, symptom control), the variability in the published predicted PEFR reference values and in the reference values from brand to brand, the inaccuracy of peak flow diaries, and the possibility that many patients may not be able to perform PEFR measurement during an acute exacerbation [",
"    <a class=\"abstract\" href=\"UTD.htm?11/23/11642/abstract/44,65\">",
"     44,65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For a subset of patients, PEFR measurements may provide a means to obtain simple, quantitative, and reproducible assessments of the existence and severity of airflow obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?11/23/11642/abstract/44\">",
"     44",
"    </a>",
"    ]. The patient's personal best PEFR measurement is the most appropriate reference value for determining percent predicted PEFR.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Radiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chest radiographs are not routinely necessary for children who are admitted to the hospital with acute asthma exacerbations [",
"    <a class=\"abstract\" href=\"UTD.htm?11/23/11642/abstract/61\">",
"     61",
"    </a>",
"    ]. However, they may be warranted in patients with:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute worsening of clinical status (to look for potential complications of asthma: atelectasis, pneumothorax, pneumomediastinum, and pneumonia). Signs of such complications include: fever &ge;38.5&ordm;C, focal examination findings (eg, rales or decreased aeration),",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      extreme tachypnea or tachycardia.",
"     </li>",
"     <li>",
"      Lack of response to asthma therapy (to look for other processes that can mimic asthma, such as vascular ring, foreign body aspiration) (",
"      <a class=\"graphic graphic_table graphicRef67370 \" href=\"UTD.htm?23/40/24204\">",
"       table 4",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/41/1689?source=see_link\">",
"       \"Wheezing illnesses other than asthma in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/5/27735?source=see_link\">",
"       \"Vascular rings\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/33/2585?source=see_link\">",
"       \"Airway foreign bodies in children\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Laboratory",
"    </span>",
"    &nbsp;&mdash;&nbsp;Routine laboratories are not necessary for children who are hospitalized for acute asthma exacerbation and receiving intermittent inhalation therapy. Children receiving continuous",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/54/39782?source=see_link\">",
"     albuterol",
"    </a>",
"    nebulization are at risk of transient hypokalemia, hypophosphatemia, and hypomagnesemia. These decreases are rarely of clinical importance in children. However, we suggest measuring serum electrolytes daily in patients receiving continuous albuterol who have been taking diuretics regularly, in patients who have coexistent cardiovascular disease, and in patients with a known predilection to electrolyte disturbances. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/17/5402?source=see_link&amp;anchor=H17666854#H17666854\">",
"     \"Causes of hypokalemia\", section on 'Elevated beta-adrenergic activity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Capillary or arterial blood gases may be used to aid in decision making for patients with tenuous respiratory status or acute worsening despite therapy. Patients in respiratory distress with normal or elevated PCO2 are at risk for imminent respiratory failure [",
"    <a class=\"abstract\" href=\"UTD.htm?11/23/11642/abstract/44\">",
"     44",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/44/22218?source=see_link\">",
"     \"Acute severe asthma exacerbations in children: Intensive care unit management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     FAILURE TO RESPOND",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients fail to improve or worsen despite frequent or continuous administration of SABA and systemic glucocorticoids. Signs of impending respiratory failure include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Poor air movement",
"     </li>",
"     <li>",
"      Worsening hypoxemia",
"     </li>",
"     <li>",
"      Fatigue",
"     </li>",
"     <li>",
"      Change in mental status",
"     </li>",
"     <li>",
"      Carbon dioxide retention",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In such patients, capillary or arterial blood gases may be used to aid in decision making. Patients in respiratory distress with normal or elevated PCO2 are at risk for imminent respiratory failure and should be transferred to the ICU [",
"    <a class=\"abstract\" href=\"UTD.htm?11/23/11642/abstract/44\">",
"     44",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/44/22218?source=see_link\">",
"     \"Acute severe asthma exacerbations in children: Intensive care unit management\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other possible reasons for worsening or failure to improve include the development of a complication (eg, atelectasis, pneumothorax, pneumomediastinum, pneumonia) or that the diagnosis of asthma is incorrect and the patient's symptoms are caused by another process (",
"    <a class=\"graphic graphic_table graphicRef67370 \" href=\"UTD.htm?23/40/24204\">",
"     table 4",
"    </a>",
"    ). Chest radiographs",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    consultation with a specialist can help to distinguish among these possibilities. (See",
"    <a class=\"local\" href=\"#H30\">",
"     'Radiography'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/25/26010?source=see_link&amp;anchor=H26#H26\">",
"     \"Chronic asthma in children younger than 12 years: Evaluation and diagnosis\", section on 'Differential diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/41/1689?source=see_link\">",
"     \"Wheezing illnesses other than asthma in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     CONSULTATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Asthma specialist",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many children with asthma respond quickly to standard care; the inpatient management of such patients need not involve an asthma specialist (eg, pediatric pulmonologist, pediatric allergist). However, consultation with an asthma specialist may be warranted in the following circumstances [",
"    <a class=\"abstract\" href=\"UTD.htm?11/23/11642/abstract/44\">",
"     44",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The diagnosis is in question or the patient fails to improve. (See",
"      <a class=\"local\" href=\"#H32\">",
"       'Failure to respond'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Life-threatening asthma exacerbation.",
"     </li>",
"     <li>",
"      Repeated hospital admission, history of ICU admission, frequent ED visits, or need for multiple or frequent drug therapies at home.",
"     </li>",
"     <li>",
"      Other conditions complicating asthma (eg, sinusitis, nasal polyps, chronic lung disease of prematurity, allergic bronchopulmonary aspergillosis, gastroesophageal reflux, obesity, food allergy, etc).",
"     </li>",
"     <li>",
"      Patients with asthma and other chronic disease (eg, cystic fibrosis, restrictive lung disease, neuromuscular weakness).",
"     </li>",
"     <li>",
"      Patient requires extensive education about allergen avoidance, problems with adherence to therapy, or complications of therapy.",
"     </li>",
"     <li>",
"      Patient is receiving ongoing care by the asthma specialist.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Social services",
"    </span>",
"    &nbsp;&mdash;&nbsp;Consultation with social services may be warranted when family resources are inadequate to ensure medication availability, adherence,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    medical follow-up and to help families connect with asthma programs available in the community [",
"    <a class=\"abstract\" href=\"UTD.htm?11/23/11642/abstract/61\">",
"     61",
"    </a>",
"    ]. Social services also may be helpful when environmental triggers related to housing play a role in asthma exacerbation (eg, rodents, cockroaches, smoke exposure). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/48/34569?source=see_link\">",
"     \"Allergen avoidance in the treatment of asthma and allergic rhinitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h1\">",
"     DISCHARGE CRITERIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specific criteria for discharge vary from institution to institution. General principles to determine appropriate discharge may be used. Patients may be discharged when:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Their asthma symptoms and signs (and scores if available) are considered mild. One study has shown that a standardized tool such as the Pediatric Dyspnea Scale (PDS) (",
"      <a class=\"graphic graphic_figure graphicRef80389 \" href=\"UTD.htm?11/59/12212\">",
"       figure 2",
"      </a>",
"      ) may be useful, since it predicts poor outcomes after discharge, including relapse and activity limitation, and may be a better indicator than measures of pulmonary function [",
"      <a class=\"abstract\" href=\"UTD.htm?11/23/11642/abstract/66\">",
"       66",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      They no longer require supplemental oxygen.",
"     </li>",
"     <li>",
"      They are receiving a treatment regimen that can be reasonably duplicated at home (eg, they are tolerating oral medications and the frequency of inhalation treatments can be managed by the caregiver). If possible, patients should be observed in the hospital for at least one interval while receiving the treatments that will be prescribed after discharge. If patients have been receiving nebulized medications they may be changed to MDI-spacer upon discharge provided they can demonstrate proper technique.",
"     </li>",
"     <li>",
"      If spirometry is readily available and the patient can perform it, FEV1 should be greater than 70 percent of expected.",
"     </li>",
"     <li>",
"      Access to medications and appropriate follow-up have to be confirmed.",
"     </li>",
"     <li>",
"      Asthma education is complete. (See",
"      <a class=\"local\" href=\"#H38\">",
"       'Discharge education'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Discharge medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hospitalization for asthma exacerbation signifies a break in control. The patient's preadmission medication regimen, asthma severity classification, and asthma control should be reviewed and controller medications adjusted as indicated (",
"    <a class=\"graphic graphic_table graphicRef80908 graphicRef71181 \" href=\"UTD.htm?28/58/29614\">",
"     table 1A-B",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef76669 graphicRef67459 \" href=\"UTD.htm?22/39/23160\">",
"     figure 1A-B",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef78322 graphicRef64986 \" href=\"UTD.htm?29/50/30510\">",
"     table 2A-B",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Discharge medications should include a SABA, either via nebulizer or MDI with a spacer, and oral glucocorticoids.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      SABA should be continued roughly every four to six hours until the patient is seen in follow-up within three to five days. Frequency can then be decreased or returned to \"as needed\" depending on the rate of clinical improvement.",
"     </li>",
"     <li>",
"      Oral glucocorticoids are usually continued for a total of five days. Patients who have a severe exacerbation that is slow to respond to treatment, who require oral glucocorticoids chronically, or who have had more than one exacerbation requiring oral glucocorticoids in the previous two months may require a longer course followed by taper [",
"      <a class=\"abstract\" href=\"UTD.htm?11/23/11642/abstract/44\">",
"       44",
"      </a>",
"      ]. The duration of glucocorticoid therapy and taper for such patients depends upon their preadmission regimen. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Systemic'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The need for daily controller therapy and preferred regimens are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37354?source=see_link\">",
"       \"Chronic asthma in children younger than 12 years: Controller medications\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Before the patient is discharged, it should be confirmed that he or she has all maintenance medications and the equipment necessary for their delivery (eg, spacer, mask, nebulizer, nebulizer tubing and mask, etc). One way of assuring this is to have the family fill the prescriptions before discharge; an advantage of this approach is that it permits the inpatient team to review the proper technique for medication administration. If the family is unable to fill the prescriptions before discharge, patient demonstrator devices may be used to review technique.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Discharge education",
"    </span>",
"    &nbsp;&mdash;&nbsp;The inpatient hospitalization is an excellent time to provide education about asthma. Every interaction should be viewed as an opportunity to educate the patient and family.",
"   </p>",
"   <p>",
"    The various aspects of asthma education can be provided by any member of the health care team. However, certain providers have areas of expertise.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nurses should discuss the importance of taking medications properly and consistently. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37354?source=see_link\">",
"       \"Chronic asthma in children younger than 12 years: Controller medications\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/47/39670?source=see_link\">",
"       \"Chronic asthma in children younger than 12 years: Quick-relief agents\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Respiratory therapists should demonstrate proper technique of medication administration throughout the hospitalization. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/42/30376?source=see_link\">",
"       \"Use of medication nebulizers in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/57/36760?source=see_link&amp;anchor=H4#H4\">",
"       \"The use of inhaler devices in children\", section on 'pMDI technique'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Clinicians should discuss all aspects of asthma care and teach patients how to monitor their asthma. Some institutions have dedicated asthma educators that assist with the education process. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/37/8794?source=see_link&amp;anchor=H12#H12\">",
"       \"An overview of asthma management\", section on 'Patient education'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/15/31991?source=see_link\">",
"       \"What do patients need to know about their asthma?\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h2\">",
"     Asthma action plan",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients should be given a written asthma action plan that includes [",
"    <a class=\"abstract\" href=\"UTD.htm?11/23/11642/abstract/44,67\">",
"     44,67",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A list of the daily medications and the time(s) of day they are to be taken.",
"     </li>",
"     <li>",
"      A list of the rescue medication(s) and a description of the symptoms for which they should be taken.",
"     </li>",
"     <li>",
"      The phone number they should call if they have questions.",
"     </li>",
"     <li>",
"      A list of triggers that may exacerbate their asthma. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/9/44184?source=see_link\">",
"       \"Trigger control to enhance asthma management\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/48/34569?source=see_link\">",
"       \"Allergen avoidance in the treatment of asthma and allergic rhinitis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The NAEPP provides sample asthma action plans for children aged 0 to 5 years (",
"    <a class=\"graphic graphic_form graphicRef71958 \" href=\"UTD.htm?38/15/39162\">",
"     form 1",
"    </a>",
"    ), patients older than 5 years (",
"    <a class=\"graphic graphic_form graphicRef55900 \" href=\"UTD.htm?36/39/37498\">",
"     form 2",
"    </a>",
"    ), and for use at school (",
"    <a class=\"graphic graphic_form graphicRef59053 graphicRef71869 graphicRef51794 \" href=\"UTD.htm?43/42/44714\">",
"     form 3A-C",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h1\">",
"     FOLLOW-UP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients discharged from the hospital should have follow-up in three to five days with their primary care provider [",
"    <a class=\"abstract\" href=\"UTD.htm?11/23/11642/abstract/44\">",
"     44",
"    </a>",
"    ]. At the follow-up visit the primary care provider can review the child's",
"    <span class=\"nowrap\">",
"     severity/control",
"    </span>",
"    classification and alter controller therapy as indicated (",
"    <a class=\"graphic graphic_table graphicRef80908 graphicRef71181 \" href=\"UTD.htm?28/58/29614\">",
"     table 1A-B",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef76669 graphicRef67459 \" href=\"UTD.htm?22/39/23160\">",
"     figure 1A-B",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef78322 graphicRef64986 \" href=\"UTD.htm?29/50/30510\">",
"     table 2A-B",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37354?source=see_link\">",
"     \"Chronic asthma in children younger than 12 years: Controller medications\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Long-term follow-up with an asthma specialist may be warranted for some patients. (See",
"    <a class=\"local\" href=\"#H34\">",
"     'Asthma specialist'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/37/8794?source=see_link&amp;anchor=H29#H29\">",
"     \"An overview of asthma management\", section on 'When to refer'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Inpatient treatment typically is a continuation of therapies and monitoring that have been started in the emergency department. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Management approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that children who are admitted to the hospital with acute asthma exacerbation receive therapy with short-acting beta 2-agonists (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Short-acting beta 2-agonists'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that children who are admitted to the hospital with acute asthma exacerbation be treated with systemic glucocorticoids (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Glucocorticoids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Humidified oxygen should be provided as needed to maintain an oxygen saturation of &ge;92 percent. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Supplemental oxygen'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinical status and response to therapy must be monitored frequently during treatment for acute asthma exacerbation. Patients are typically assessed every 15 minutes to every four hours, depending upon the clinical status. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Monitoring'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Chest radiographs are not routinely necessary for children who are admitted to the hospital with acute asthma exacerbations. However, they may be warranted in patients with acute worsening of clinical status or lack of response to asthma therapy. (See",
"      <a class=\"local\" href=\"#H30\">",
"       'Radiography'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Failure to respond to standard asthma therapy may indicate impending respiratory failure, development of a complication, or a disease process other than asthma. (See",
"      <a class=\"local\" href=\"#H32\">",
"       'Failure to respond'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1324521\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The editorial staff at UpToDate, Inc. would like to acknowledge Dr. Jonathan Steinfeld, who contributed to an earlier version of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Bloom B, Dey AN, Freeman G. Summary health statistics for U.S. children: National Health Interview Survey, 2005. Vital Health Stat 10, 2006. p.1.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11642/abstract/2\">",
"      Moorman JE, Rudd RA, Johnson CA, et al. National surveillance for asthma--United States, 1980-2004. MMWR Surveill Summ 2007; 56:1.",
"     </a>",
"    </li>",
"    <li>",
"     Asthma team CCHMC. Evidence based care guideline for managing an acute exacerbation of asthma. www.cincinnatichildrens.org/svc/alpha/h/health-policy/ev-based/asthma.htm (Accessed on February 08, 2008).",
"    </li>",
"    <li>",
"     National Asthma Education and Prevention Program: Expert panel report III: Guidelines for the diagnosis and management of asthma. Bethesda, MD: National Heart, Lung, and Blood Institute, 2007. (NIH publication no. 08-4051). www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm (Accessed on February 08, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11642/abstract/5\">",
"      Nkoy FL, Fassl BA, Simon TD, et al. Quality of care for children hospitalized with asthma. Pediatrics 2008; 122:1055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11642/abstract/6\">",
"      Craven D, Kercsmar CM, Myers TR, et al. Ipratropium bromide plus nebulized albuterol for the treatment of hospitalized children with acute asthma. J Pediatr 2001; 138:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11642/abstract/7\">",
"      Ben-Zvi Z, Lam C, Hoffman J, et al. An evaluation of the initial treatment of acute asthma. Pediatrics 1982; 70:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11642/abstract/8\">",
"      Mandelberg A, Tsehori S, Houri S, et al. Is nebulized aerosol treatment necessary in the pediatric emergency department? Chest 2000; 117:1309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11642/abstract/9\">",
"      Wildhaber JH, Dore ND, Wilson JM, et al. Inhalation therapy in asthma: nebulizer or pressurized metered-dose inhaler with holding chamber? In vivo comparison of lung deposition in children. J Pediatr 1999; 135:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11642/abstract/10\">",
"      Portnoy J, Nadel G, Amado M, Willsie-Ediger S. Continuous nebulization for status asthmaticus. Ann Allergy 1992; 69:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11642/abstract/11\">",
"      Craig VL, Bigos D, Brilli RJ. Efficacy and safety of continuous albuterol nebulization in children with severe status asthmaticus. Pediatr Emerg Care 1996; 12:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11642/abstract/12\">",
"      Katz RW, Kelly HW, Crowley MR, et al. Safety of continuous nebulized albuterol for bronchospasm in infants and children. Pediatrics 1993; 92:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11642/abstract/13\">",
"      Papo MC, Frank J, Thompson AE. A prospective, randomized study of continuous versus intermittent nebulized albuterol for severe status asthmaticus in children. Crit Care Med 1993; 21:1479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11642/abstract/14\">",
"      Montgomery VL, Eid NS. Low-dose beta-agonist continuous nebulization therapy for status asthmaticus in children. J Asthma 1994; 31:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11642/abstract/15\">",
"      Wazeka A, Valacer DJ, Cooper M, et al. Impact of a pediatric asthma clinical pathway on hospital cost and length of stay. Pediatr Pulmonol 2001; 32:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11642/abstract/16\">",
"      Johnson KB, Blaisdell CJ, Walker A, Eggleston P. Effectiveness of a clinical pathway for inpatient asthma management. Pediatrics 2000; 106:1006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11642/abstract/17\">",
"      Banasiak NC, Meadows-Oliver M. Inpatient asthma clinical pathways for the pediatric patient: an integrative review of the literature. Pediatr Nurs 2004; 30:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11642/abstract/18\">",
"      Camargo CA Jr, Spooner CH, Rowe BH. Continuous versus intermittent beta-agonists in the treatment of acute asthma. Cochrane Database Syst Rev 2003; :CD001115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11642/abstract/19\">",
"      Rodrigo GJ, Rodrigo C. Continuous vs intermittent beta-agonists in the treatment of acute adult asthma: a systematic review with meta-analysis. Chest 2002; 122:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11642/abstract/20\">",
"      Andrews T, McGintee E, Mittal MK, et al. High-dose continuous nebulized levalbuterol for pediatric status asthmaticus: a randomized trial. J Pediatr 2009; 155:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11642/abstract/21\">",
"      Kercsmar CM, McDowell KM. Love it or lev it: levalbuterol for severe acute asthma--for now, leave it. J Pediatr 2009; 155:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11642/abstract/22\">",
"      Rowe BH, Spooner C, Ducharme FM, et al. Early emergency department treatment of acute asthma with systemic corticosteroids. Cochrane Database Syst Rev 2001; :CD002178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11642/abstract/23\">",
"      Becker JM, Arora A, Scarfone RJ, et al. Oral versus intravenous corticosteroids in children hospitalized with asthma. J Allergy Clin Immunol 1999; 103:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11642/abstract/24\">",
"      Schuh S, Dick PT, Stephens D, et al. High-dose inhaled fluticasone does not replace oral prednisolone in children with mild to moderate acute asthma. Pediatrics 2006; 118:644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11642/abstract/25\">",
"      Schuh S, Reisman J, Alshehri M, et al. A comparison of inhaled fluticasone and oral prednisone for children with severe acute asthma. N Engl J Med 2000; 343:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11642/abstract/26\">",
"      FitzGerald JM, Becker A, Sears MR, et al. Doubling the dose of budesonide versus maintenance treatment in asthma exacerbations. Thorax 2004; 59:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11642/abstract/27\">",
"      Garrett J, Williams S, Wong C, Holdaway D. Treatment of acute asthmatic exacerbations with an increased dose of inhaled steroid. Arch Dis Child 1998; 79:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11642/abstract/28\">",
"      Harrison TW, Oborne J, Newton S, Tattersfield AE. Doubling the dose of inhaled corticosteroid to prevent asthma exacerbations: randomised controlled trial. Lancet 2004; 363:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11642/abstract/29\">",
"      Rice-McDonald G, Bowler S, Staines G, Mitchell C. Doubling daily inhaled corticosteroid dose is ineffective in mild to moderately severe attacks of asthma in adults. Intern Med J 2005; 35:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11642/abstract/30\">",
"      Rodrigo GJ. Comparison of inhaled fluticasone with intravenous hydrocortisone in the treatment of adult acute asthma. Am J Respir Crit Care Med 2005; 171:1231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11642/abstract/31\">",
"      Rodrigo G, Rodrigo C. Inhaled flunisolide for acute severe asthma. Am J Respir Crit Care Med 1998; 157:698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11642/abstract/32\">",
"      Singhi S, Banerjee S, Nanjundaswamy H. Inhaled budesonide in acute asthma. J Paediatr Child Health 1999; 35:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11642/abstract/33\">",
"      Tal A, Pasterkamp H, Leahy F. Arterial oxygen desaturation following salbutamol inhalation in acute asthma. Chest 1984; 86:868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11642/abstract/34\">",
"      Bass JL, Corwin M, Gozal D, et al. The effect of chronic or intermittent hypoxia on cognition in childhood: a review of the evidence. Pediatrics 2004; 114:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11642/abstract/35\">",
"      Rodrigo GJ, Rodriquez Verde M, Peregalli V, Rodrigo C. Effects of short-term 28% and 100% oxygen on PaCO2 and peak expiratory flow rate in acute asthma: a randomized trial. Chest 2003; 124:1312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11642/abstract/36\">",
"      Browne GJ, Lam LT. Single-dose intravenous salbutamol bolus for managing children with acute severe asthma in the emergency department:Reanalysis of data. Pediatr Crit Care Med 2002; 3:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11642/abstract/37\">",
"      Travers A, Jones AP, Kelly K, et al. Intravenous beta2-agonists for acute asthma in the emergency department. Cochrane Database Syst Rev 2001; :CD002988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11642/abstract/38\">",
"      Goggin N, Macarthur C, Parkin PC. Randomized trial of the addition of ipratropium bromide to albuterol and corticosteroid therapy in children hospitalized because of an acute asthma exacerbation. Arch Pediatr Adolesc Med 2001; 155:1329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11642/abstract/39\">",
"      Mitra A, Bassler D, Goodman K, et al. Intravenous aminophylline for acute severe asthma in children over two years receiving inhaled bronchodilators. Cochrane Database Syst Rev 2005; :CD001276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11642/abstract/40\">",
"      Strauss RE, Wertheim DL, Bonagura VR, Valacer DJ. Aminophylline therapy does not improve outcome and increases adverse effects in children hospitalized with acute asthmatic exacerbations. Pediatrics 1994; 93:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11642/abstract/41\">",
"      Needleman JP, Kaifer MC, Nold JT, et al. Theophylline does not shorten hospital stay for children admitted for asthma. Arch Pediatr Adolesc Med 1995; 149:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11642/abstract/42\">",
"      Carter E, Cruz M, Chesrown S, et al. Efficacy of intravenously administered theophylline in children hospitalized with severe asthma. J Pediatr 1993; 122:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11642/abstract/43\">",
"      DiGiulio GA, Kercsmar CM, Krug SE, et al. Hospital treatment of asthma: lack of benefit from theophylline given in addition to nebulized albuterol and intravenously administered corticosteroid. J Pediatr 1993; 122:464.",
"     </a>",
"    </li>",
"    <li>",
"     National Asthma Education and Prevention Program: Expert panel report III: Guidelines for the diagnosis and management of asthma. Bethesda, MD: National Heart, Lung, and Blood Institute, 2007. (NIH publication no. 08-4051). www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm (Accessed on February 09, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11642/abstract/45\">",
"      Wheeler DS, Jacobs BR, Kenreigh CA, et al. Theophylline versus terbutaline in treating critically ill children with status asthmaticus: a prospective, randomized, controlled trial. Pediatr Crit Care Med 2005; 6:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11642/abstract/46\">",
"      Graham VA, Milton AF, Knowles GK, Davies RJ. Routine antibiotics in hospital management of acute asthma. Lancet 1982; 1:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11642/abstract/47\">",
"      Rowe BH, Bretzlaff JA, Bourdon C, et al. Intravenous magnesium sulfate treatment for acute asthma in the emergency department: a systematic review of the literature. Ann Emerg Med 2000; 36:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11642/abstract/48\">",
"      Rowe BH, Bretzlaff JA, Bourdon C, et al. Magnesium sulfate for treating exacerbations of acute asthma in the emergency department. Cochrane Database Syst Rev 2000; :CD001490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11642/abstract/49\">",
"      Cheuk DK, Chau TC, Lee SL. A meta-analysis on intravenous magnesium sulphate for treating acute asthma. Arch Dis Child 2005; 90:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11642/abstract/50\">",
"      Ciarallo L, Sauer AH, Shannon MW. Intravenous magnesium therapy for moderate to severe pediatric asthma: results of a randomized, placebo-controlled trial. J Pediatr 1996; 129:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11642/abstract/51\">",
"      Scarfone RJ, Loiselle JM, Joffe MD, et al. A randomized trial of magnesium in the emergency department treatment of children with asthma. Ann Emerg Med 2000; 36:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11642/abstract/52\">",
"      Hondras MA, Linde K, Jones AP. Manual therapy for asthma. Cochrane Database Syst Rev 2002; :CD001002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11642/abstract/53\">",
"      Wright RO, Santucci KA, Jay GD, Steele DW. Evaluation of pre- and posttreatment pulse oximetry in acute childhood asthma. Acad Emerg Med 1997; 4:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11642/abstract/54\">",
"      Sol&eacute; D, Komatsu MK, Carvalho KV, Naspitz CK. Pulse oximetry in the evaluation of the severity of acute asthma and/or wheezing in children. J Asthma 1999; 36:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11642/abstract/55\">",
"      Gorelick MH, Stevens MW, Schultz T, Scribano PV. Difficulty in obtaining peak expiratory flow measurements in children with acute asthma. Pediatr Emerg Care 2004; 20:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11642/abstract/56\">",
"      Smith SR, Baty JD, Hodge D 3rd. Validation of the pulmonary score: an asthma severity score for children. Acad Emerg Med 2002; 9:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11642/abstract/57\">",
"      Becker AB, Nelson NA, Simons FE. The pulmonary index. Assessment of a clinical score for asthma. Am J Dis Child 1984; 138:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11642/abstract/58\">",
"      Carroll CL, Sekaran AK, Lerer TJ, Schramm CM. A modified pulmonary index score with predictive value for pediatric asthma exacerbations. Ann Allergy Asthma Immunol 2005; 94:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11642/abstract/59\">",
"      Scarfone RJ, Fuchs SM, Nager AL, Shane SA. Controlled trial of oral prednisone in the emergency department treatment of children with acute asthma. Pediatrics 1993; 92:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11642/abstract/60\">",
"      Smith SR, Strunk RC. Acute asthma in the pediatric emergency department. Pediatr Clin North Am 1999; 46:1145.",
"     </a>",
"    </li>",
"    <li>",
"     Asthma team CCHMC. Evidence based care guideline for managing an acute exacerbation of asthma. www.cincinnatichildrens.org/svc/alpha/h/health-policy/ev-based/asthma.htm (Accessed on February 09, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11642/abstract/62\">",
"      Ducharme FM, Chalut D, Plotnick L, et al. The Pediatric Respiratory Assessment Measure: a valid clinical score for assessing acute asthma severity from toddlers to teenagers. J Pediatr 2008; 152:476.",
"     </a>",
"    </li>",
"    <li>",
"     Asthma team CCHMC care guideline for managing an acute exacerbation of asthma. www.cincinnatichildrens.org/workarea/linkit.aspx?linkidentifier=id&amp;itemid=87887&amp;libid=87575 (Accessed on April 10, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11642/abstract/64\">",
"      Birken CS, Parkin PC, Macarthur C. Asthma severity scores for preschoolers displayed weaknesses in reliability, validity, and responsiveness. J Clin Epidemiol 2004; 57:1177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11642/abstract/65\">",
"      Kamps AW, Roorda RJ, Brand PL. Peak flow diaries in childhood asthma are unreliable. Thorax 2001; 56:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11642/abstract/66\">",
"      Khan FI, Reddy RC, Baptist AP. Pediatric Dyspnea Scale for use in hospitalized patients with asthma. J Allergy Clin Immunol 2009; 123:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/23/11642/abstract/67\">",
"      Bhogal S, Zemek R, Ducharme FM. Written action plans for asthma in children. Cochrane Database Syst Rev 2006; :CD005306.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5748 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-194.187.108.93-69C8FD1B77-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_23_11642=[""].join("\n");
var outline_f11_23_11642=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H41\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Criteria for admission",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Management approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      STANDARD THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Short-acting beta 2-agonists",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Administration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Dose",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Frequency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Continuous therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Systemic",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Inhaled",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Supplemental oxygen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Monitoring and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      THERAPIES RESERVED FOR SPECIAL CIRCUMSTANCES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Systemic beta agonists",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Ipratropium bromide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Methylxanthines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Leukotriene receptor antagonists",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Antibiotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Magnesium sulfate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Chest PT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      MONITORING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Clinical assessment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Asthma scores",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Pulmonary function",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Spirometry",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Peak flow",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Radiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Laboratory",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      FAILURE TO RESPOND",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      CONSULTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Asthma specialist",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Social services",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      DISCHARGE CRITERIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Discharge medications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Discharge education",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      Asthma action plan",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1324521\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/5748\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/5748|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?25/62/26600\" title=\"algorithm 1\">",
"      Emergency Rx severe asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/5748|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/40/37506\" title=\"figure 1A\">",
"      Stepwise asthma Rx 0 to 4 yrs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?1/41/1684\" title=\"figure 1B\">",
"      Stepwise asthma Rx 5 to 11 yrs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?11/59/12212\" title=\"figure 2\">",
"      Pediatric Dyspnea Scale",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/5748|Form\">",
"      <a href=\"#\" title=\"FORMS\">",
"       FORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_form\" href=\"UTD.htm?38/15/39162\" title=\"form 1\">",
"      Child asthma action plan",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_form\" href=\"UTD.htm?36/39/37498\" title=\"form 2\">",
"      Asthma action plan",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_form\" href=\"UTD.htm?28/14/28905\" title=\"form 3A\">",
"      School action plan A",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_form\" href=\"UTD.htm?38/31/39416\" title=\"form 3B\">",
"      School action plan B",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_form\" href=\"UTD.htm?35/59/36794\" title=\"form 3C\">",
"      School action plan C",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/5748|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/40/9869\" title=\"table 1A\">",
"      Initiating Rx 0 to 4 yrs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/62/27629\" title=\"table 1B\">",
"      Initiating Rx 5 to 11 yrs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/62/12269\" title=\"table 2A\">",
"      Adjusting Rx 0 to 4 yrs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/13/26845\" title=\"table 2B\">",
"      Adjusting Rx 5 to 11 yrs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/24/33165\" title=\"table 3\">",
"      Doses drugs asthma attack",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/40/24204\" title=\"table 4\">",
"      Causes of wheeze in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/16/33034?source=related_link\">",
"      Acute asthma exacerbations in children: Outpatient management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/58/42921?source=related_link\">",
"      Acute bacterial rhinosinusitis in children: Microbiology and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/44/22218?source=related_link\">",
"      Acute severe asthma exacerbations in children: Intensive care unit management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/33/2585?source=related_link\">",
"      Airway foreign bodies in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/48/34569?source=related_link\">",
"      Allergen avoidance in the treatment of asthma and allergic rhinitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/37/8794?source=related_link\">",
"      An overview of asthma management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/5/34903?source=related_link\">",
"      Atelectasis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/17/5402?source=related_link\">",
"      Causes of hypokalemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37354?source=related_link\">",
"      Chronic asthma in children younger than 12 years: Controller medications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/25/26010?source=related_link\">",
"      Chronic asthma in children younger than 12 years: Evaluation and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/47/39670?source=related_link\">",
"      Chronic asthma in children younger than 12 years: Quick-relief agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/2/9258?source=related_link\">",
"      Clinical manifestations and treatment of hypokalemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/24/27014?source=related_link\">",
"      Continuous oxygen delivery systems for infants, children, and adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/48/25354?source=related_link\">",
"      Inpatient treatment of pneumonia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/27/29112?source=related_link\">",
"      Overview of pulmonary function testing in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/53/854?source=related_link\">",
"      Peak expiratory flow rate monitoring in asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/57/36760?source=related_link\">",
"      The use of inhaler devices in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/9/44184?source=related_link\">",
"      Trigger control to enhance asthma management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/42/30376?source=related_link\">",
"      Use of medication nebulizers in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/5/27735?source=related_link\">",
"      Vascular rings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/15/31991?source=related_link\">",
"      What do patients need to know about their asthma?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/41/1689?source=related_link\">",
"      Wheezing illnesses other than asthma in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_23_11643="Associations with eso webs";
var content_f11_23_11643=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F68674&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F68674&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Conditions associated with esophageal webs",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Dermatologic diseases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Epidermolysis bullosa (EB)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        EB dystrophica",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        EB junctional",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        EB simplex",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        EB acquisita",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bullous pemphigoid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pemphigus vulgaris",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stevens-Johnson syndrome (toxic epidermal necrolysis)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Psoriasis (?)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Immunologic disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Graft-versus-host disease",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_23_11643=[""].join("\n");
var outline_f11_23_11643=null;
var title_f11_23_11644="Treatment Turner I";
var content_f11_23_11644=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F50455&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F50455&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Management of Turner syndrome: Gonadal dysgenesis, growth failure, skeletal dysgenesis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Characteristic",
"       </td>",
"       <td class=\"subtitle1\">",
"        Neonatal period or at diagnosis",
"       </td>",
"       <td class=\"subtitle1\">",
"        Childhood",
"       </td>",
"       <td class=\"subtitle1\">",
"        Adolescence",
"       </td>",
"       <td class=\"subtitle1\">",
"        Adulthood",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gonadal dysgenesis",
"       </td>",
"       <td>",
"        <p>",
"         Look for mosaicism.",
"        </p>",
"        <p>",
"         Look for Y-chromosome material if marker chromosome or virilization is present.",
"        </p>",
"       </td>",
"       <td>",
"        Discuss reproductive options when appropriate.",
"       </td>",
"       <td>",
"        <p>",
"         Check follicle-stimulating hormone and luteinizing hormone before initiating hormone-replacement therapy around 12 years of age.",
"        </p>",
"        <p>",
"         Begin therapy with low doses of estradiol, and gradually increase during the next two to four years.",
"        </p>",
"       </td>",
"       <td>",
"        Continue hormone replacement.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Growth failure",
"       </td>",
"       <td>",
"        Plot growth on growth curve specific for those with Turner syndrome.",
"       </td>",
"       <td>",
"        <p>",
"         Continue to monitor growth.",
"        </p>",
"        <p>",
"         Check thyroxine and thyrotropin levels. Check for obesity.",
"        </p>",
"        <p>",
"         Institute dietary counseling.",
"        </p>",
"        <p>",
"         Start growth horomone therapy with or without anabolic steroid when growth velocity declines.",
"        </p>",
"       </td>",
"       <td>",
"        Stop growth hormone when bone age exceeds 15 years or growth velocity drops below 2 cm/year.",
"       </td>",
"       <td>",
"        <p>",
"         Check thyroxine and thyrotropin levels.",
"        </p>",
"        <p>",
"         Check thyroid antibodies every&nbsp;three to&nbsp;five years.",
"        </p>",
"        <p>",
"         Continue dietary counseling.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Skeletal dysgenesis",
"       </td>",
"       <td>",
"        Check for dislocated hips.",
"       </td>",
"       <td>",
"        <p>",
"         Watch for scoliosis.",
"        </p>",
"        <p>",
"         Watch knee for tibial problems.",
"        </p>",
"       </td>",
"       <td>",
"        Watch for scoliosis, lordosis, and kyphosis.",
"       </td>",
"       <td>",
"        <p>",
"         Ensure adequate calcium intake (1.2 g/day).",
"        </p>",
"        <p>",
"         Encourage weight-bearing exercise.",
"        </p>",
"        <p>",
"         Check bone mineral density every&nbsp;three to&nbsp;five years.",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_23_11644=[""].join("\n");
var outline_f11_23_11644=null;
var title_f11_23_11645="Causes of male infertility";
var content_f11_23_11645=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F54356&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F54356&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of male infertility",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Hypothalamic-pituitary disorders (GnRH; LH and FSH deficiency)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       Congenital disorders",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Congenital GnRH deficiency (Kallmann syndrome)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Hemochromatosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Multiorgan genetic disorders (Prader-Willi syndrome, Laurence-Moon-Beidl syndrome, familial cerebellar ataxia)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       Acquired disorders",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Pituitary and hypothalamic tumors (macroadenoma, craniopharyngioma)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Infiltrative disorders (sarcoidosis, histiocytosis, tuberculosis, fungal infections)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Trauma, postsurgery, postirradiation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Vascular (infarction, aneurysm)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Hormonal (hyperprolactinemia, androgen excess, estrogen excess, cortisol excess)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Drugs (opioids and psychotropic drugs, GnRH agonists or antagonists)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       Systemic disorders",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Chronic illnesses",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Nutritional deficiencies",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Obesity",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Primary gonadal disorders",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       Congenital disorders",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Klinefelter's syndrome (XXY) and its variants (XXY/XY; XXXY)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Cryptorchidism",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Myotonic dystrophy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Functional prepubertal castrate syndrome (congenital anorchia)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Varicocele",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Androgen insensitivity syndromes",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       5-alpha-reductase deficiency",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Y chromosome deletions",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       Acquired disorders",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Viral orchitis (mumps, echovirus, arbovirus)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Granulomatous orchitis (leprosy, tuberculosis)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Epididymo-orchitis (gonorrhea, chlamydia)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Drugs (eg, alkylating agents, alcohol, marijuana, antiandrogens, ketoconazole, spironolactone, histamine2 receptor antagonists)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Ionizing radiation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Environmental toxins (eg, dibromochloropropane, carbon disulfide, cadmium, lead, mercury, environmental estrogens and phytoestrogens)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Hyperthermia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Immunologic disorders, including polyglandular autoimmune disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Trauma",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Torsion",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Castration",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Systemic illness (eg renal failure, hepatic cirrhosis, cancer, sickle cell disease, amyloidosis, vasculitis, celiac disease)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Disorders of sperm transport",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Epididymal dysfunction (drugs, infection)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Abnormalities of the vas deferens (congenital absence, Young's syndrome, infection, vasectomy)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Ejaculatory dysfunction (spinal cord disease, autonomic dysfunction, premature ejaculation)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Unexplained male factor infertility",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_23_11645=[""].join("\n");
var outline_f11_23_11645=null;
var title_f11_23_11646="Free estradiol and cognition";
var content_f11_23_11646=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F62774&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F62774&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 493px\">",
"   <div class=\"ttl\">",
"    Free estradiol and cognitive function",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 473px; height: 356px; background-image: url(data:image/gif;base64,R0lGODlh2QFkAcQAAP///yBzOQAzmYCAgP8AAAAAABA5HAAZTEBAQMDAwH8AABAQEHBwcNDQ0KCgoCAgIFBQUODg4DAwMPDw8LCwsGBgYJCQkAgcDgAMJj8AAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAADZAWQBAAX/ICCOZGmeaKqubOu+cCzPdG3feK7vfO//wKBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY6PkJGSk2sNCREiCQ1SDAgtDQgOPQ4Im4IRCammoKI7CAwAnSikpiK0lHoIBQ8TAAWeRgMFCbMDLQkFxjzCxILCBdAQABEDzToDoroozCTcuHi6yb7AFBAIFpkDFBUIFCYO1QgVvfARFpgWCBDuEboVohHYVdgEb5q6TspIIGPAzh2ABuwY9EowABPFCNQoIBTRwJwua4CEDZgAzWCzfPts/yHQ545CRQDwJiTwiA4ANgDaYq0caLOABQgQNnELKK/Wtze6dDX4BYBCAQgMCsAStiAcJhL+okrTtWBYVAYQClBo8KCABAYRFkgYsGABzgIAkP3q2moEsgcDJBRokHat2p7EmMlFQDftggEfBwl7JQ6Zsa9h3UEdUDaCA58AFjywWQFxAVFMc+JloLknArZumfVFfTSOrgi/mIbtJSH1sFjDwsHNqfdtr8wSAJCUxs1Cgc4ftTlumkxuc3FOBxh3F7UBN8HQkxkX5S2QsAe6HqAS93e4QQRlE0xQu9TYhJ96jYWGG7dTV8C4KQ4zjvx2azfaPONJTgHexowlqbwlgv82OY0jAlPXHTfAhP3AtZxjMqUynjGORahfYMNcmIyHiokj0nJMjdOXAxXc1mKLmNRmgXHyDQiXU/v05iEzwnRG4X8AwrUeUzTiiF93C+73lIIiRCYMOicuJQEFCTAAioWNiaPQcQno1cBSECTwgFvGrZWeiNU8lUBiznCplwPLOekTMmEm5lSKu1Qpznw9qVNWTxZQ0BZgUlJpJZBt5HQZMKQ91QuJWO3ySy8NThDWArBMU5Y0FOhlVoVxZZlQJgV0tUArDpQlwSYT6CJBWKmIipta/nkHTakcimNpqZm2SGszZaEKjS41KjiBXg/8SdUuQt3WKTQSXIVoIQ1Oa+3/tX1Ui+223Hbr7bfghivuuN+yglOmJshCbhCv6DRLKetGkuILy910grbxnoBkC0wVpG+t+QJCyjkilCNPApfhZVlF98y0Uk0TsBOWMfYaXBO+4DoskXCdnFbhP9QkQIEoHfNkkzz9KgPRK48CHHAfkPl0GQQD0BxVVVd2RVF/oujF0J6e4PgVk+MKveSYAzDwAFlmMYBMV56MVppWiym42l/7vryHZhP+Uqa9Kery23sQxLdUBaEWOxsAtREt7sSUwdVWZ5hws5Bd9sm9mYPaTIebdS5rrccuE97kmVQOEi0jjWjyTR+D9I1LbOEPQVDWAtTcthxzOcKFp41HDpO1/+B4TIywdE7P7MsDlzSYZ1QjaaZnsUUuibG3xoW5Dk5wKnXi5iJR8KcuI/MJppi2gUR6HhGb6mc0Le/V4GWxGeMA1ECL0CgElEY+btxLhrULQJtufuwufzKdFJOpmtWs8svHL//89Ndv//3456///vz37///AAygAAdIwAIa8IAITKACF8jABjrwgRCMoAQZmCAlWOIqqCAIvEZgLhtUEBWYaNcJbuGGCiIhgyLI0ENCUQIRerAZIDzXu4zCwJIoQRfSAEBZPHGRLY1qBjYUiU3qUoLRocGGSKCKCFoEl5CVYF41CKKJiNiNwCkQiRwrSlwGQBD32KsGVrkTD18SMf99aCmK9BFixeQxIUA1hA1YnEAneEKRLgrnizN4hgNIUhInnqxFwLCBFCnWCgqwkWI+eWMNvVebvGBuKbAoSwOcUhMw7gIsO8SPz1r0QxlAY0LEcpBTzAQXqlhlDVhsZG0iAEkd7oWSNviOBCxQFiw95ilVu8EnPVOsUcatJ1WBhrQSiMRWwvIBqzJL0gowzBnowgJdMY4nDnSctOnyVp90XAhLeZuowK8MxUTcMZO5lqg0MwZPKpVxbJmZvUGRBtjM5ny2iR9vLtIusmoRA84igX7iQGxmQcY0QyQrQaYxewTiJoi+SQYkNk6f/PRnLIehFz5a83M4GKTjkhQ6hhL/cJfGkF1YNnEnC8gFXZZ8yHgGqh7Zwe6aIhAiU2AnPIXiRw0gbedM9sKcOUEDpXkcBit9wU7iLSqjBy0WTZVlICsWMJ4PQVZdurIJqv4zcgLFz/WqB9M+OahV6LOpEccA1QZIdQRWtepErVGS5ajvnUBM6lfDw9SFTnAPlkHYXySY1+sF566BaEBXnkJDBwo2GoUFrGIXy9jGfmsC8NijYye7B724irKYtYORIpPZzsZBjVqiSOFGWziP0kC0pE2talfL2ta69rWwja1sZ6ta0yIBtbTNrW53y9veyta2dwCtMnCb2tP0YAAYOIByl8vc5jr3udB9LgYuYIDqWve6/9jNrna3q90LZEAB4A2veMdL3vKat7wZ6CQTkBvd9rr3vQeYLnfnS9/6GsC7582vfvergPQKwjiwiEolVdDGZRxAAAhOsIIXzOAGO7jBBzBAACZM4Qpb+MIYzjCGDaAAAnj4wyAOsYhHTOIRK0C9SxjAgR/M4ha7OMIajrGMZxwADpf4xjjOMQFOfIo8VaYFBd6Bil1M5CIrGMY0TrKSbazjJjuZx1EYspGn3GIkK/nKMWayk7d8YygHon0PoGIKgnyNFVP5zAy2MpbXbGEtc/nNIfbyE6SM5jojWM1szrOb4cxnOUuCzDmgs53RjOc8r3nPfH6zn5sg6EFTudCGvv+yAb7L30pb2r+4ADQOGu1oI0M60klGdKK3vOj1mrnTU/40qGdsgNP4drfAVYSmb8BpVL9Ywqs+dIdH3WcUK6HWtmaxqnOtYQP4Gn+zjuWpg31rYmNZ1LzWcalTvGxmCxvXzg71se+X7BoA29ppxna2Wb3raHN52r+uNrghLO5xZ3nb9us2Db697gQP290Uhra5uwzvYKi73kduN7433G/6yTuP/wb4nQU+8DaXe99NRncS6A3wew/c2AE8uAwoXm+L41vfEDdxwYnA8XV73N0YB6DG0ZlwhZ983CAPeZxHPoSSg/vl2U75/1YOA5tbG+fOjrnMPyzxJLa84gxveL7/aR4/nr/A58wGOrGFPvQdMz0IUA+21HOtc/853QVZt/XWV031oRf9CGFH9dhB3fX+fR3IR+940pVe44dXncRn97fCH7z2SLedf29nQdo73XdDl13meS/C4B1deD1fnXSBX8HiB914Nh8+5IknedxNPnel/31/kSfw5m/e+YZfHuKZr/nof176iz9ecKEf8+qj3vqP2/3uIk69ECZv58of+vVai/02Zq/12qP89rgHse6xTnyxGx/mwH+Z8PXVfLU/P+fIT76Hlw8E3tfZ98+OfsCmbwLvE/r6Qc++9rn/A/OfGfySFn++yF/E6hMe/VNXf/LZ7wP3Pxr/XCd/8UJ//91gf4wHgGSnf7jHf8dlgJSHgGwngOtCgCPgf6kGgX6ngHfHgAa2dw4Gf0smgYpgD+qAAqjwG2AngjHlgL2HgYangVXHgULGgt/ngo7nLYbhMyUwAc8SaxWogjZBg+dHdxl2evsmg2XmgexGhATnLQKWGQWAgqECDT4YU0BogZ5mg5YHg2YHhN4mhO+nhb/nLYnBJpGiPMRFWsbVgUq4YCAYalyIeF44b2D4f0x4YZ93FM+QG7dhhiPgh1vEWms4g23ohmL4bHGIeXOIcIUYcHfYZovoB6iQCrviDl5iAoAoeVdYhxf4iBU2aZYWivuFaVCAhUX2hjSWh4gyM07hTv+eIBN6YQGJtQ2b2Ij2doiS5mqvlltVqHq2uHCeuHTf0iir8iA8hE2BJHi1+IuoyGqR6AWmSGTNKGOqiGzLaIvT+G5/EI3NFow19ozcQoEr+IsCkI3FBo5cwI1VhoshmHHX2IjmWITouAXqeG3e+I3u2IDkGI9N6Af1yHfsqG35yIbYGJCpOI9a8I8faJDOOJCEyIwMSY0ImQUKuYTeWI3c9o6FyI94OJFYUJHhdo8YGW8a2YYcCYnbyIlZKJIeiSjiGIT7GJHa6I8qeYoyeY4OmYQQyZIpGZM8WQgyEZQfWZJKeJKf2JJWAJKG+JODQD1dAlRT8JJK6YgXiZRVMJX/t8iUgoBMrIMYQ6mPO1mVPRmWwTiSeZAbVZKMVCCVNSmNNymPY1mQWhkID1ABfgGVUsCWPimWNLmXZWmVWnAnpXJOeUmUHmiUwtiXZOmJZpkH1nEPFGmYe4eYE9aYn9WW3fiXhcAAeHmVkulyb9mPfYCVwMiXg8AO6fiZSDeXekCa5RiaHVkI0FQ4YlaYYCmXpskHrkmZ+EgIugFXtkmQ8AibKKmYuKmZhIAgqvCVwrmRxHmUcTmcrBkImpCQqil304kHu/mciTkIh2UWUriW18l52RlcmLmO5ckHyZI0C4A2V6CXi/mIlgkH25mee+AfXskEaThag6iTx8mYgBmV/+dpj7lJl7ojAe65BPtZOP0ZaAMKkPZJB/VZoAJzKwswi6U4nqQXoXMwociZnNJBmMH5kP8pnwGalw+6kBxaOsGRFidKYBrKeit6mX4JoIUgFtqjllEZo7Q3o/SZohb5oYKAo+7ynjxafD76Bh5qo4QAAZjyhEZ6m9JJoXmwpCZaCEwDnsxJolMqpHtgpXc4n3dQnZEppc6ZpG4ApkwopnTAAFykGeG5o2ZqktxZmS9aikAaklTqB6fipJiypf7ZpUw6mnm6lHvaB8PwADSjoyMaqGd6qHagpkTIpnOgqMmgLkl5pM6Hpm0gqXRHqXJgHJjzAJ2ZoXNalHXam4Rao/9XiqURIJRR2px0yqls4Kmed6eTAJ8lGqa46gS2anq9Ggm6Kqituqrxyas56aCsiqzGSazMunOaan20uga/6nolEguwsBKAqqzHuqbBamrL6q3Xqq3aGqtc+qhe2pqFSpXpOpq7MSCMGmXRen/TqgbV+nHfOmfxBJzyeqqHmaqgSq3rmpWQWqX7Gq+mKquoWq9pcK8ol6+OMKzoOqi6ObCl2a58IBOY4BIiKgMk6BAkwIMTgqH6Mq8HyLBo4LDQpxiYcyeYgwM5iDhVdCtVKLGzWrASarGvibJrIA8AEBYV8Kc38IRdIYWXAACc9HQm+4A8awYqm3MQ2wTGdR/5aQP/ZRg4eSEeCtFaDbppOsubAWuvXwuwUcsEdnlUmNpzNHu18IMeS7O1gri0Ldi0ZfC0QVe2CnorokCqMzCJ6sFZl2gCWZWC/jqZZBudE1usX2Zca9KLs/AUrWiMP9sZepGgyli4oEm3ZGC3U4e3a0CMpgAhgzUPSou5q4mzHTq2mnsGe3grCDtncluDqysGnBuAJRJPr+ursTuEqCsHtUt2npsEV8JC1mm62Nm7NNqtkxq8ShABN1O8CvuvsxsGvxuBhDABcZND2+q14bq8iHuzGLsH1BMKy2mujgq+FPulqou8Enqw20tr6xu+kRq/6esHaVib/Rq9hju9YFC9fse8/4dgswvLvkpKv4r7B/f7vsrWvZ8KwLtnwM8aEu5rvty6q+LarIkbwX+wTrqIvwl7ruh7wOrKwLdKCAnQIg8wYJlqvORJwGkKwRc8CO+BRSusv5nrwp0Kw957CqTRniT7wec7wPJbB/5reA6seNCyEi7kmSy8oThcqzrcwLeLjAr8hSQMrN8rxPULersbhvz7BUV8gyrXxXb4xAJ7xdY6xk0so2YstmiMr8nKvcorxRgcwhoMeGTciW3csFFcwsnpEUssnmvco3ucsn2MxYRQS8NSxXT4xg+bxdJbyG2wJPSYxyspyU57yGk8CFARBQsKSpZsk18MjZoMx4QQtEpcqv9E8MmIEcpuOcpdEMaWd8RG8Ju5y2iunJlbrJ2l/MhqbMOnO8Q568gr+8epzMiMOMd+bKwWvMOD4CmLTMFy3Mx0zMzOGsNDehlIW7YCHMnCnLrEDLU3KiZpicwb18vFbM0ZjM10OQBMpL1MDMzH+82+i87inJwNYCncY84sF853C8n7i8lsEJTqwc89Z8//XMdaLMJ/4JRnYdBPh9CdC9A3TM93wJUUccvrlcvoKdCbK9G2SwhombaCLM8tbNE/6s8Tnch2yRaqrLuDjKQePQayPIaEIJgvK83wq9Ihrc52zM6BFaJlatJOjNIFzNPAawjK+cO4HNObOtO0C9JJ3aT/VKzTC6zMiOzTC33Hf6BME+LBsOvU0grV1CvV1uubL52/ILzVQF2lZv2/hZAAVbESab3RYk2vZN2/b23EhTBY0VzDa+3Nu2yeSH3WgyC00BvYAW3UL1zYcE0InZAKZArYQSzYDM3Ljs3XvlnVlF3B1+zMFZvZYtyUowXWME3UbMzYOSzas/wtH2sCfnu0hIvahKzaUMzaNs0tMQtUrTty3bzYgz2/uB1+TogZRVtFFaAhpUvbMm3bZ4zVm7wtbFtF4DEScLtaXbvT0G3KWm3ZXO0HclQKKbFxa9uHAOMAbloWKMXK2X3V1LzMob3dvszJVFgB8PwCfluJbMNTgsuv/yV71yeb12C816M9pPmQ0TjAirsguRDQGWXh2xxNoM7txvKdzkNqSGty3zQAupLLFrzScxEOoQJOysMdf4UQtJrxGRANdgTe2grt3W0N3pdS13bN3E894Xxc4u34y4pd0cFNxC2e24LQMUqswo3q2esM2uqr4wK52fFk2ikW4io64rEc5MRNCBLQDMih0RMn5UH648Nc4fc8CJihE1UrpzY+1jhuyEx+kNTyC5VL0mpd2cB92YQt5gntneHAPXDS2dP82dUc3++d1V7n5Xq65qxr5SZuzHS94nDX5g354nX+3X2gyP4d1mmO14ieyZAukTeq4X6u3YMe3UuO5yvNyf80fto9HsxgDs6m3tOCgMqNbtVW/OpT3d2THuPZwtnxvOrz3Or13OkzCa0AzrRUno6KvuMybAG06eiCl+xNjus+bud8ID5/3et0Pu2ULty2bthD6k3tDcRI/tNKPsLd/thkLtfUwOW/ZuiGuul1C+1uTgh9Oibs3uXFPrfHTo/yHulN6QCCdaHOLnn97umSru26bo35Lrv7npAFP+yCsFXXXtJCllzwdfEYjwGH648Wj/Ee314aD8tiADWzrqBcC4SsvIuCuPF9kPIqr1oIwPKCgNhOwN60TGAy/z05DwgMkZr2uvPhMgBAzwf7eumqzrpD/y1CL/JfoMROn+r43rD/Se8tS9/wX4AKwlHQtE69U98tVQ/vavAqwlGXA/+eXR+OZ3+WzXDmFI/0TB/AaY8HC1ATQFH2SRn31/L1wH4HLdJPKr71/Yv31qL31L4HEfPhdn+Vgj8thL/tGfnzb28IjZ/wjy/1kV8Ik1/uXAz5Vo/5i788L8lonw8kmR/ogVCuie32nU8IpQ/f3nHvNZ6yo/8frU/ogRAVxwz4YDz7rVH7pA4Itpz4a8n7ekj843fzY2b8mab8bfAeza770Mj8uSr9a2DtRt/Ulr/6ikH9OAXu3Iz828D9kOD73D2k6s72aC77l8/64o8G9V4Vwh+V7R+x828GDgDwbcHULfDa/yUAAk0yJg1woqk6DKr7wrE80+5gBLm+873/+wytGrFoPCKTytcN6HxCA8IltWqlTRLZiTWyWEgKDBWiYC4giqwru9qMwuPTNr1uv77jeuf87v+jOJglSIxVMRRYACwUcKGIJJRVqA0BWqLk7Wny9F16frJlbo52gpoiPUg8JAykVZUlAMC6RJhFpLCy6O4iVJ7aiY5qlv4WG9vgCAsTHzenFEQmMLgeDZxFQstmq1QUTOLuhrf6OrtdGKCnq6+zt7u3X5CXz38GK8vJ0x8/VEgMLBg6EoHEBAgFKAAIYyJFrQK3KOmrkkscxYoWL+qKFXEjIHv3ojDjaIrCmQUPqf8IgkDywQk0JyRVyydyJs2adDx+fBLSpqUGAyycPMRIwkKXCQqYjMlzKdOmapLl1LPTKR0LGmuuoap1K1OcUX9M5fqqwAOgNLOKTat2ntevPcKuRdKAwQMzKkWijat376W2bnfA5UtkggNGdjnmFax4sRuof3XKZFwDkZkKDipQ05dYMufOMvw+lhLZMwwEEhw4mrmZNGvPoB8Hbg0gNdbRsm/rff03tuwGmfHaxi1crG63vFsftbl6OHPijkODDY47ee3m1tcW/3qcNfWz0q+Dx/sc+tvv4TWbP6/eWfao2zk7cADgnxjv6+9jHU8ecPrOvRqcUUB/oCyHn4HNtJf/03uSIVDBUSZA8Bt6B1JIT4IfLciYBQIukAAFEkCg2oAVkniTfvvlkOFiE4QRIELAlRjjLxfeo+KKFiDQ4FWIjSijj0nQqIyNP97UI5FH0hDkMkYiGQqTTUKZgpKkPBnlEgVameUMU24ypJZIYPmlmFKeiKKXYxIRJppicjlMlWsm+SacJLa5x5lzxqAmnlHWKZWce9rwJ6D39YnPoElMRFEvh645wDnvQBqppPEwekSi4ixaqZiXYtSpp7vsqCkVeopaqqmnkHqqqqvekSqrr8J6paCx0kqrq7XimusKs+raq6a3+hrsq8AKW6ypxBqbLKPIKtssnsw6G+2Y0Epb/62V1Fqb7ZHYqhWBBQO8qIJPAyx0wrihJustuC+Mu9BAJATlLLdieQFGfSmsVNeL3TyQabP1hhHQCfkeNF+AvFY6b0QRgDvNi5DACwAiijBCm0IASgBASrgyTIHD5pIwwi0TL9JIChcXkLE1DiYQb7MK63PUAwMopM3B2sQyCwpmtFQAAAaV0WGsMtNcgAll3DyLzj0zbU2/A9AmL8LOHNUCSZEpvQ3TAPBchgUbsgRr1QBcHUPWO/LMtc8OMDBAXQJLrdjYY0+TY47yGYRQzShUPAFSP2eT9qtzCyix3XcDrrfRKfT9NwpHSagszPQc5WDNDoQTS0orATB2Nyx4o/9xARBsGLmplROyOOagiq4SWZ0X/vnKP1fgduHVTj6PzEjJJwMDQ5kwdkF2OfI7GlGruvsCvcdgPFGwtzD86FzQB1C2uZcztrZFaL+9H9hTfbv3NHQ/fh3gm59+U+qGm4JPZkGkvvy3AXxvIGR94XKeU8/fP0ckV4xxjRDEN2qAPv8hcB5ne0YjIAcOi+ToUxKcIAUraMELYjCDGtwgBzvowQ+CMITiQBd7rrFAFPArDJnhFC96IcIXwjCGMpwhDWtowxtq0F/0eJcW8paQxaGAMKAzzwETiDv+XWFzr+NaGkZQmKSkCYlGlFYRreC8oqTBGqMrlwGlOMW43aaKX5RjnBd5NMYzfqaMGxEjGoXFxoi8sY29iqOF1CjHOdpxQne8Ix3Zksc91qqP5RAkIIf1R92RsJAJHIEiG+nIR0IykpKcJCUraclLYjKTmtwkJzvpyU+CMpSiHCUpS2nKU6JSWSEAADs=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Six-year decrease in mean Mini-Mental State Examination (MMSE) score according to tertile of estradiol concentration in older women not taking hormone replacement therapy. Women with the highest levels of free estradiol and bioavailable estradiol (perhaps representing estradiol available to the brain) showed less cognitive decline over time.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Yaffe, K, Browner, W, Cauley, J, et al. J Am Geriatr Soc 1999; 47:1176.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_23_11646=[""].join("\n");
var outline_f11_23_11646=null;
var title_f11_23_11647="Technique for oocyte recovery";
var content_f11_23_11647=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F82492&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F82492&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Follicle aspiration",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 226px; height: 327px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematized representation of transvaginal ultrasound-guided follicle aspiration. The ultrasound probe is covered with a sterile plastic sheath.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_23_11647=[""].join("\n");
var outline_f11_23_11647=null;
